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Thesis Summary 
A number of studies have suggested that mesenchymal stem cells (MSCs) may undergo genetic 
alterations and spontaneous malignant transformation to form tumour cells, or at least can become 
contaminated with other cell types following extended periods in culture. Possible transformation 
or contamination of MSCs during cell culture expansion prior to their use in transplantation 
therapies is a risk, which should be taken into account. There is a continued need for the 
development of improved tools for monitoring safety and release criteria of cells intended for cell-
based therapies.  
In order to help address these risks, this thesis aimed to develop improved safety measures in MSC-
based cell therapies. Initially, this was investigated through the use of microscopic imaging and 
image analysis platforms to screen, characterise and distinguish between cultures of non-
transformed MSCs and MSC-derived tumour cells, i.e. the osteosarcoma cell lines, SAOS2 and 
MG63, as well as cells derived from a chondrosarcoma. High content screening (HCS) and live-cell 
imaging and analysis platforms were used to enable these experiments. Phenotypic features that 
distinguished the normal versus malignant cell types were identified, including immunoreactivity 
for the proliferation-associated Ki67 antigen and pluripotency marker Oct4, as well as significant 
differences in nuclear morphology. These findings help inform release criteria for therapeutic MSCs.  
To further potentially improve the safety of MSC-based therapies, research was also performed to 
address the possibility that tumour cells in MSC cultures might remain undetected, thereby still 
providing a risk in MSC transplantations. Novel combinatorial regimes of potential anti-tumour 
drugs, i.e. bezafibrate, medroxyprogesterone, and valproic acid (termed V-BAP) were tested in vitro 
for their effects on MSCs versus SAOS2 and MG63 cells. At determined concentrations, these drugs 
were shown to significantly inhibit the growth of the osteosarcoma cells, but had little effect on 
MSCs.  
Thus, this thesis has made inroads into improved safety of MSC-based therapies by (i) 
demonstrating the application of imaging-based cell screening platforms to help characterise MSC 
cultures intended for cell transplantation, and (ii) identifying a novel drug regime that selectively 
targets osteosarcoma cells whilst having little effect on MSCs. The findings on V-BAP also have 
application in anti-tumour treatments for osteosarcoma. 
  
Key words: Mesenchymal stem cell; High content screening; Live cell image analysis; 
Osteosarcoma; Cell-based therapy.
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1.1 Regenerative Medicine 
The focus of regenerative medicine is replacing or regenerating damaged or impaired tissues, to 
restore and establish normal function (Daar and Greenwood, 2007). Wound healing involves the 
recruitment and proliferation of cells capable of restoring tissues and even organs to their original 
form and function. This happens naturally within the body often without our knowledge; however, 
ageing, tissue loss and damage due to trauma or disease can take the body beyond the point of 
self-repair (Rosenthal, 2003). In these circumstances, cell therapies and tissue engineering, which 
are part of the broader remit of regenerative medicine, aim to deliver safe, effective and consistent 
therapies (Polak, 2009).  
Cell based therapies include the use of somatic cells, such as the treatment of deep cartilage defects 
by autologous chondrocyte implantation (ACI) (Brittberg et al., 1994, Roberts et al., 2003); skin cells, 
such as the treatment of full-thickness wounds with cultured keratinocytes (Wright et al., 1998); or 
stem cells. The use of these cells for cell-based therapies will be discussed in more detail in context 
of specific clinical applications further along in this review.  
Broadly speaking, there are two main types of stem cells - embryonic and non-embryonic (also 
termed adult-derived stem cells). Embryonic stem cells (ESC) are derived from the inner cell mass 
of mammalian blastocysts and have the ability to grow indefinitely while maintaining pluripotency, 
that is, the ability to differentiate into cells of all three germ layers (Evans and Kaufman, 1981, 
Martin, 1981).  
Non-embryonic stem cells include: 
(i) induced pluripotent stem cells (iPSCs), which are differentiated somatic-derived cells 
reprogrammed into an undifferentiated pluripotent state by the introduction of four transcription 
factors (Oct-3/4, Sox2, c-Myc and KLF4) (Takahashi and Yamanaka, 2006, Takahashi et al., 2007);  
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(ii) umbilical cord derived stem cells, which contain multipotent haematopoietic stem cells 
(Gluckman et al., 1989) and mesenchymal progenitor cells isolated from the umbilical cord blood 
(Erices, Conget and Minguell, 2000), as well as mesenchymal stem cells isolated from the Wharton’s 
Jelly (Wang et al., 2004);  
(iii) bone-marrow derived haematopoietic stem cells (HSCs), which are the multipotent self-
renewing stem cells of the blood system and have the ability to differentiate into all the distinct 
mature blood cell types, as reviewed by Seita and Weissman, (2010); 
(iv) mesenchymal stem cells (MSCs), which are multipotent plastic adherent stromal cells, 
typically isolated from the bone marrow and partially defined by their ability to differentiate into 
bone, fat and cartilage (Pittenger, 1999). MSCs are a common cell type used in orthopaedic disease 
and injury and were the stem cell used throughout this thesis. 
This review will briefly discuss the history, isolation, identification and differentiation of adult 
human derived MSCs, whilst focusing on the safe use and provision of MSCs within clinical 
applications, notably within orthopaedic pathologies, spinal cord injury (SCI) and its sequalea, 
namely pressure ulcers and finally skin wound healing. Issues surrounding these clinical applications 
and the safe GMP culture expansion and manufacturing of MSCs will also be considered. Lastly, the 
proposed use of a high content screening (HCS) and live-cell imaging platform to facilitate the safe 
provision, characterisation and screening of MSCs for cell-based therapies, will be discussed in 
relation to known and current technologies, such as flow cytometry and selective cell sorting.  
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1.2 Mesenchymal Stem Cells 
The history of MSCs: 
The suggestion of a stem cell population as the origin of non-haematopoietic bone marrow cells, 
which contribute to wound repair and have a fibroblastic-like morphology, was made almost 150 
years ago by the German-Jewish Pathologist, Julius Friedrich Cohnheim (Cohnheim, 1867, Prockop, 
1997). The subsequent work conducted by the Russian Scientist, Alexander Friedenstein, from the 
late 1960s through the 1970s, credited him with the discovery of MSCs. He showed the critical 
observation that the bone marrow, in postnatal life, is a reservoir of stem cells for mesenchymal 
tissues. From rodent bone marrow, Friedenstein and colleagues isolated adherent, fibroblast-like 
clonogenic cells, termed colony forming unit-fibroblastic (CFU-F), which have a high replicative 
capacity in vitro (Friedenstein et al., 1968, Chailakhyan, Fridenshtein and Vasil'ev, 1970, 
Friedenstein, Chailakhjan and Lalykina, 1970, Friedenstein et al., 1974b).  
From the late 1970s through 1990s, Friedenstein, amongst many others, went on to show that 
these bone marrow-derived stromal cells were responsible for transferring the microenvironment 
of the haemopoietic tissues (Friedenstein et al., 1974a) and that there were fibroblast precursor 
cells in and amongst this heterogeneous population (Friedenstein et al., 1974b). They examined in 
vitro cloning of the CFU-F and re-transplantation of the cells in vivo (Friedenstein, 1980) and found 
that the marrow microenvironment was able to be transferred by heterotropic transplantation of 
freshly isolated and cultured cells into porous sponges (Friedenstein et al., 1982). Soon after, CFU-
F were shown to have osteogenic differentiation potential in vivo (Ashton et al., 1984) and 
mineralised in vitro (Howlett et al., 1986, Friedenstein, Chailakhyan and Gerasimov, 1987). The cells 
were described as a heterogeneous stem and progenitor population of cells based on observed 
variations in colony size, morphology and alkaline phosphatase (ALP) activity (Owen, Cave and 
Joyner, 1987). Bab et al., (1988) went on to isolate human marrow derived CFU-F, which formed 
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osteogenic tissue consisting of a mineralizing fibrous component as well as cartilage, when 
incubated in intraperitoneal implanted diffusion chambers within athymic mice (Bab et al., 1988).  
In Owen and Friedenstein’s (1988) review, they recounted that some CFU-F demonstrated self-
renewal and multipotency in vivo and when examined in vitro, studies showed that CFU-F were a 
heterogeneous population of stem and progenitor cells whose differentiation could be modified at 
the colony level by the addition of different factors to the culture medium. They concluded that the 
number and hierarchy of cell lines belonging to the stromal fibroblastic system had not yet been 
fully elucidated (Owen and Friedenstein, 1988).  
Based on the embryonic perspective of multipotent progenitor cells located within the mesodermal 
layer, Caplan (1991) posed a hypothetical and comprehensive scheme. He proposed that within 
adult bone marrow there was a population of mesenchymal stem cells (MSCs) which could likewise 
give rise to a spectrum of mesenchymal tissues by differentiating along separate and distinct 
lineage pathways (Caplan, 1991). In 1999, Pittenger demonstrated this, by showing how cells 
isolated from human adult bone marrow aspirates displayed a stable phenotype in in vitro 
monolayer culture and were able to be induced to differentiate exclusively into the osteogenic, 
adipogenic, or chondrogenic lineages as shown in Figure 1.1 (Pittenger, 1999). 
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Figure 1.1: Isolated bone marrow-derived stem cells differentiate to mesenchymal lineages. 
Cultured cells from donors were tested for the ability to differentiate in vitro to multiple lineages. 
Three donors (A through O) were each shown to differentiate appropriately to the adipogenic 
(Adipo), chondrogenic (Chondro), and osteogenic (Osteo) lineages. Adipogenesis was indicated by 
the accumulation of neutral lipid vacuoles that stain with oil red O (A, D, and G), and such changes 
were not evident (J) with Hs27 new-born skin fibroblasts or (M) with 1087Sk adult mammary tissue 
fibroblasts. Chondrogenesis was shown by staining with the C4F6 monoclonal antibody to type II 
collagen and by morphological changes (B, E, and H), which were not seen by similarly culturing (K) 
Hs27 or (N) 1087Sk cells. Osteogenesis was indicated by the increase in alkaline phosphatase (ALP) 
(C, F, and I) and calcium deposition, which was not seen in the (L) Hs27 or (O) 1087Sk cells (see Web 
Fig. 4). Figure from Pittenger, (1999). 
~ 24 ~ 
 
Nearly half a century has passed since Friedenstien first described the stem cell properties of bone 
marrow stromal cells and the field of MSC research has thrived. The exact location of MSCs is still 
broadly disputed; however, as shown by Mendez-Ferrer et al., (2010), MSCs have been shown to 
be located within the endosteal niche, where they line the bone surface and physically associate 
with osteoblasts, as well as within the vascular niche, where it was shown that perivascular MSCs 
play a critical role in maintaining a quiescent HSC pool within the bone marrow (Mendez-Ferrer et 
al., 2010).  
Some debate has occurred regarding the correct nomenclature of MSCs, proposing the cells should 
be known as multipotent mesenchymal stromal cells, whilst maintaining the acronym yet 
withholding the title ‘stem cells’ until they have been shown to meet specific stem cell criteria 
(Horwitz et al., 2005). In 2008, Caplan called into question whether MSCs and perivascular cells 
(termed pericytes) are synonymous (Caplan, 2008). This was in response to a study that showed 
the perivascular niche as a possible location for MSCs. The study also showed that pericytes 
exhibited osteogenic, adipogenic, and chondrogenic potentials at the clonal level, expressed MSC 
markers of identification and migrated in a culture model of chemotaxis (Crisan et al., 2008). Caplan 
concluded that this team, led by Bruno Péault, provided a solid set of observations which clearly 
linked MSCs with pericytes and that all MSCs may indeed be pericytes (that is perivascular in 
location), however, not all pericytes can be thought of as MSCs (Caplan, 2008).  
The name ‘medicinal signalling cells’ has also been suggested for MSCs (Caplan, 2010). MSCs 
function as surveyors of their microenvironments and during local injury, they are released from 
their perivascular location, become activated, and establish a regenerative microenvironment by 
secreting bioactive molecules and regulating the local immune response, as reviewed by Caplan 
and Dennis, (2006). These trophic and immunomodulatory activities suggest that MSCs may indeed 
serve as site-regulated ‘‘drugstores’’ in vivo (Caplan and Dennis, 2006, Caplan and Correa, 2011b).  
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Identification of MSCs: 
Bearing in mind the heterogeneous population of stem and progenitor cells collectively termed as 
CFU-F, scientists wanted to differentiate between the different cell phenotypes and reduce 
inconsistent identification and reporting between researchers. In 2006 the Mesenchymal and 
Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) proposed three 
‘minimal criteria’ which should be used to define human MSCs (Dominici et al., 2006).  
MSCs were primarily isolated from bone marrow (BMMSCs), as demonstrated by Friedenstein’s 
work. However, MSCs have been isolated from many other tissues (Hass et al., 2011), which include 
(but are not limited to) adipose tissue (ATMSCs) (Peroni et al., 2008), umbilical cord tissue (Erices, 
Conget and Minguell, 2000), amniotic fluid (In 'T Anker et al., 2004) and dental pulp (Perry et al., 
2008). However, some argue that these minimal criteria for the identification of MSCs are ‘a loose 
set of criteria’ (Bianco et al., 2013) allowing MSCs to be isolated from every tissue.  
The ISCT’s minimal criteria are briefly discussed below.  
Firstly, they proposed that MSCs must be plastic-adherent when maintained in standard culture 
conditions (Dominici et al., 2006). Friedenstein’s initial isolation of MSCs was performed based on 
plastic adherence (Chailakhyan, Fridenshtein and Vasil'ev, 1970, Friedenstein, Chailakhjan and 
Lalykina, 1970), and it was shown to be a property of the stromal cells, which were recognised to 
support haemopoiesis in vitro and regenerate it in vivo (Friedenstein et al., 1974a). 
Secondly, MSCs must express the cluster of differentiation (CD) surface antigens; CD73 (SH-3/4), 
CD90 (Thy-1) and CD105 (endoglin or SH-2) in greater than 95% of the culture, and lack expression 
of; CD11b, CD14, CD19, CD34, CD45, CD79α or human leukocyte antigen-DR (HLA-DR) in greater 
than 95% of the culture (Dominici et al., 2006). As reviewed by Murphy, Moncivais and Caplan, 
(2013), the first MSC specific markers identified were CD73 and CD105, followed soon after by CD90 
and CD44, which collectively discriminated these cells from those of haematopoietic origin, but not 
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from fibroblasts. To ensure the isolated populations of MSC are not contaminated by other cells, 
cells are excluded if they are positive for CD markers associated with haematopoietic cells. As 
reviewed by Murphy, Moncivais and Caplan, (2013), CD11b and CD14 are prominently expressed 
on monocytes and macrophages, the most likely haematopoietic cells to be found in a primary MSC 
culture; CD34 marks primitive haematopoietic progenitors and endothelial cells; CD45 is a pan-
leukocyte marker; CD19 and CD79a are markers of B cells that may also adhere to MSC in culture 
and remain vital through stromal interactions; and HLA-DR molecules which are not expressed on 
MSC unless stimulated. Interestingly, Niehage et al., (2011) conducted an extensive study into the 
cell surface proteome of human MSCs and identified over 200 plasma membrane proteins. Of 
these, 33 were identified as cell adhesion molecules (CAMs), 26 were signalling receptors and 41 
CD markers, 5 of which (CD97, CD112, CD239, CD276 and CD316) were novel markers for MSCs 
(Niehage et al., 2011).Likewise, Martinez et al., (2007) reported the potential use of the neural 
ganglioside GD2 as a single surface marker unique to BMMSCs, distinguishing them from other bone 
marrow cells as well as foreskin fibroblasts. As shown, MSC phenotypic characterization has been 
widely researched and published, but unfortunately there still remains no single CD antigen marker 
unique to MSCs accepted by the scientific community (Murphy, Moncivais and Caplan, 2013).  
Thirdly, MSCs must differentiate into osteoblasts, adipocytes and chondrocytes in vitro (Dominici 
et al., 2006) since they are known to be of mesodermal origin. The in vitro differentiation techniques 
and staining of MSCs along these differentiation pathways were elegantly shown by Pittenger, 
(1999) (Figure 1.1). Following treatment with β-glycerophosphate, ascorbic acid and 
dexamethasone, osteoblastic differentiation of MSCs is commonly shown by up regulation of 
alkaline phosphatase (ALP) activity and deposition of a calcium-rich mineralised extracellular matrix 
seen with von Kossa staining (Pittenger, 1999). Janicki et al., (2011) demonstrated that in contrast 
to in vitro osteogenic differentiation parameters, a doubling-time of MSCs below 43.23 hours 
allowed to predict ectopic bone formation at high sensitivity (81.8%) and specificity (100%). They 
~ 27 ~ 
 
also showed that gene expression profiling confirmed the key role of proliferation status toward 
the bone forming ability (Janicki et al., 2011).  
Adipogenic differentiation of MSCs is commonly shown by the accumulation of lipid-rich vacuoles 
within cells, and then stained with the lipophilic stains, Oil-Red-O or Nile-red-O, following treatment 
with dexamethasone, 1-methyl-3-isobutylxanthine (IBMX), insulin and indomethacin (Pittenger, 
1999).  
Finally, chondrogenic differentiation of MSCs is stimulated by culturing cells in 3D micro-pellets and 
inducing differentiation by treating the pellets with transforming growth factor-β3 (TGF-β3) and 
dexamethasone (Mackay et al., 1998). Safranin-O, toluidine blue monochromatic staining for 
glycosaminoglycan (GAG) and immunostaining with an antibody specific for type II collagen have 
been used to indicate the formation of cartilage matrix (Pittenger, 1999, Kohli et al., 2015).  
A study performed by Rasini et al., (2013) endeavoured to identify and characterise MSCs within 
their natural bone marrow environment, by performing multi-parametric immunohistochemistry 
on trabecular bone biopsy specimens. Describing differences in cell morphology and micro-
anatomic localisation in relationship to a precise pattern of MSC antigen expression; they were able 
to locate within the bone marrow, an identifiable and distinct population of progenitor cells with 
overlapping in vivo expression of antigens similarly characterised during ex vivo expansion of 
BMMSCs (Rasini et al., 2013). These antigens included CD10, CD73, CD140b, CD146, GD2 and 
CD271. The identification of cells positive for the pluripotency markers, Oct4, Nanog and SSEA-4 
revealed subpopulations of different progenitor cells within the trabecular bone and bone marrow 
(Rasini et al., 2013).  
Others have proposed a multiparameter approach to the isolations and identification of MSCs. A 
multiparameter flow cytometry approach to enhance characterisation of MSCs and ultimately 
provide a pure population of cells with a defined cell surface phenotype was demonstrated by Chan 
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et al., (2014). They were able to isolate a triple gated population of MSCs which had an expression 
phenotype of 94.5 ± 1.3% for CD73+ve/CD105+ve/CD90+ve/HLA-DR-ve/CD34-ve. The combination of this 
multiparameter approach (Chan et al., 2014) and understanding the phenotypic characterisation of 
MSCs located in vivo within trabecular bone and the bone marrow (Rasini et al., 2013) will help to 
standardise the characterisation, research and provision of MSCs towards clinical applications in 
regenerative medicine. 
Other differentiation potentials of MSCs: There is also literature stating that MSCs are also able to 
trans-differentiate into myogenic cells (Wakitani, Saito and Caplan, 1995, Toma et al., 2002), as well 
as cells from the ectodermal (neuronal-like cells) (Jiang et al., 2002, D'ippolito et al., 2004) and 
endodermal (pancreatic islet-like cells) (D'ippolito et al., 2004, Zanini et al., 2011) germ layers. The 
derivation of MSCs and their differentiation potential has been illustrated in Figure 1.2. 
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Figure 1.2: The in vitro differentiation potential and sites of derivation of MSCs. 
A schematic illustration of the ISCT’s required minimal criteria for the differentiation of MSCs. 
Differentiation inducing factors are shown for driving MSCs towards osteoblastic (cell with high ALP 
activity), adipocytic (cell with positive Oil-Red-O staining) and chondrogenic lineages (cell in matrix 
stained with toluidine blue) are shown here. Similarly, other differentiation capabilities and areas 
of isolation of MSCs are reported.  
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1.3 The use of MSCs in cell based therapies 
As knowledge of the multipotency potential and tissue engineering capabilities of MSCs expanded, 
the question of MSC’s intrinsic physiological role in situ, within the bone marrow and other tissues 
of origin, became more pressing. Understanding this role would help advance the use of MSCs for 
cell based clinical applications. Although there is great controversy with regard to the exploit of 
non-progenitor MSC functions to treat diseases outside of the skeletal system (Bianco et al., 2013, 
Caplan and Ricordi, 2013, Phinney et al., 2013), MSCs have exhibited a broad range of angiogenic, 
trophic, anti-inflammatory, and immunomodulatory activities (Caplan and Correa, 2011a) whilst 
being used in a variety of experimental paradigms (Dimarino, Caplan and Bonfield, 2013, Zhao et 
al., 2014). Since MSCs are thought to be found as perivascular cells, surveying their 
microenvironment ready to function at various sites of tissue injury (Crisan et al., 2008), their 
potential role in wound repair and regeneration is only just starting to be understood (Caplan and 
Correa, 2011b). 
MSCs which have been successfully used in clinical cell based applications include, but are not 
limited to; (i) the successful treatment of refractory tibial non-union using calcium sulphate and 
bone marrow stromal cells (Bajada et al., 2007); (ii) the treatment of a full thickness articular 
cartilage defect in the femoral chondyle of an athlete with autologous bone marrow stromal cells 
(Kuroda et al., 2007); (iii) the use of autologous culture-expanded BMMSCs delivered in a fibrin 
spray which accelerated healing in human cutaneous wounds (Falanga et al., 2007); (iv) culture-
expanded autologous BMMSCs injected into spinal cord injury (SCI) patients, with some improved 
motor functions seen (Park et al., 2012); (v) the treatment of severe refractory acute graft-vs-host 
disease (Prasad et al., 2011).  
It is noteworthy that as of 12th September 2016, there were 221 open recruiting studies (with 
known status) involving the use of “mesenchymal stem cells” in some manner, listed on 
ClinicalTrials.gov (www.clinicaltrials.gov). Similarly, on the EU Clinical Trial Register, there are 63 
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ongoing trials involving the use of “mesenchymal stem cells” (www.clinicaltrialsregister.eu). These 
clinical trials include the use of MSCs for the treatment of many diseases and disorders, such as 
cardiovascular diseases, neurological disorders, pancreatic disorders and liver diseases, skin 
diseases, autoimmune diseases, and bone and cartilage defects and diseases, amongst many 
others.  
The identification and characterisation of 1342 active cell based therapies up to 1st January 2014 
and the translation of these trials focusing on the clinical landscape and manufacturing challenges 
was recently reviewed by Heathman et al., (2015a). It was reported that 382 of the cell based 
therapies involved the use of MSCs which had been isolated from endometrial tissue (3), placental 
tissue (7), unspecified locations (15), adipose tissue (59), umbilical cord (61) and bone marrow 
(237). The cell based therapies were divided into 18 clinical categories and the majority of these 
trials performed within neurological, cardiovascular, and autoimmune indications. Notably, 339  of 
the 382 cell based therapies were reported to be within clinical trials where 232 were Phase I, 88 
trials were Phase II, 19 trials were Phase III and no trials within Phase IV. Figure 1.3 shows the four 
most targeted diseases according to trial phase from active cell based therapies involving the use 
of MSCs as described by Heathman et al., (2015a). 
Clinical studies detailing the use of MSCs will be discussed within this review specifically in the 
context of orthopaedic pathology, particularly bone and joint injury, osteoarthritis and chondral 
defects, spinal cord injury and its sequalea, namely pressure ulcers and skin wound healing. In these 
cases, disease aetiology, current treatments, as well as current or possible MSC therapies will be 
briefly described.  
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Figure 1.3: Active cell based therapy clinical trials involving MSCs. 
A total of 382 of 1342 cell based therapies involved the use of MSCs. These MSCs were isolated 
from a variety of tissues. The cell based therapies were divided into 18 clinical categories and the 
four most targeted diseases are shown above according to trial phase development. Figure adapted 
from Heathman et al., (2015a). 
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1.3.1 Orthopaedic Pathologies 
Bone and joint injury, especially fracture non-union: 
Five-20% of all bone fracture cases are associated with unsuccessful union of the fracture leading 
to fracture non-union or delayed healing (Tzioupis and Giannoudis, 2007). Bone repair due to 
fracture involves a series of complex, but well-coordinated processes. These processes are 
characterised by cellular and molecular events in a four-stage model as proposed by Schindeler et 
al (2008). These stages involve; an initial inflammatory response, soft callus formation, and hard 
callus formation, followed by initial bone union and remodelling (Schindeler et al., 2008). The 
different stages and cellular participation during each stage of fracture repair are shown in Figure 
1.4. 
The inflammatory response details the disruption of the local tissue integrity, interruption to 
normal vascular function, and a distortion of the marrow architecture. This disruption is met by an 
influx of inflammatory cells and a plethora of cytokines and growth factors, further recruiting 
additional inflammatory cells. This leads to the recruitment, migration and invasion of MSCs 
implicated in bone formation and repair. An uncontrolled or insufficient inflammatory response or 
lack of reparative cells can lead to further complications at such an early stage.  
The second stage of bone fracture healing sees the influx of fibroblasts and chondrocytes forming 
a semi-rigid soft callus. This is accompanied by three stages of tissue regeneration; replacement of 
cartilage matrix by mesenchymal-derived chondrocytes, the expression of growth factors and bone 
morphogenetic proteins (BMPs) stimulating fibroblastic proliferation and chondrogenic 
differentiation, as well as an increased production of extracellular matrix proteins by the 
chondrocytes. Vascular invasion is also observed. Reforming the bone structure and extracellular 
matrix is crucial at this point, thus disruption or inhibition of healing would be detrimental to the 
overall outcome. 
~ 34 ~ 
 
The most active stage of cellular osteogenesis occurs during hard callus formation. The presence of 
osteogenic factors leads to osteoprogenitor cell differentiation into mature osteoblasts resulting in 
synthesis of mineralised extracellular bone matrix. These osteoprogenitor cells are thought to come 
from the periosteum, bone marrow, circulation, and vasculature. Failed recruitment of 
osteoprogenitor cells can therefore slow down or halt bone formation within the wound site. 
The final stage of fracture healing involves remodelling the hard bony callus into cortical or 
trabecular bone by osteoclastic resorption and osteoblastic bone reformation. This process is a very 
complex balancing act of pro and inhibitory cytokines and growth factors affecting osteoclast 
differentiation, survival and activity. Osteoblast involvement is also crucial (Schindeler et al., 2008). 
There is great potential for cellular therapy throughout these different stages of wound healing and 
regeneration. Notably, the introduction of cells may begin the repair process earlier or facilitate 
recruitment of repairing cells, stimulate extracellular matrix formation, as well as increase the 
potential to better co-ordinate osteoblast and osteoclast function. 
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Figure 1.4: The four stage model of fracture repair and the cellular participants. 
Representative images of histology sections of tissue during the 4 different stages of fracture 
healing are shown in the top four panels, from inflammation at stage 1 (left panel) through soft 
callus formation at stage 2 (second from left panel) and hard callus formation during stage 3 (third 
from left panel) to the stage of bone remodelling in stage 4 (right panel). The contributions of many 
different cells during the fracture repair process are shown below the panels. Notably, MSCs start 
to play a role within fracture repair from the end of stage 1, differentiating into osteoblasts at 
approximately stage 2 to 3, through to the remodelling of the bone in stage 4. Figure adapted from 
Schindeler et al., (2008). 
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The use of MSCs for the treatment of fracture non-union:  
According to their radiological criteria, fracture non-unions can be classified as; hypertrophic non-
unions showing inadequate mobility but with sufficient blood supply, or atrophic non-unions 
defined as a non-union which is poorly or inadequately vascularized (Megas, 2005, Sun, Yuan and 
Zhang, 2011). Current treatments for fracture non-union include bone autograph to augment bone 
healing (which is the gold standard treatment), the use of osteoinductive or osteoconductive 
capabilities (such as demineralised bone matrix), the use of stimulatory proteins or growth factors 
(such as BMPs) to stimulate osteoblast activity at the site of non-union, as well as the use of and 
physical stimulation (Bajada et al., 2009, Gómez-Barrena et al., 2015). 
Recruiting MSCs to the site of injury is crucial to the healing process, allowing regeneration of 
osteoblasts and re-mineralisation of the fracture site. Sun, Yuan and Zhang, (2011) reported finding 
MSCs at the site of atrophic non-union, though at low levels, and noting that treatment may need 
to focus on the reactivation of endogenous MSCs as well as transplant of autologous MSCs (Sun, 
Yuan and Zhang, 2011).  
It should be noted that MSC are currently being used to treat patients with fracture non-unions 
(Bajada et al., 2007, Rastegar et al., 2010, Centeno et al., 2011, Cox et al., 2011). Treatment involves 
in vitro culture expansion of autologous MSCs or stromal cells isolated from the patient’s bone 
marrow for a period of approximately 3 weeks, followed by transplantation into the fracture site. 
Successful treatment of a 9 year tibial non-union has already been demonstrated by Bajada et al., 
(2007), when autologous MSCs were culture-expanded in vitro then transplanted into the fracture 
site mixed with calcium sulphate pellets. Two years post-operative examination showed full weight 
bearing capabilities, and radiography showed union across the fracture (Bajada et al., 2007).  
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Chondral defects and autologous chondrocyte implantation: 
Chondral defects usually occur after sports injuries. Following a traumatic injury, chondrocytes are 
irreversibly lost leading to an unbalanced articular cartilage environment and an increase in 
inflammation, which may ultimately lead to osteoarthritis (OA). As reported by Trattnig et al., 
(2005) a retrospective review of over 30,000 knee arthroscopies reported that 63% of patients had 
chondral lesions, 20% of patients had full-thickness articular cartilage lesions with exposed bone, 
of which, 5% occurred in patients under 40 years old (Curl et al., 1997, Trattnig et al., 2005).  
Symptomatic relief or repair of articular cartilage lesions include; osteochondral cylinder 
transplantation (mosaicplasty), marrow stimulation (microfracturing), arthroscopic lavage and 
debridement, or ACI following a surgical clean-up of the joint to re-establish the cartilage layer 
(Brittberg et al., 1994, Roberts et al., 2003, Noth, Steinert and Tuan, 2008, Falah et al., 2010). Here 
this review will focus on the use of ACI for the treatment of osteochondral defects because it 
involves the use of chondral and culture-expanded stromal cells.  
ACI is a surgical procedure performed to re-establish the chondral layer in chondral and 
osteochondral lesions in joints. This technique involves four stages of treatment. Firstly, the defect 
is cleaned by debridement of the cartilage, and then some articular cartilage is harvested from a 
less-weight-bearing area of the joint through a separate arthroscopic incision. Thirdly, following 
enzymatic digestion of the cartilage biopsy, harvested chondrocytes are culture-expanded in vitro 
to increase cell number. Finally, these culture-expanded cells are implanted back into the defect 
and covered with a periosteal flap or collagen membrane (Chondo-Gide®) (Marlovits et al., 2006, 
Schulze-Tanzil, 2009). This surgical procedure is illustrated in Figure 1.5.  
It is crucial to ensure the periosteal or artificial membrane is securely attached in order to prevent 
leakage of the injected cells (Kim and Shettey, 2011). New matrices and gel mixtures have been 
developed and tested to assist the successful seeding and integration of culture-expanded cells into 
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the injury site (Gibson, Mcdonnell and Price, 2006, Eyrich et al., 2007, Kim and Shettey, 2011). The 
use of ACI treatment has successfully been performed in the Robert Jones and Agnes Hunt (RJAH) 
Orthopaedic Hospital in Oswestry (Roberts et al., 2003). As a matter of fact, the mid to long term 
longitudinal outcome for patients who received ACI treatments at the RJAH orthopaedic hospital, 
reported that 81% of the treated patients presented with improved clinical outcome, with the 
remainder showing a decline. They also showed that the patient-reported clinical outcome at 15 
months is a major predictor of the mid- to long term success of the treatment (Bhosale et al., 2009).  
As noted by Hourd et al., (2008), there are currently two licensed cell based advanced therapy 
medicinal products (ATMPs) within the European market. These are MACI (matrix-induced 
autologous chondrocyte implantation), intended for the repair of cartilage defects 
(Genzyme/Sanofi, France) and ChondroCelect® (TiGenix, Belgium). Notably, since ChondroCelect® 
was the first ATMP to be registered, it may set the standard for the standard for the clinical 
development of cell based therapeutics.  
The use of MSCs for the treatment of chondral defects: 
As reported by Wakitani et al., (2007), articular cartilage defects in the patella-femoral joint were 
repaired using autologous culture-expanded BMMSC. Three weeks prior to transplantation, cells 
were isolated from the iliac crest and culture-expanded. 5x106cells/ml of single-passaged cells were 
embedded into a collagen solution, placed on a collagen sheet, transplanted into the defect and 
covered with autologous periosteum or synovium. Histological examination of one patient 12 
months following the transplantation showed a fibro-cartilaginous tissue repair (Wakitani et al., 
2007).  
Similarly, in 2010, a small study investigated the application of autologous, culture-expanded 
BMMSCs for full-thickness articular cartilage defects in five patients. Autologous BMMSCs were 
culture-expanded in vitro, approximately 15x106 cells were placed in platelet-rich fibrin glue and 
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then transplanted into full-thickness cartilage defects and covered with an autologous periosteal 
flap. All patients experienced symptom improvement over the course of 12 months post procedure, 
and the two patients who consented to arthroscopy had nearly normal International Cartilage 
Repair Society (ICRS) arthroscopic scores (Haleem et al., 2010).  
Other trials are also examining the use of MSCs for the repair and regeneration of chondral defects. 
A phase II-III clinical trial being conducted in Cairo (NCT00891501), is examining “The Use of 
Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects”. 
Within this study, autologous bone marrow is aspirated from the patient’s iliac crest, from which 
BMMSCs are isolated and culture-expanded for 2-3 weeks in vitro. Then these culture-expanded 
BMMSCs are pelleted and implanted into the osteochondral knee defect and covered with an 
autologous periosteal flap from the proximal tibia and finally the wound is sealed with human fibrin 
glue. 
An investigation was performed by Kohli et al., (2015), examining the incorporation, growth and 
chondrogenic potential of BMMSCs and ATMSCs within 2 scaffolds, Chondro-Gide and Alpha 
Chondro Shield. They noted that more BMMSCs and ATMSCs adhered to and were incorporated 
into Chondro-Gide than into Alpha Chondro Shield; although this incorporation was less than 2% of 
the cells seeded, a marked increase in cell proliferation of BMMSCs and chondrogenic 
differentiation of both BMMSCs and ATMSCs was seen (Kohli et al., 2015).  
Therefore, it can be seen that the clinical application of MSCs, along with the investigation for 
improved application of MSCs, is very much at the forefront of the treatment chondral defects.    
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Figure 1.5 Autologous Chondrocyte Implantation.  
Articular cartilage is isolated from a non-weight baring region, enzymatically digested and culture-
expanded in vitro for 11-21 days. 2.6x106 - 5x106 culture-expanded cells are then injected into the 
cleaned site of injury. Traditionally a harvested periosteal membrane was used to encapsulate 
freshly injected cells; however artificial membranes (e.g. Chondro-Gide) are now commonly used 
(Kohli et al., 2015). Image from Brittberg et al., (1994). 
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Osteoarthritis: 
Osteoarthritis (OA) is a form of chronic arthritis, which affects mostly cartilage and bone, causing 
progressive loss of function leading to the eventual breakdown of articular cartilage and often 
inflammation. It is also a disease associated with age, affecting 70% of people over 65 years of age 
(Scharstuhl et al., 2007). Radiological observation shows joint space narrowing, cartilage thinning 
and defects, subchondral bone sclerosis and osteophyte formation as seen in Figure 1.6 (Luyten, 
Tylzanowski and Lories, 2009, Si et al., 2011). Understanding the biology of the cartilage-
subchondral bone unit and cellular function within the unit will help drive the potential for cell-
based regenerative therapy. 
Although the exact cause of OA is unknown, there are multiple phenotypes, which can influence 
both the initiation, and progression of the disease. For example, OA has been characterised as a 
disease of mechanics, a disease with a metabolic phenotype, a disease substantially influenced by 
inflammatory mediators as well as a disease that is driven by aberrant joint structure, morphology 
and genetics, as discussed by Andriacchi et al., (2014). Since chondrocytes make up only 1-2% of 
articular cartilage volume, regeneration is either very slow or non-existent (Glass, 2006).  
As reviewed by Roughley and Mort (2014), the structure of aggrecan (a large proteoglycan bearing 
numerous chondroitin sulfate and keratan sulfate chains which provides articular cartilage with its 
ability to withstand compressive loads) is not constant throughout life, but changes due to both 
synthetic and degradative events. These events can be viewed as detrimental to cartilage function 
and are enhanced in osteoarthritic cartilage. This results in aggrecan depletion and predisposing to 
cartilage erosion. Likewise, the up-regulated production of matrix metalloproteinases (MMPs) and 
aggrecanases, which are associated with mediators of joint inflammation and overloading, play a 
major role in aggrecan degradation. Enhancing the production of aggrecan and inhibiting its 
degradation may retard the destructive process occurring during the early stages of OA (Roughley 
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and Mort, 2014). The structure and function of aggrecan in articular cartilage and the age related 
changes in its structure can be seen in Figure 1.7. 
On a molecular level, the Wnt/β-catenin signalling pathway has been strongly implicated in both 
cartilage and bone formation and turnover in OA patients, where increased signalling leads to the 
loss of tissue structure and function through reprogramming of articular chondrocytes toward 
catabolism and unstable phenotypes (Luyten, Tylzanowski and Lories, 2009).  
The treatment of OA must deal with relieving pain associated with the large degeneration of the 
whole joint, the prevention of any further dysfunction, and assisting in the potential regeneration 
of lost tissue and restoration of function to patients. This poses quite a challenge. Current non-
pharmacological or surgical treatment for OA includes; a change of diet or increased exercise to 
encourage weight loss, ice massage, joint bracing specifically in knee OA, lateral wedge insoles, 
acupuncture, and a more extreme hypothetically beneficial treatment with electrical stimulation. 
These treatments do show some pain relief, however they do not provide a cure of OA (Glass, 2006).  
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Figure 1.6: An Osteoarthritic Knee Joint.  
A schematic illustration of the anatomy of a healthy knee joint compared to an osteoarthritic knee 
joint and an X-ray image of an osteoarthritic knee are shown, along with the typical changes 
associated with osteoarthritis. The illustration of the normal knee shows the bone marrow (dark 
brown), bone (light brown), cartilage lining the bone (clear) and the synovial membrane (orange 
band). The illustration of the osteoarthritic knee shows subchondral sclerosis within the bone (dark 
brow shading), osteophyte formation, joint space narrowing, degradation of the cartilage, as well 
as inflammation of the synovial membrane (synovitis). The X-ray was obtained from 
Radiopaedia.org care of Dr M. Osama Yonso.  
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Figure 1.7: The structure and function of aggrecan in articular cartilage and age related changes 
in its structure. 
Proteoglycan aggregates with many aggrecan molecules are depicted as being entrapped by 
collagen fibrils (A), in the relaxed state (left panel) compared to the compressed state (right panel). 
Water is displaced as a result of compression. An enlarged aggrecan molecule from a proteoglycan 
aggregate is shown with the different domains of the aggrecan core protein (B). Changes in 
aggrecan structure can also be seen for the synthesis and degradation of aggrecan molecules (C). 
Image adapted from Roughley and Mort, (2014). 
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Pharmacological treatments usually function as pain management and relief for OA. Such 
treatments include topical applications of anti-inflammatories, oral anti-inflammatories, and the 
use of natural compounds for pain management or wound therapy, reviewed by Glass, (2006). One 
‘non-surgical’ procedure reviewed by Glass (2006) is an intra-articular injection of hyaluronic acid 
for short-term treatment increasing the viscoelasticity of the synovial fluid in the knee providing 
symptomatic relief. It has been reported that following intra-articular injections of hyaluronic acid 
(HA) into patients with OA, that the presence of activated CD4 T cells and Th17 (CD4+CXCR3-CCR6+) 
cells were lowered (Lurati et al., Article in press, 2014). This confirms the immunological and 
inflammatory involvement with OA. 
Surgical treatments include arthroscopic surgery to trim torn and damaged cartilage (arthroscopic 
debridement), realignment of a joint to alter its weight bearing properties (osteotomy), or total 
joint replacement. Unfortunately these treatments still do not completely cure the problem (Glass, 
2006).  
The use of MSCs for the treatment of osteoarthritis:  
Comparative treatment of MSC transplantation for OA and ACI for chondral defects are in principle 
much the same, however, it is worth remembering that ACI is used for the repair of focal chondral 
defects within relatively healthy joints, where as an osteoarthritic joint has a hostile inflammatory 
environment with a much larger defect area. Therefore, MSCs may be more suitable for this 
treatment due to their anti-inflammatory activity (Caplan and Correa, 2011b).  
The capacity of MSCs for chondrogenic and osteogenic differentiation, their proliferative potential, 
the ability of MSC to promote endogenous wound healing, along with their anti-inflammatory 
functions, makes them very attractive for use within cell based regenerative treatments of OA (Si 
et al., 2011) . However, Noch et al., (2008) explains some of the challenges and requirements that 
need to be met for the successful, clinical use of MSCs to treat OA. For example, the delivery system 
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of the cells to the site of disease may be performed by either direct intra-articular injection or by 
graft of an engineered construct derived from a cell-seeded scaffold (Noth, Steinert and Tuan, 
2008).  
One issue facing the use of MSC transplantation for OA, is the viability and differentiation capability 
of MSCs isolated from elderly patients. However, Scharstuhl et al., (2007), demonstrated that 
sufficient MSCs could be isolated from aged patients, which possessed adequate chondrogenic 
differentiation potential (Scharstuhl et al., 2007). This was similarly reported for the osteogenic 
potential of MSCs in vitro and in vivo (Siddappa et al., 2007). However, Choudhery et al., (2014) 
reported contradicting results showing a significantly reduced differentiation potential for MSCs 
isolated from aged patients (>60 years old) when compared to those isolated from young patients 
(<30 years old) (Choudhery et al., 2014).  
According to clinicaltrails.gov, there are currently 38 open and closed studies with a known status, 
involving the use of MSCs for the treatment of OA. One such study conducted in Spain 
(NCT01586312) is a multi-centre, phase I-II clinical trial; which is randomised, blinded, and 
controlled. Within this study, patients in the experimental arm were given an intra-articular 
transplantation of 40x106 autologous MSCs expanded in vitro for 3-4 weeks, according to GMP-
compliant procedures. The clinical outcome at the first and 2nd year follow ups reported that 
patients exhibited rapid and progressive improvement of algofunctional indices that approached 
65% to 78%, comparing favourably with the results of conventional treatments. Additionally, 
quantification of cartilage quality by T2 MRI relaxation measurements demonstrated a highly 
significant decrease of poor cartilage areas (on average, 27%), with improvement of cartilage 
quality in 11 of the 12 patients (Orozco et al., 2013, Orozco et al., 2014). 
Therefore, it can be seen that MSCs are currently being used within regeneration of OA and ACI.   
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1.3.2 Spinal Cord Injury and its sequalea, namely pressure ulcers 
Spinal Cord Injury (SCI) results in disruption of the blood brain barrier, neuronal cell death, scarring 
and a loss of functional mobility or sensation (Ramer, Harper and Bradbury, 2000). SCI damage can 
result from direct trauma (e.g. car accidents), degeneration of the surrounding bone (e.g. 
osteoporosis) or disease (e.g. polio). Upon axonal damage in the central nervous system, an 
inflammatory response is initiated accompanied by an influx of inflammatory cells (Popovich et al., 
2002) and expression of toxins such as matrix metalloproteinases (MMPs) (Noble et al., 2002). This 
very high reactive response leads to secondary cell death. The inflammatory response may then 
lead to the formation of a cyst cavity, glial scarring involving astrocytes and oligodendrocytes, and 
demyelination. Subsequently axonal re-growth and neuronal function is inhibited (Willerth and 
Sakiyama-Elbert, 2008, Wright et al., 2011).  
Following injury, immediate medical attention is given and the patient immobilised, preventing 
further damage. After medical assessment and based on the severity of the injury, treatments may 
focus on targeting inflammation in the acute period with drugs such as methylprednisilone (Trivedi, 
Olivas and Noble-Haeusslein, 2006, Kim, Caldwell and Bellamkonda, 2009). Treatments may also 
target the inhibitory matrix (glial scar) in the sub-acute/chronic stage, for example, with enzyme 
infusion of chondroitinase ABC (Bradbury et al., 2002). 
Current cell therapies for SCI: 
After initial mechanical injury, secondary injuries in the wound include ischaemia, inflammation, 
apoptosis and free radical mediated cell death. Treatment of the SCI requires therapies to address 
this secondary injury cascade as well as replacing lost cells, bridging gaps in the cord and inhibiting 
scarring of the wound (Willerth and Sakiyama-Elbert, 2008). Many cell types have been investigated 
in the context of SCI. As reviewed by Willerth and Sakiyama-Elbert, (2008), human and mouse 
BMMSCs and olfactory ensheathing cells (OECs) have been examined to reduce scar and cyst 
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formation in animal models, which lead to a clinical trial of human autologous OECs being 
performed in Australia; Schwann cells and ESC-derived oligodendrocytes have also been examined 
for re-myelination and possible bridging within the wound in animal models (Willerth and 
Sakiyama-Elbert, 2008).  
Similarly, human neural stem cells (NSCs) have been examined (Enzmann et al., 2005), especially to 
replace lost and damaged neurons. In 2009, the US Food and Drug Administration (FDA) approved 
the use of Geron Corporation’s product - GRNOPC1 for the treatment of SCI (Alper, 2009). As a part 
of the clinical trial (clinicaltrials.gov, NCT01217008), recruited patients were intended to receive a 
single injection of 2x106 GRNOPC1, which are oligodendrocytes differentiated from human ESCs 
(Keirstead et al., 2005). However, in 2011, Geron announced that the trial was to be completely 
terminated owing to financial concerns (Frantz, 2012). 
MSC implantation for SCI: 
MSCs’ immunosuppressive nature, ease of isolation and expansion, expression of growth and 
neurotrophic factors, as well as ability to provide a supportive environment for regeneration 
strongly support their use within regenerative cell therapies for SCI (Wright et al., 2011). However 
the trans- differentiation of MSC along glial or neuronal pathways to act as replacement cells within 
SCI is a matter of much debate and research (Lu and Tuszynski, 2005).  
Clinical trials which have been conducted on humans include the use of autologous OECs (Féron et 
al., 2005, Mackay-Sim et al., 2008), Schwann cells (Saberi et al., 2008), BMMSCs (Wright et al., 2011) 
and ATMSCs (Ra et al., 2011). The long-term safety of autologous culture-expanded BMMSCs has 
been reported, as determined by MRI and the absence of permanent complications associated with 
the transplant (Park et al., 2012).  
~ 49 ~ 
 
Pressure ulcers associated with SCI: 
Pressure ulcers (also known as decubitus ulcers) are a major complication associated with SCI, as 
patients with neurological deficits maybe immobilised and without sensation. Ulcers are also 
common amongst neuropathic, diabetic and aged patients. Pressure ulcers can be described as a 
breakdown of the layers of skin and underlying tissue occurring as a result of excessive pressure, 
compression, friction and shear forces between a bony prominence and an external surface for 
extended periods of time (Grey, Harding and Enoch, 2006). Sites of ulceration are usually located 
around the sacrum, heels, hips and other compression points experienced when patients lie in the 
supine, prone or lateral position, as shown in Figure 1.8. These pressure ulcers significantly increase 
the risk of patients developing further medical complications such as gangrene. Prevention of 
ulceration is the first stage of treatment, initially by regular turning of the patient, ensuring not to 
apply sheer stress to the areas of compromised tissue structure (Grey, Harding and Enoch, 2006, 
Reddy, Gill and Rochon, 2006).  
Within the Consortium for Spinal Cord Medicine Clinical Practice Guidelines., (2001), surgical 
debridgement of necrotic or devitalised tissue should be undertaken when appropriate. It is then 
essential to dress the wound, maintaining a moist environment allowing the wound to heal.  
The use of MSCs for the treatment of pressure ulcers 
The treatment of pressure ulcers with autologous BMMNCs in patients with SCI reported that 
wounds treated with the cells were fully healed within an average time of 21 days. No unresolved 
ulcers recurred when examined during the follow-up of 19months (Sarasua et al., 2011).  
Likewise, a recent  study performed by (Dulamea et al., 2015) reported a single case study where 
autologous BMMSCs were used to treat a patient with two stage IV pressure ulcers on his legs due 
to neuromyelitis optica induced paraplegia. BMMSCs were isolated and culture expanded in vitro 
through three passages, then embedded into a tridimentiosnal collagen-rich matrix applied to the 
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wound. Complete epithelisation of the left lateral femoral pressure ulcer was observed within 2 
months of treatment and within 5 months, the left malleolar pressure ulcer completely healed 
restoring normal function to the ankle. No relapse or adverse effects were reported up to 76 
months following treatment. Surprisingly, the patient also experienced a sustained remission and 
improvement of the neuromyelitis optica associated disability, which may be explained due to the 
promotion and optimization of recovery mechanisms within the central nervous system (Dulamea 
et al., 2015). 
The comparison of BMMSCs with BMMNCs for treatment of diabetic critical limb ischemia and foot 
ulcer within a double-blind, randomised, controlled trial was recently published (Lu et al., 2011). 
They reported that BMMSC treated wounds healed much faster than those treated with BMMNCs; 
likewise, the 24 week follow-up showed that BMMSCs also significantly improved limb perfusion.  
Therefore, it can be seen that MSCs along with many other cell types are within clinical application 
or investigation towards the treatment of both SCI and pressure ulcers.    
~ 51 ~ 
 
 
Figure 1.8: Common incidence site for pressure ulceration. 
The schematic illustration shows the common areas for pressure ulcers incidence. Pressure ulcers 
are caused by a local breakdown of soft tissue because of compression between a bony prominence 
and an external surface. They usually develop on the lower half of the body. The three laying down 
positions shown (supine, prone and lateral) highlight bony prominences which are likely to develop 
into areas of ulceration. Image adapted from Grey, Harding and Enoch, (2006). 
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1.3.3 MSC and skin wound healing 
Skin wound healing is a dynamic process classically divided into three overlapping phases; 
inflammation, proliferation, and remodelling which involves interactions between epidermal and 
dermal cells, fibroblasts, inflammatory cells, blood cells, the extracellular matrix and angiogenesis 
(Harding, Morris and Patel, 2002). These interactions are coordinated by an array of cytokines and 
growth factors. Inflammation is predominately associated with wound clean up. Proliferation 
focuses on restoring the barrier function of the skin, by an incredible interplay between inward 
migrating fibroblasts, synthesis of new extracellular matrix, degradation of old extracellular matrix, 
re-epithelialisation and wound closure. Remodelling of the wound occurs over time, observing a 
reduction in inflammation and reformation of controlled blood flow into the scar tissue (Harding, 
Morris and Patel, 2002, Metcalfe and Ferguson, 2007).  
MSC-based therapies have shown accelerated wound closure with increased epithelialization, 
connective tissue formation and angiogenesis, as reviewed by Hocking and Gibran, (2010). MSCs 
are recruited into the wounded skin and contribute to the wound repair by trans-differentiation 
into multiple skin types (Sasaki et al., 2008). MSCs’ enhancing abilities in wound healing have been 
thought to occur by differentiation into epidermal keratinocytes, endothelial cells and pericytes 
which contribute to regeneration of damaged tissue. Their contribution towards the regulation of 
local responses to injury through paracrine signalling, such as the secretion of interleukin-6 (IL-6), 
IL-8, transforming growth factor-β (TGF-β), monocyte chemotactic protein-1 (MCP-1) and RANTES 
has also been shown (Hocking and Gibran, 2010, Walter et al., 2010).  
The uses of MSCs in skin wound healing are still being tested clinically. The Sheba Medical centre in 
Israel will soon be recruiting patients for a study aimed at examining the safety of allogeneic 
BMMSC for the treatment of diabetic foot ulcers (ClinicalTrials.gov NCT01686139). Within this 
study, patients who have type I or type II diabetes mellitus, with a diabetic foot ulcer will be treated 
with up to 20x106 culture-expanded allogeneic BMMSCs.  
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1.4 MSCs as an ATMP and production within GMP 
As shown, MSCs, as well as many other cells, are currently being used or researched for their 
application in cell based therapies; however, it should be noted that within the clinical studies 
reported, very little mention was made regarding the screening for safe provision of the cells within 
the clinical trials, prior to their re-transplantation.  
Likewise, within a study examining the clinical application of autologous culture-expanded BMMSCs 
for the treatment of articular cartilage defects, the culture-expanded MSCs were characterised by 
their adhesive fusiform (spindle-like) shape and by flow cytometry for MSC specific markers; yet no 
mention was made regarding the screening method, protocol or standard release criteria of the 
‘characterised fusiform shaped cells’ for potential tumorigenic transformation (Haleem et al., 
2010).  
On the other hand, the phase I-II study conducted in Spain (NCT01586312), examining autologous 
BMMSCs for the treatment of OA within the knee, did specify that cells were produced according 
to current Good Manufacturing Practice (GMP) standards. Notably, that bone marrow collection 
from patients, mesenchymal cells’ isolation and expansion under GMP conditions were conducted 
according to the IBGM-Valladolid protocol (Instituto de Biologia y Genetica Molecular, University 
of Vallavdolid, Spain); however, there is little information available regarding the specifics of these 
protocols. Only a brief mention of the examination of the morphology of the cells is referenced 
according to a previous study (Orozco et al., 2011, Orozco et al., 2013). 
According to the ‘article in press’  (Soler et al., 2016) reporting results from a very similar clinical 
study (NCT01183728), autologous MSCs were manufactured according to GMP (Banc de Sang i 
Teixits, Barcelona, Spain) and delivered as the product named XCEL-M-ALPHA, towards the 
treatment of osteoarthritis of the knee (Soler et al., 2016). Within this study, prior to release of the 
cell product, the MSC suspension was only tested for bacteria and endotoxin before infusion. 
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MSC are now considered as Advanced Therapy Medicinal Products (ATMPs) by the European 
Medicines Agency (EMA) according to regulation No. [EC] 1394/2007 of the European Commission) 
(European Parliament, 2007); therefore, these cells must be produced in compliance with GMP 
standards.  
The UK Medicines and Healthcare Products Agency (MHRA) participated in the production of a 
regulatory route map for stem cell research and manufacture, as shown in Figure 1.9. This route 
map was developed by the Department of Health with the support of regulatory bodies and the 
Gene Therapy Advisory Committee. This interim UK regulatory route map is intended to be a 
reference tool for those who wish to develop a program of stem cell research and manufacture 
ultimately leading to clinical application. As shown, non-genetically modified MSCs intended for use 
within humans, and manufactured into an ATMP, must be produced as GMP compliant according 
to a GMP license from the MHRA.  
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Figure 1.9: Illustrative UK regulatory route map for stem cell research and manufacture. 
Abbreviations: HTA, human tissue authority; NHS, National Health Service; GLP, Good Laboratory 
Practice; GMP, Good Manufacturing Practice; R&D, Research and Development; HFEA, The Human 
Fertilisation and Embryology Authority; REC, Research Ethics Committee; ATMP, Advanced Therapy 
Medicinal Products; EMEA, European Medicines Agency; EudraCT, a database of all clinical trials 
commencing in the European Union from May 1, 2004 onward. (See 
http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON041337) 
Figure adapted from Goldring et al., (2011). 
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The GMP standards are intended to ensure the provision of somatic or xenogeneic cells for cell-
based therapies and tissue engineering products are produced or re-produced under the highest 
level of sterility, quality control and documentation following a standard operating procedure. 
These defining standards are listed below:  
1. Where they are available, authorised sources (i.e. authorised medicinal products or CE marked 
medical devices) of additional substances (such as cellular products, bio-molecules, 
biomaterials, scaffolds, matrices) should be used in the manufacture of these products. 
2. Where devices, including custom-made devices, are incorporated as part of the products: 
a. There should be written agreement between the manufacturer of the medicinal product and 
the manufacturer of the medical device, which should provide enough information on the 
medical device to avoid alteration of its properties during manufacturing of the ATMP. This 
should include the requirement to control changes proposed for the medical device. 
b. The technical agreement should also require the exchange of information on deviations in the 
manufacture of the medical device.  
3. Since somatic cells are obtained either from humans (autologous or allogeneic) or from 
animals (xenogeneic), there is a potential risk of contamination by adventitious agents. Special 
considerations must be applied to the segregation of autologous materials obtained from 
infected donors. The robustness of the control and test measures put in place for these source 
materials should be ensured.  
4. Manufacturing steps should be conducted aseptically where sterilisation of the finished 
product cannot be achieved using standard methods such as filtration.  
5. Careful attention should be paid to specific requirements at any cryopreservation stages, e.g. 
the rate of temperature change during freezing or thawing. The type of storage chamber, 
placement and retrieval process should minimise the risk of cross-contamination, maintain the 
quality of the products and facilitate their accurate retrieval. Documented procedures should 
be in place for the secure handling and storage of products with positive serological markers. 
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6. Sterility tests should be conducted on antibiotic-free cultures of cells or cell banks to provide 
evidence for absence of bacterial and fungal contamination and consider the detection of 
fastidious organism.  
7. Where relevant, a stability-monitoring programme should be in place together with reference 
and retain samples in sufficient quantity to permit further examination. 
Similarly, for biological medicinal products with a short shelf life (a period of approximately 14 days 
or less, and which need batch certification before completion of all end product quality control tests 
(e.g. sterility tests), a suitable control strategy must be in place. “Such controls need to be built on 
enhanced understanding of product and process performance and take into account the controls 
and attributes of starting and raw materials. The exact and detailed description of the entire release 
procedure, including the responsibilities of the different personnel involved in assessment of 
production and analytical data is essential. A continuous assessment of the effectiveness of the 
quality assurance system must be in place including records kept in a manner which permit trend 
evaluation. Where end product tests are not available due to their short shelf life, alternative 
methods of obtaining equivalent data to permit initial batch certification should be considered (e.g. 
rapid microbiological methods). The procedure for batch certification and release may be carried 
out in two or more stages:  
a) Assessment by designated person(s) of batch processing records, results from 
environmental monitoring (where available) which should cover production conditions, all 
deviations from normal procedures and the available analytical results for review in 
preparation for the initial certification by the Qualified Person.  
b) Assessment of the final analytical tests and other information available for final certification 
by the Qualified Person.  
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A procedure should be in place to describe the measures to be taken (including liaison with clinical 
staff) where out of specification test results are obtained. Such events should be fully investigated 
and the relevant corrective and preventive actions taken to prevent recurrence documented.” 
These standards were taken from the document “EudraLex, The Rules Governing Medicinal 
Products in the European Union, Volume 4, EU guidelines for Good Manufacturing Practice for 
Medicinal Products for Human and Veterinary Use, Annex 2 - Manufacture of Biological active 
substances and Medicinal Products for Human Use. B10. Somatic and xenogeneic cell therapy 
products and tissue engineering products” The document provides guidance for the interpretation 
of the principles and guidelines of GMP for medicinal products as laid down in Directive 2003/94/EC 
for medicinal products for human use and Directive 91/412/EEC for veterinary use 
(http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm).  
The standard mentioned in point 7 above leaves room for ambiguity and misunderstanding. The 
tools for investigating the ‘stability-monitoring programme’ are not clearly and strictly defined, thus 
it is difficult to set an appropriate level of ‘release criteria’.  
It should also be noted that due to the quality control and release criteria depending on a ‘Qualified 
Person’, these may be seen subjectively between assessments, as well as they may vary between 
examiners.  
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1.5 The need to screen cells intended for cell therapies 
Every step in the process of developing cell based therapies requires rigorous scrutiny, from the 
origin and isolation of the cells used through expansion, manipulation, and preclinical evaluation to 
eventual engraftment into the host. To achieve this, genetic and phenotypic profiling is required, 
along with the analysis of cell differentiation status or capacity and the cell’s bio-distribution 
potential to ensure the clinical effects are predictable and controllable, as shown in Figure 1.10 
(Goldring et al., 2011). 
As the passage number of cell lines increase and the culture conditions change, so too does the 
potential for chromosomal aberrations, therefore it is important to minimize and monitor culture 
time and environment. MSCs as well as human pluripotent stem cells (PSCs, i.e. iPSCs and ESCs), all 
of which are being investigated for clinical applications, have been reported to accumulate 
chromosomal aberrations during initial and extended in vitro culture expansion, which can lead to 
the accumulation of chromosomal, subchromosomal and single-base level abnormalities (Mayshar 
et al., 2010, Ben-David, Mayshar and Benvenisty, 2011, Gore et al., 2011, Hussein et al., 2011, Lister 
et al., 2011, Pera, 2011).  
A study conducted by Hussein et al., (2011) regarding the potential use of iPSCs towards clinical 
therapy, reported that significantly more copy number variations (CNVs) were present in early stage 
iPSCs than intermediate passage iPSCs, fibroblasts and ESCs; however, although most of the CNVs 
were seen to form de novo during the iPSC reprogramming process, the expansion of the cells 
selected against these mutated cells, ultimately driving the population towards a state resembling 
ESCs. Gore et al., (2011) focused on reprogramming-associated mutation effects on iPSCs at the 
single nucleotide level. They reported that pre-existing and new mutations occurred during and 
after reprogramming of the cells, and that simply re-programming the cells may not be the cause 
to the observed mutations, but that selection during reprogramming, colony picking and 
subsequent culturing may be the contributing factors (Gore et al., 2011).  Similarly, Lister et al., 
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(2011) found that the epigenome of iPSCs featured variable reprogramming, incomplete 
reprogramming of DNA methylation; as well as cells which retained their somatic cell memory.  
Global gene expression analysis of iPSCs and ESCs chromosomal integrity reported a substantial 
number of cell lines examined, had full or partial chromosomal aberrations. Several of these 
aberrations resulted from adaptation of the cells to culture expansion. The analysis also revealed a 
high incidence of duplicated chromosome 12, resulting in a significant enrichment for cell cycle-
regulated genes (Mayshar et al., 2010).  
A similar and in-depth study using global gene expression analysis of the genetic integrity of over 
400 human multipotent stem cells revealed that MSCs, PSCs and NSCs acquired characteristic 
large chromosomal aberrations within a few passages of culture expansion, as illustrated in  
Figure 1.11 (Ben-David, Mayshar and Benvenisty, 2011). One such chromosomal abnormality 
detected in two MSC cell lines, was a monosomy of chromosome 13, which lead to the significant 
down-regulation of retinoblastoma (RB1) which is located on chromosome 13q14. This particular 
chromosomal deletion has been similarly seen in mesenchymal tumours (Yamaguchi et al., 1996, 
Dahlen et al., 2003).  
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Figure 1.10: Workflow for stem cell-derived therapeutic development. 
Genetic and phenotypic analysis must be a continuous process throughout product development, 
and differentiation status and bio-distribution potential need to be tracked closely to ensure clinical 
effects are predictable and controllable. Figure from Goldring et al., (2011). 
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Figure 1.11: Different types of stem cells acquire distinct chromosomal 
aberrations.  
(A–C) Ideograms representing the chromosomal aberrations identified in 
(A) PSCs, (B) MSCs, and (C) NSCs. Bars to the right of the chromosome 
represent gains, and bars to the left of the chromosome represent 
deletions. In the ideogram of PSCs (A), red and orange represent human 
ESCs and iPSCs, respectively. (D–F) Some of the recurrent aberrations 
detected in stem cells are the most common aberrations in tumours of the 
same tissue origin. The frequency of chromosomal aberrations in various 
types of tumours was calculated using the National Cancer Institute 
‘‘Recurrent Chromosomal Aberrations in Cancer Database. Figure from 
Ben-David, Mayshar and Benvenisty, (2011).  
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Extended culture increases the potential for cell transformation, (although, to the author’s best 
knowledge, this has not yet been observed or reported within MSCs), or ultimately contamination 
by other cell types could lead to population transformation (Bernardo et al., 2007, Rubio et al., 
2008a, Garcia et al., 2010). In 2005, Rubio et al., reported the spontaneous malignant 
transformation of human MSCs following extended culture in vitro (4-5 months), shown in Figure 
1.12 (Rubio et al., 2005). This report was followed by a counter-report, arguing and reporting the 
safety of BMMSCs through extended culture expansion (Bernardo et al., 2007). Rubio and co-
workers subsequently published two more reports supporting the earlier finding of spontaneous 
MSC transformation by characterising the genetic changes of the transformed cells using 
microarrays (Rubio et al., 2008b) and protein analysis (Rubio et al., 2008a). ,A two-centred study 
conducted by other researchers, i.e. Rosland et al., (2009) also reported the spontaneous 
transformation of MSCs, which was characterised by increased proliferation rate, altered 
morphology and a malignant phenotype (Rosland et al., 2009). However, after a more extensive 
examination of these cells, it was discovered that the MSC population had been contaminated with 
the human fibrosarcoma connective tissue cell line, HT1080 cells (Garcia et al., 2010). This finding 
of contamination of MSC cultures with tumour cell lines was also suggested to be the case in the 
initial study by (Rubio et al., 2005), ultimately leading to retractions of these previously published 
findings (Torsvik et al., 2010). 
There are distinct categories of malignant bone tumours: osteosarcoma, chondrosarcoma, Ewing's 
sarcoma, spindle cell sarcoma, sarcoma (not otherwise specified), chordoma, with the remainder 
composed of rare variants. Osteosarcoma, chondrosarcoma and Ewing's sarcoma collectively 
represent approximately 75% of the cases. Evidence exists to support an MSC as well as committed 
osteoblast precursors as the cell of origin for osteosarcoma. Increasing numbers of experimental 
models have begun to shed light on to the likely cell population that gives rise to osteosarcoma in 
vivo with the weight of evidence favouring an osteoblastic population as the cell of origin rather 
than an undifferentiated MSC (Gibbs et al., 2005, Mutsaers and Walkley, 2014). 
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Figure 1.12: Transformed Mesenchymal Cell (TMC) Characterization.  
The evolution of MSC morphology (A) is shown during in vitro culture (left to right), from a normal 
morphological appearance, through a cell crisis phase, to a transformed mesenchymal cell (TMC). 
G-banded karyotype analysis (B) of a normal MSC line (left) presented with a normal 2n karyotype, 
i.e. 46 chromosomes, including the XY chromosomes; whereas, 30% of post-senescence/pre-crisis 
MSC line presented with 47 chromosomes, including the XY chromosomes, and trisomy of 
chromosome 8. Figure from Rubio et al., (2005) (article retracted (Torsvik et al., 2010). 
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An interesting study showed that induced expression of the Ewing’s sarcoma EWS-FLI-1 fusion gene 
within human MSCs was stably maintained by the cells and induced a gene expression profile 
bearing striking similarity to that of Ewing’s sarcomas. They further hypothesised that this 
expression of EWS-FLI-1 in the MSCs may recapitulate the early steps in Ewing’s sarcoma 
development and pathogenesis (Riggi et al., 2008). 
Although it was shown that the supposed transformed MSCs observed by Rubio et al., (2005) 
(article retracted (Torsvik et al., 2010)) had not in fact transformed, but had rather been 
contaminated; and although it has also been reported and shown that MSCs do not undergo 
spontaneous transformation and are safe for clinical cell based therapies (Prockop and Keating, 
2012, Sensebé et al., 2012), these studies have highlighted the need to safely monitor and screen 
cells during in vitro culture expansion. 
Bearing this in mind, some exemplary studies addressing the safety of MSCs were performed by 
Fekete et al., (2012a). Initially, they established an animal-free expansion protocol using haemo-
derivate platelet lysate (PL) as a medium supplement rather than xenogeneic additives, such as 
foetal calf serum (FCS) which is still widely utilised for cell culture and associated with many risks 
regarding its use in the clinical context (Fekete et al., 2012a). They were able to confirm the safety 
and feasibility of PL intended for large-scale MSC isolation and expansion. Then, having eliminated 
animal products from their cultivation system, they further optimised their procedural-steps and 
developed five GMP-compliant standardized protocols, which were designed for the safe, reliable, 
efficient and economical isolation and expansion of BMMSCs for clinical application (Fekete et al., 
2012b). When they performed sterility tests and monitored cell stability, they reported that all 
samples (freshly isolated BM, intermediate cultured cells, and final harvested cells), were negative 
following BacT/ALERT testing, endotoxin concentrations of all samples were less than 1 I.U./mL and 
no chromosomal abnormalities were found by karyotyping in any of the large-scale expansions of 
cultures analysed.  
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Within this study Fekete et al., (2012b) did determine clonogenicity by performing the CFU-F assays, 
performed quality controls on starting, intermediate and final products by testing sterility and 
endotoxin concentrations, characterised the cells intended for clinical application by examining the 
chemokine and integrin receptor and characterised the MSCs by flow cytometry for specific 
phenotypic expression. This suggests that the MSCs produced from the examined systems were 
safe, truly MSCs and showed equal characteristics of homing and adhesion. However, visualisation 
of the cell throughout the culture period would have provided further colony characterisation, cell 
specific behaviour, as well as identifying potential tumorigenesis or abnormal cell behaviour. 
Similar studies were performed by Heathman et al., (2015b) and (2016b) examining the use of 
human PL or serum free media (SFM) as an alternative to FCS, improving product yield and 
highlighting the need for consistency of MSCs towards a manufacturing process in monolayer and 
micro carrier culture conditions, especially considering donor to donor and colony heterogeneity 
which may be seen (Phinney et al., 1999, Phinney and Prockop, 2007, Heathman et al., 2015b, 
Heathman et al., 2016b). Within each study; the cells were characterised using flow cytometry for 
MSC specific markers, observed with phase contrast microscopy and the cumulative population 
doublings were reported along with the mean cell diameter of cells in suspension during cell 
counting. However, continuous imaging and image analysis could have provided additional cell and 
clonal characterisation of cells in monocultures, as well as the potential identification of abnormal 
or tumorigenic behaviour.  
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1.6 Technologies for screening cells intended for cell therapies 
Flow cytometry involves the examination of cells in a single cell suspension passing through a laser 
either as a continuous stream, or as a series of small single cell droplets. The flow of the cell stream 
of single cell droplets through a laser allows the detection and measurement of light scattered 
forward through the cells (FSC) and orthogonal to the cells as a side scatter (SSC). Additionally, cells 
fluorescently labelled with monoclonal antibodies (Abs) can be detected. A flow assisted cell sorting 
(FACS) system loads the single cell droplets with a slight positive of negative electrostatic charge 
and as they pass some highly charged metal plates, the droplets are sorted accordingly into 
collection tubes. A schematic diagram of FACS and a traditional scatter plot of obtained results can 
be seen in Figure 1.13.  
As previously mentioned, flow cytometry has been adopted by the ISCT as the standard technique 
to immunophenotype MSCs based on the presence or absence of cell surface antigens (Dominici et 
al., 2006). Similarly, flow cytometry and FACS are currently being implemented as screening tools 
and as treatment strategies respectively, within clinical practice (Jaye et al., 2012). Namely, they 
have been used within cancer diagnosis and prognosis, immunologic diseases, as well as within cell 
therapy and transplantation, such as transplant of haematopoietic stem cells (HSCT) (Appelbaum, 
2002). Notably, the World Health Organisation (WHO) released a worldwide consensus on the 
diagnosis and classification of hematolymphoid neoplasms using a multidisciplinary approach 
where flow cytometric immunophentyping of cells is integrated alongside morphologic, cytogenetic 
and molecular genetic data for the provision of an accurate diagnosis (Campo et al., 2011).  
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Figure 1.13: Schematic of FACS and an example of data.  
(A) Cells suspended in a core stream (green) are carried in sheath fluid (light grey) to the flow cell (yellow sphere) where they are interrogated by an excitation 
laser beam. Cells in the stream are detected by light scattered through the cells forward scatter (FSC) and orthogonal to the cells side scatter (SSC); cells 
labelled with fluorescently labelled monoclonal Abs are detected by emitted fluorescent light (FL1). Following detection of FSC, SSC, and FL1 signals, droplets 
are formed and loaded with positive or negative electrostatic charges. Droplets containing single cells are deflected to the left or right by highly charged metal 
plates, and sorted cells are collected into tubes. (B) FOXP31 CD41 regulatory T cells are identified from a mixture of lymphocytes using multiparameter flow 
cytometry. Figure adapted from Jaye et al., (2012).  
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It should be noted that the use of flow cytometry and FACS in clinical therapy or screening, is mostly 
associated with haematological diseases, dealing with cells within serum suspension. Likewise, 
apart from phenotypic classification of MSCs for antigen profiling by flow cytometry, these same 
cells must be plastic adherent with a fibroblastic appearance in order to be classified as MSCs 
(Dominici et al., 2006). However, there does not appear to be a screening tool specific to this step 
of cell identification and classification. 
The use of high content screening (HCS) imaging and live-cell imaging, along with the appropriate 
image analysis may facilitate the provision of tools needed to set clear and strict release criteria 
along with and similarly to those set by flow cytometry.  
The aptly named HCS supplies large amounts of data following analysis of acquired images of cells 
in culture. HCS platforms collect images of formalin fixed fluorescent immunocytochemistry (ICC) 
labelled cells (e.g. Cellomics ArrayScan, Thermo Fisher); however, this platform can also be used to 
collect phase contrast and bright field images of cells in live-cell culture. The HCS platform collects 
images of the cells, traditionally cultured within 6 to 384 well multiwell plates; then uses complex 
algorithms to analyse the images on a pixel-by-pixel basis, finally reporting differences between 
individual cells within populations as well as whole cell populations which have been analysed. The 
imaging and analysis is robust and reproducible.  
HCS was initially introduced to meet the need for automation of information-rich cellular assays 
within pharmaceutical industry mostly towards drug discovery as reviewed by Zanella, Lorens and 
Link, (2010). Figure 1.14 shows a detailed explanation of the use of HCS towards the interrogation 
of FOXO3a nuclear translocation as an identifier of potent and selective inhibitors of 
phosphoinositide 3-kinases.  
HCS has also become closely associated with academic research into stem cell biology (Wright, 
Griffiths and Johnson, 2010, Matsuoka et al., 2013). One such study conducted by Wright, Griffiths 
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and Johnson, (2010) compared the use of HCS and manual analysis to measure the effects of MSC-
conditioned media (MSC-CM) on neurite outgrowths from both the human SHSY5Y neuroblastoma 
cell line and chick dorsal root ganglia (DRG) explants. They concluded that MSC-CM significantly 
increased neurite outgrowth, and HCS was able to gather these results from multiple samples 
within minutes, compared to the manual analysis which would take over an hour per sample; 
however, they also noted that optimization of the analysis algorithm is essential for the desired 
result.  
A HCS study performed by Matsuoka et al., (2013) reported a morphology-based prediction of 
osteogenic differentiation potential of MSCs. Within the study they applied computational machine 
learning, combining cell morphology features with corresponding biochemical osteogenic assay 
results (ALP activity and calcium deposition), and developed a prediction model of osteogenic 
differentiation. Using a dataset of 9,990 images automatically acquired by the BioStation CT during 
osteogenic differentiation culture of MSCs, 666 morphometric features were extracted as 
parameters. Using time-course morphological features throughout differentiation culture, the 
prediction results highly correlated with the experimentally defined differentiation marker values 
(Matsuoka et al., 2013). 
The collection of very large data sets following HCS presents a challenge to users in two ways; (i) 
firstly, users must sort through the data to identify the specific results applicable to the research or 
application at hand; (ii) secondly, progress in data sharing is hampered by the lack of 
standardisation in ICC techniques, image collection, data analysis and reporting, all challenges 
similarly faced by the flow cytometry community (Jaye et al., 2012). Another challenge to the use 
of HCS based on ICC techniques is the permanent removal of cells from the culture, giving 
quantitative data on a subset of the population of cells intended for clinical research or application. 
As expressed by Gore et al., (2011), determining significant cell functions still remain to be 
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determined even after the identification of characterising reprogramming-associated mutations 
were identified within iPSCs. This may be facilitated by the use of live-cell imaging.  
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Figure 1.14: HCS on a compound library of small molecules. 
(a) High-throughput cellular imaging assay that follows the intracellular location of the FOXO3a 
protein (FOXO) in tumour cells has been used as a primary filter to screen a collection of 33,992 
small molecules. (b) The DAPI-stained nucleus was used as a seed for segmentation. The cytoplasm 
was defined independently of the cell size by an outer ring region with user-specified pixel width 
around the nucleus. (c–k) Original images from the primary compound library screen. Figure 
adapted from Zanella, Lorens and Link, (2010).  
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Alternatively, continuous live-cell imaging allows user defined identification and intermittent 
imaging of regions of interest (ROIs) via bright field, phase contrast or fluorescence imaging for a 
defined period of time. Depending on the platform, this can be done within large t-flasks to multi-
well cell culture plates. Continuous imaging allows the rapid review of characteristic cell behaviour; 
however, it is important to obtain quantitative data from the images to correlate and compare cell 
behaviour. The Cell-IQ live-cell imaging and analysis platform (CM Technologies Oy, Finland) 
enables the imaging of cells in bright field, phase contrast and up to three fluorescent channels, 
during culture periods determined by the user. Work performed by Smith, (2014) demonstrated 
the use of this non-invasive imaging by the Cell-IQ platform towards the process monitoring and 
control for the manufacture of ESCs and HSCs within cell therapies.  
As expressed by Heathman et al., (2015a), the safe and consistent provision of MSCs for large scale 
manufacture is essential to provide a consistent product, as well as the need for potency assays for 
batch release tests to validate the quality and quantity of the cell product. Screening of cells prior 
to their use in clinical application and the manufacture process is therefore essential. Live-cell 
imaging system allows simple automated non-invasive assessment of cells during their initial stages 
of culture, where cell confluence, the number of cells, as well as other behavioural characteristics 
can be determined.  
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1.7 Aims of the thesis 
The overriding aim of this study was to investigate the use of the Cellomics ArrayScan© HCS Reader 
platform and the Cell-IQ ImagenTM and AnalyserTM live-cell imaging platform towards phenotypic 
and behavioural screening of cells intended for clinical or manufacturing applications within cell-
based regenerative medicine. In particular, the thesis aimed to produce a standard method of 
identification and safe screening of human MSCs, compared to mesenchymal-derived sarcomas. 
The analysis was performed in collaboration with Imagen Biotech Ltd, a HCS industrial partner 
specialising in the analysis of cells in culture using antibody based ICC techniques.  
Specific objectives: 
 To determine whether human MSCs can be distinguished from two human 
osteosarcoma cell lines according to their phenotypic immuno-profile for a variety of 
cell biomarkers related to cell proliferation, osteoblastic differentiation and stem cell 
characteristics. This evaluation was conducted in a 96 well plate format, which would 
minimize the loss of cells that has been culture-expanded to treat patients.  
 To examine whether human MSCs can be distinguished from human osteosarcoma cell 
lines, and a primary sarcoma derived cell line, according to characteristic cell 
behaviours as well as their appearance under phase contrast microscopy alone using 
the non-invasive live-cell imaging platform Cell-IQ.  
 To test whether a novel combination of drugs could be used to selectively target 
sarcoma cells versus MSCs, and evaluate such selective targeting using live-cell imaging 
and image analysis. 
In this way, the thesis has set out to increase the knowledge of, and improve the screening, safe 
delivery and characterisation of MSCs within MSC based cell therapies.  
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2 Chapter 2: Materials and Methods 
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2.1 Cell culture 
2.1.1 Isolation of mesenchymal stem cells 
Primary human MSCs were cultured from bone marrow or adipose tissue samples kindly provided 
by Mr Martyn Snow at the Royal Orthopaedic Hospital, Birmingham, or were provided already 
culture-expanded cells from bone marrow by Dr Karina Wright at the Robert and Agnes Hunt (RJAH) 
Orthopaedic Hospital, Oswestry. Cells were isolated and culture-expanded from donated bone 
marrow or adipose tissue, following local research ethical committee (LREC) approval and with 
informed consent (LREC number 12/EE/0136 for ROH and 03/74RJH for RJAH). Cells were isolated 
from bone marrow aspirates or adipose tissue from ten donors, ranging in age from 22 to 90 years 
old (Table 1). 
Isolation of bone marrow-derived MSCs: 
For the isolation and culture expansion of BMMSCs, mononuclear cells were initially isolated from 
bone marrow aspirates and then MSCs selected according to preferential adhesion to tissue culture 
plastic, as described (Pittenger, 1999, D'ippolito et al., 2006). Briefly, this was performed as follows: 
(i) bone marrow aspirates (2-5ml) were harvested with a Jamshedi needle and mixed with 5ml 
phosphate buffered saline (PBS) (PAA, Yeovil, Somerset, UK), (ii) then gently layered over an aliquot 
of 5ml of Ficoll-PaqueTM PLUS (GE Healthcare, Buckinghamshire, UK) in a sterile 15ml conical 
centrifuge tube (SLS, East Riding of Yorkshire, UK). (iii) The mononuclear cells were then isolated by 
density gradient centrifugation for 20mins at 900g. The “buffy coat” containing the mononucleated 
cells was removed with a Pasteur pipette and added to 10ml of complete media; i.e. dulbecco’s 
modified Eagle’s medium (DMEM)/Ham’s F12 with 10% (v/v) foetal calf serum (FCS) with 1% (v/v) 
penicillin (50U/ml) and streptomycin (50μg/ml) (All from PAA, Yeovil, Somerset, UK). (iv) This cell 
suspension was then centrifuged for 10mins at 200g, the supernatant discarded and the cell pellet 
re-suspended in 2ml complete media, from which a viable cell count was performed by trypan blue 
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exclusion (see section 2.1.6). (v) Viable cells were then seeded in 20ml of complete media at a 
seeding density of 2x107 cells per 75cm2 flask. (vi) After incubating in a humidified atmosphere at 
37oC with 5% CO2 for 24hrs, the medium containing any non-adherent cells was removed and the 
flask was gently washed with PBS. (vii) Flasks were then fed with 20ml of complete media every 2-
3 days, and maintained in a humidified atmosphere at 37oC with 5% CO2. Upon reaching 70% 
confluence, cells were passaged by treatment with 0.25% trypsin-1mM EDTA (PAA, Yeovil, 
Somerset, UK) and routinely re-seeded into new culture flasks at 5x103cells/cm2. At passage II-III 
cells were characterised by CD profiling, or by assessment of their differentiation potential. 
Isolation of adipose tissue-derived MSCs: 
For the isolation and culture expansion of ATMSCs, human knee fat-pad tissue was washed, 
digested with collagenase and then MSCs selected according to preferential adhesion to tissue 
culture plastic, as described (Peroni et al., 2008). Briefly, this was performed as follows: (i) fat-pad 
tissue was washed twice in sterile PBS and then manually minced in 2ml of 0.1% collagenase (Sigma-
Aldrich, Gillingham, Dorset, UK) using a sterile disposable scalpel (SLS). (ii) Minced adipose tissue 
was then incubated in a T25 flask (upright) in 5-10ml of 0.1% collagenase for 24hrs in a humidified 
atmosphere at 37oC with 5% CO2. (iii) Following incubation, 10ml of complete medium was added 
to neutralise the collagenase and the digested tissue was centrifuged in a 50ml BD Falcon conical 
centrifuge tube (SLS) at 200g for 10mins. (v) The supernatant was discarded, the cell pellet was re-
suspended in 2-5ml of complete media and a cell viability count performed using trypan blue 
exclusion (see section 2.1.6). (vi) Viable cells were then seeded in 20ml of complete media into 
75cm2 flasks at a seeding density of 5x103cells/cm2. (vii) Flasks were then fed with 20ml of complete 
media every 2-3 days, and maintained in a humidified atmosphere at 37oC with 5% CO2. Upon 
reaching 70% confluence, cells were passaged by treatment with 0.25% trypsin-1mM EDTA and 
routinely re-seeded into new culture flasks at 5x103cells/cm2. At passage II-III cells were 
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characterised by CD profiling, or by assessment of their differentiation potential. Within this thesis, 
both BMMSCs and ATMSCs were used and collectively termed as MSCs.  
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Table 1: MSC donor details.  
Tissue of origin Provided by Sex Age Anonymous ID ID in Appendix Chapter Experiment 
ATMSC: Knee fat-pad ROH F 78 BMS001 MSC 1 
Ch3 HCS Biomarker identification 
Ch4 HCS Live-cell identification 
Ch5 MTT & Live-cell identification 
ATMSC: Knee fat-pad ROH F 22 BMS003 MSC 7 
Ch4 HCS & Live-cell identification 
Ch5 MTT & Live-cell identification 
ATMSC: Knee fat-pad ROH F 73 BMS005 MSC 8 
Ch4 HCS & Live-cell identification 
Ch5 MTT & Live-cell identification 
ATMSC: Knee fat-pad ROH M 90 BMS006 MSC 2 
Ch3 HCS Biomarker identification 
Ch4 HCS Live-cell identification 
Ch5 MTT & Live-cell identification  
ATMSC: Knee fat-pad ROH M 57 BMS010 MSC Ch3 HCS Biomarker identification 
ATMSC: Knee fat-pad ROH F 27 BMS101 MSC 9 Ch5 MTT & Live-cell identification 
BMMSC: Knee RJAH M 55 09/001 MSC Ch3  HCS ALP Activity 
BMMSC: Hip RJAH M 71 09/002 MSC Ch3 HCS Biomarker identification 
BMMSC: Hip RJAH F 68 09/005 MSC Ch3 HCS Biomarker identification 
BMMSC: Hip RJAH M 29 10/369 MSC 10 Ch3 HCS Biomarker identification 
Abbreviations: RJAH, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry; ROH, Royal Orthopaedic Hospital, Birmingham; HCS, High Content 
Screening; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ATMSC, Adipose Tissue Derived Mesenchymal Stem Cells; BMMSC, Bone 
Marrow Derived Mesenchymal Stem Cell; M, Male; F, Female; Ch, Chapter; ID, Identification.  
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2.1.2 Isolation of primary cells from chondrosarcoma tissue samples 
Cells were isolated and cultured from tissues from a single donor with chondrosarcoma, following 
LREC approval and informed consent (LREC number: ROH12ONC01). The surgical procedure of 
excision, irradiation, and re-implantation of a primary chondrosarcoma is shown in Figure 2.1. The 
surgical procedure was conducted as follows: (i) the central section of the humerus was excised 
from the left arm and the tumour was curettaged from the medulla cavity of the excised bone 
fragment. (ii) A sample of tumour tissue was taken from the curettaged fragment. This sample was 
referred to as the non-radio sample. (iii) The bone fragment and another sample of tumour tissue 
were treated with a single fraction of 90Gy deep X-ray therapy (DXT). This sample was referred to 
as the post-radio sample. (iv) Following irradiation, the bone fragment was packed with non-
vascularised bone cement and fixed back into place.  
Briefly, the isolation and culture expansion of cells from the two chondrosarcoma tissue samples 
was performed as follows: (i) under aseptic conditions, the two tissue samples (non-radio and post-
radio therapy) were gently rinsed twice with PBS. (ii) Each sample was weighed (non-radio = 0.860g 
and post-radio = 1.103g) and then divided into two halves. (iii) One-half was manually minced and 
then seeded in 8mls of complete media in a 25cm2 flask. (iv) The other half was digested using 0.1% 
collagenase for 24hrs in a humidified atmosphere at 37oC with 5% CO2. (v) Following incubation, 
10ml of complete media was added to neutralise the collagenase and the digested tissue was 
centrifuged in a 15ml BD Falcon conical centrifuge tube (SLS) at 200g for 10mins. (vi) The 
supernatant was discarded, the cell pellet was re-suspended in 2-5ml of complete media and a 
viable cell count was performed by trypan blue exclusion (see section 2.1.6). (vi) All viable cells were 
then seeded in 10ml of complete media into 25cm2 flasks. (vii) All flasks were fed with 10ml of 
complete media every 2-3 days, and maintained in a humidified atmosphere at 37oC with 5% CO2. 
Upon reaching 70% confluence, cells were passaged by treatment with 0.25% trypsin-1mM EDTA 
and routinely re-seeded into new culture flasks. 
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Representative phase contrast microscopy images of these isolates in culture are shown in Figure 
2.2. As shown, 10-11 days post seeding, cells from the non-radio treated sample adhered to the 
tissue culture plastic from both the explant sample (top left panel) 11 days post seeding and the 
24hr collagenase digest sample (top right panel) 10 days post seeding. These appeared as 
proliferative viable cultures. In contrast, from the post-radio treated sample, only debris was found 
within the explant prepared sample (bottom left panel) and single stressed cells were identified in 
the collagenase digested sample (bottom right panel). With further time in culture, the non-radio 
treated cells continued to proliferate and colonies increased in size. In contrast, the post-radio 
treated cells showed no signs of proliferation throughout the culture period where only single cells 
were observed from 13 through 56 days post seeding. 
Two techniques discussed in previous studies (Van Oosterwijk et al., 2012, Monderer et al., 2013) 
to isolate cells from tumour tissue were used here to examine potential differences in isolation and 
proliferation of the isolated cells. As seen in Figure 2.3, explant cells showed slow proliferation 
through the first three passages, with a high proliferation between passages 3-4. In contrast, cells 
isolated following 24hr collagenase digestion showed a gradual fold increase through all four 
passages 1-4. These differences in growth kinetics may be due to the techniques used, with 
different populations of cells possibly being isolated, e.g. fibroblast-like cells, de-differentiated 
chondrocytes, or tumorigenic chondrosarcoma cells. Further characterisation of these isolated cells 
may help identify these differences and compare them to the parental tumour tissue. Within this 
thesis, cells derived from chondrosarcoma tissue were collectively termed as CS cells.  
A detailed description of the diagnosis and treatment of the primary grade I chondrosarcoma can 
be seen in Appendix 7.2.2, illustrated within Figure 7.26 through Figure 7.29. 
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Figure 2.1: The surgical procedure of excision, irradiation and re-implantation. 
Clockwise from the left. The central section of the humerus was excised from the left arm (a-b) and 
the tumour was curettaged from the medulla cavity of the excised bone fragment (c). A sample of 
tumour tissue was taken from the curettaged fragment (d). This sample is referred to as the Non-
radio sample. The bone fragment and another sample of tumour tissue were treated with a single 
fraction of 90Gy deep X-ray therapy (DXT) (e-f). This sample is referred to as the Post-Radio sample. 
Following irradiation, the bone fragment was packed with non-vascularised bone cement and fixed 
back into place (g).  
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Figure 2.2: Adherent cells were isolated from both the non-radio and post-radiotherapy treated samples; however, only non-radiotherapy treated cells 
proliferated. 
Cell adhesion of P0 cells are shown from the grade I chondrosarcoma following non-radio therapy (top panels) and post-radio therapy (bottom panels) from 
explant cultures (single left row panels) and 24hr digest samples (four right row panels). Cells were imaged at 10, 11, 13, 25 and 56 days post seeding as 
indicated below the images. Images were taken at 10 x magnification. Bar=100µm. 
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Figure 2.3: Non-radio therapy treated chondrosarcoma derived cells continued to proliferate 
following passage.  
The graph shows the proliferation of the total viable non-radio therapy treated chondrosarcoma 
derived cells over a period of four passages. 24Hr digest isolated non-radio treated cells can be seen 
to proliferate from P1 through P4, spanning 321 days of culture. Explant isolated non-radio therapy 
treated explant tissue proliferated from P1 through P4, spanning 302 days of culture. Following P4, 
cell DNA was isolated for sequencing of IDH1/2 mutations. 
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2.1.3 Maintenance of all primary cells 
All cells were cultured and maintained in DMEM/Ham’s F12 (DMEM/F12) (PAA, Yeovil, Somerset, 
UK), supplemented with 10% (v/v) foetal calf serum (FCS) (PAA), and 1% (v/v) penicillin (50U/ml) 
and streptomycin (50μg/ml) in a humidified atmosphere at 370C with 5% CO2. Upon reaching 70% 
confluence, cultures were passaged using 0.25% trypsin-1mM EDTA (PAA) and a viable cell count 
was performed by trypan blue exclusion (see section 2.1.6). 
2.1.4 Maintenance of cell lines 
The two cell lines used to model human osteosarcoma were the osteogenic sarcoma cell line, 
SAOS2, and the human osteosarcoma cell line, MG63. The SAOS2 cell line (ATCC HTB-85) was 
derived from an osteogenic sarcoma removed from an 11yr old Caucasian female patient who was 
undergoing extensive treatment with chemotherapeutic agents including methotrexate, 
Adriamycin, vincristine, cytoxan, and aramycin-C (Fogh, Fogh and Orfeo, 1977). The MG63 cell line 
(ATCC CRL-1427) was derived from an osteosarcoma removed from a 14yr old Caucasian male 
patient (Billiau et al., 1977). Both cell types were cultured and maintained at exponential growth as 
described in the previous section. 
2.1.5 Passage of monolayer cells by trypsinisation 
Upon reaching 70% confluence, cultures were passaged using 0.25% trypsin-1mM EDTA (PAA) and 
a viable cell count was performed by trypan blue exclusion (see section 2.1.6). Briefly, this was 
performed as follows: (i) confluent monolayer cultures were washed with 5mls of PBS, which was 
then discarded. (ii) Cells were incubated for 5 minutes in 5mls of 0.25% trypsin-EDTA (PAA) at 370C 
until the cells became dislodged from the tissue culture plastic. (iii) When the cells had dislodged, 
5mls of complete culture medium was added to neutralise the trypsin-EDTA. (iv) This cell-rich 
suspension was then centrifuged for 10mins at 1000rpm (1200rcf), the supernatant discarded and 
the cell pellet re-suspended in 2ml complete media, from which a viable cell count was performed 
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by trypan blue exclusion (see section 2.1.6). (v) The cell suspension was diluted appropriately and 
cells were seeded into new flasks or used for experiments.  
2.1.6 Cell viability measured by trypan blue exclusion 
Cell viability was assessed based on trypan blue exclusion. The intact membrane of a viable cell is 
able to exclude the trypan blue dye, giving the cell a phase bright appearance; however, when a 
cell membrane becomes perforated, the dye stains the nucleus of the cell making it appear blue. 
Briefly, the viable cell count was performed as follows: (i) 20µl of cell suspension was added to an 
equal volume of 0.4% (w/v) trypan blue solution (Sigma-Aldrich). (ii) The resultant cell suspension 
was mixed thoroughly by pipetting and then loaded onto an haemocytometer (Fisher Scientific, 
Loughborough, Leicester, UK). (iii) The number and proportion of viable cells (phase bright and not 
stained) and non-viable cells (phase dark and stained blue) were recorded after scoring a minimum 
of 200 cells per sample. 
2.1.7 Testing for mycoplasma  
Mycoplasma are a genus of bacteria which lack a cell wall and are unaffected by many common 
antibiotics such as penicillin or other beta-lactam antibiotics that target cell wall synthesis 
(reviewed by Waites and Talkington, (2004). Unfortunately, mycoplasmas have the ability to alter 
their host culture’s cell function, growth, metabolism, morphology, attachment, membranes, 
chromosomal aberrations and damage. The diameter of mycoplasma is between 0.3 – 0.8µm. The 
EZ-PCR Mycoplasma Test Kit (Geneflow, Lichfield, Staffordshire, UK) is designed to detect the 
presence of mycoplasma within cell culture via polymerase chain reaction (PCR) testing.  
The EZ-PCR Mycoplasma Test Kit was used to screen for contamination in all cell cultures and 
performed according to manufacturer’s protocol as follows: (i) Test sample preparation: 0.5-1.0ml 
of cell culture supernatant was transferred into a 2ml micro-centrifuge tube and cellular debris was 
pelleted by centrifugation at 250g briefly. The supernatant was transferred into a fresh sterile 
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micro-centrifuge tube and centrifuged at 15,000 – 20,000g for 10 minutes to sediment any 
mycoplasma. The supernatant was carefully decanted and the pellet keep (the pellet may not 
always be visible). The pellet was re-suspended with 50μl of the Buffer Solution and mixed 
thoroughly with a micro-pipet and heated to 95°C for 3 minutes. (ii) Reaction mixture preparation: 
the following reagents were combined in a PCR tube: 35μl of H2O, 10μl of reaction mix, 5μl of test 
sample. A positive template control was also prepared by adding 1μl of positive template in lieu of 
the 5µl sample. (iii) All tubes were placed into a DNA thermal cycler and the following parameters 
were set to amplify the DNA: 30 seconds at 94°C, then 35 cycles of; 30 seconds at 94°C then 120 
seconds at 60°C then 60 seconds at 72°C, followed by 30 seconds at 94°C, 120 seconds at 60°C and 
finally 5 minutes at 72°C. (iv) Analysis of the amplified products by gel electrophoresis: a 2% agarose 
gel was made and allowed to set. 20μl of the PCR product (without loading buffer) was applied to 
the gel electrophoresis. 
2.1.8 Seeding densities for experiments 
Following cell culture and trypsinisation, viable cells were seeded at the following densities for 
respective experiments. For all Cellomics ArrayScan© HCS experiments, cells were seeded at a 
density of 5x103 cells per well in a black clear-bottom 96 well plate (Greiner Bio-One Ltd, 
Gloucestershire, UK). For live-cell imaging using the Cell-IQ platform, cells were seeded at a density 
of 1x104 cells per well in a clear 24 well plate (Corning by Appleton Woods Ltd, Birmingham, UK). 
For MTT viability assays, cells were seeded at a density of 5x103 cells per well in a 96 well (Corning 
by Appleton Woods Ltd). For 3D micro pellet formation and treatment, cells were seeded at a 
density of 12.5x104 cells per pellet in 1.5ml micro-centrifuge tubes (Fisher Scientific). For live-cell 
imaging of selective cell killing following drug treatments, cells were seeded at a density of 4x103 
cells per well in a 48 well plate (Corning by Appleton Woods Ltd).  
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2.1.9 Cryopreservation of cells  
Cryopreservation was performed as follows: (i) upon reaching 70% confluence, cells were 
trypsinised, washed and pelleted by centrifugation at 1000rpm (1200rcf) for 10 minutes. (ii) The 
supernatant was discarded and the cell pellet was re-suspended in 1ml of freezing mix – FCS with 
10% (v/v) dimethylsulphoxide (DMSO) (Sigma-Aldrich). (iii) A viable cell count was performed by 
trypan blue exclusion (see section 2.1.6) and then cells were placed into an appropriately labelled 
cryovial at a concentration of 1x106 cells/ml. (iv) Cryovials were frozen overnight at -80°C in a 
Nalgene™ Cryo 1oC Freezing Container, ‘Mr Frosty’ (Fisher Scientific) containing isopropyl alcohol, 
then transferred and stored within a -800C freezer. 
2.1.10 Recovery of cells from cryopreservation 
The recovery of cells from cryopreservation was performed as follows: (i) cryovials were recovered 
from a -800C freezer and then rapidly thawed under a running tap of warm water. (ii) 1ml of ice cold 
complete media was added drop-wise over one minute. (iii) An additional 5ml of ice cold complete 
media was added drop wise over 5 minutes. (iv) After allowing to stand at room temperature for 5 
minutes, 4ml of ice cold complete media was added drop wise. (v) The resultant cell suspension 
was transferred into a 15ml Falcon tube and pelleted by centrifugation at 1000rpm for 10 minutes. 
(vi) The cell pellet was re-suspended in 5ml of room temp culture medium, a viable cell count 
recorded and then cells were seeded into an appropriate culture flask and maintained in a 
humidified atmosphere at 37oC with 5% CO2. 
2.2 Phenotypic characterisation of primary cultures of stromal 
cells 
Phenotypic characterisation of isolated primary cultures of stromal cells was done according to the 
ISCT’s minimal criteria to confirm their identity as MSCs (Dominici et al., 2006). CD profiling 
examined immunoreactivity for CD34-ve, CD45-ve, CD73+ve, CD90+ve and CD105+ve and cells were 
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induced to differentiate along osteogenic, adipogenic and chondrogenic differentiation as shown 
in Figure 2.4. This work was performed in collaboration with Nupur Kohli (PhD student; Johnson 
laboratory, Aston University) to whom I am grateful for the provision of data and associated figures. 
2.2.1 Cluster of differentiation (CD) profiling 
Culture-expanded stromal cells were harvested at passage II-III by trypsinisation and suspended in 
PBS containing 2% bovine serum albumin (BSA) (Sigma-Aldrich). The cells were then blocked with 
10% normal human immunoglobulin (Ig) (Grifols,Cambridge, UK) prior to incubation at 4 °C with 
the following phycoerythrin (PE) conjugated mouse monoclonal anti-human Abs: CD34, CD45, 
CD105 (Immunotools, Friesoythe, Germany), CD73 and CD90 (BD Biosciences, UK). Non-specific 
fluorescence was determined by incubating cells with isotype-matched control phycoerythrin-
conjugated antibodies IgG2a and IgG1 (Immunotools). Immunoreactivity for each CD marker was 
assessed by flow cytometry using a Beckman Coulter FC500 Flow Cytometer and data were 
analysed using Kaluza® Analysis Software. 
2.2.2 Osteogenic differentiation 
Passage III ATMSCs were cultured in a 24-well plate and allowed to reach 70-80% confluence. The 
cells were then maintained under osteogenic conditions, consisting of standard culture medium 
supplemented with; 10mM β-glycerophosphate, 50μM ascorbic 2-phosphate and 10nM 
dexamethasone (DEX) (All from Sigma-Aldrich) for 28 days, as previously described (Bajada et al., 
2009). Control cultures were maintained in complete media alone. Both induction and control 
media were completely replaced every 2–3 days. Differentiation along the osteogenic lineage was 
evaluated by increased ALP activity. 
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2.2.3 Adipogenic differentiation 
Passage III ATMSCs were cultured in a 24-well plate and allowed to reach 70-80% confluence. The 
cells were then maintained under adipogenic conditions, consisting of standard culture medium 
supplemented with; 1μM DEX, 0.5mM IBMX (Sigma-Aldrich), insulin, transferrin and selenium (ITS-
X100 pre-mix; PAA) and 100μM indomethacin (Sigma-Aldrich), for 28 days as previously described 
(Bajada et al., 2009). Control cells were maintained in complete media alone. Both test and control 
medium were completely replaced every 2–3 days. Differentiation along an adipogenic lineage was 
evaluated by cellular accumulation of neutral lipid vacuoles by staining with Oil Red O (Sigma-
Aldrich). 
2.2.4 Chondrogenic differentiation 
A cell suspension of 2x105 cells was prepared per 1ml of standard culture medium, following routine 
trypsinisation. 1ml of the cell suspension was transferred into a 1.5 ml eppendorfs and pelleted by 
centrifugation at 500g for 5 minutes (Johnstone et al., 1998). The medium was then replaced with 
DMEM/High glucose with 2% FCS plus carriers in control cultures and DMEM/High glucose 
supplemented with 100nM DEX, 37.5μg/ml ascorbate-2-phosphate, ITS-X, 10 ng/ml TGF-β1 
(PeproTech Ltd., London, UK), and 1.25μg/ml BSA and antibiotics. The pellets were maintained at 
37°C and 5% CO2 for 28 days and the medium was replaced every 2-3 days, after which the 
differentiation status of the pellets was examined by embedding and staining for Toluidine Blue. 
2.3 Formalin fixation of cell cultures 
Formalin fixation of cells was performed as follows: (i) cells were seeded into various plate formats 
(24, 48 or 96 well plates) and maintained for 24hrs at 37°C with 5% CO2. (ii) Culture medium was 
removed from the wells and cells were washed twice with PBS. (iii) 4% formaldehyde was added to 
the wells and the plates were incubated for 20 minutes at room temperature. (iv) The formaldehyde 
was removed and the cells were washed twice with PBS, then stored in fresh sterile PBS at 0-40C. 
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2.4 Alkaline phosphatase staining 
Alkaline phosphatase (ALP) is an ectoenzyme whose activity is used as an early marker of 
osteoblastic differentiation. Increased expression and subsequent activity is associated with 
progression along the osteoblastic lineage (Jaiswal et al., 1997). The production of an insoluble red 
dye at the site of enzymatic activity is due to the alkaline phosphatase mediated reaction between 
naphthol phosphate and the diazonium salt, fast red TR. SAOS2 osteosarcoma cells were seeded as 
a positive control at a density of 1x104cells/cm2 24hrs prior to staining (Ali, Rowe and Teich, 1996).  
ALP staining for phenotypic characterisation of stromal cells was done as follows: (i) a staining 
solution was prepared immediately prior to staining as described here; 10 mg of fast red TR (Sigma-
Aldrich) was added to 8.4mls of 0.1M Tris-hydrochloride (Tris-HCl) buffer and 1.6mls of naphthol 
(Sigma-Aldrich) was added and filtered through Whatman No.1 filter paper (Maidstone, UK) just 
before use. (ii) Controls and test cultures were fixed with 4% formaldehyde for 1 minute and then 
washed twice for 1 minute at each wash with Tris-phosphate buffered saline with tween 20 (TBS-
T) (Molekula, Gillingham, Dorset, UK). (iii) 500µl of staining solution was added to each well of a 24 
well plate and then incubated at room temperature for 3-5 minutes. Alkaline phosphatase 
enzymatic activity was marked by the formation of dark red cellular precipitates (performed by 
Nupur Kohli). 
ALP staining for HCS was done as follows: (i) following the appropriate culture period, control and 
test culture cells were gently washed twice with PBS then fixed in 4% formaldehyde for 1 minute at 
room temperature. (ii) The formaldehyde solution was removed and the cells were gently washed 
twice with TBS-T. (iii) A staining solution was prepared immediately prior to staining as described; 
for a 10ml solution, 10mg of Fast Red TR was added to 8.4ml of 0.1M Tris-HCl buffer at pH 8.6 
(Molekula). 1.6ml of naphthol AS-MX phosphate solution (Sigma-Aldrich) was added to the Fast Red 
TR/Tris-HCl solution and gently mixed by inverting the tube. The TBS-T was removed and the cells 
stained for 5mins. The stain was discarded and the cells washed twice with PBS. Cells were then 
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fixed for a further 20mins at room temperature with 4% formaldehyde. Following fixation, cells 
were washed twice with PBS and stored in PBS at 4oC until imaging. This protocol was adapted from 
Dr. N. Y. Yeh’s Ph.D thesis, Aston University, 2013. Figures and results of ALP stained MSCs, SAOS2 
and MG63 cells can be seen in section 7.1.3 and 7.1.4 with Figure 7.17.  
2.5 Oil Red O staining 
Oil red O is a dye that binds to lipids, specifically triglycerides and therefore, was used as a marker 
to assess adipogenic differentiation (Ramírez-Zacarías, Castro-Muñozledo and Kuri-Harcuch, 1992). 
The staining was performed as follows: (i) a staining solution was prepared by dissolving 60mg of 
oil red o powder (Sigma-Aldrich) into 20ml of isopropanol. (ii) 6ml of this stock solution was mixed 
with 4ml of distilled water. (iii) This staining solution was filtered through a Whatman No.1 filter 
paper, prior to staining. (iv) Control and test cultures were washed and fixed with 4% formaldehyde 
for 30 minutes at room temperature. (v) 500µl of staining solution was added to each well of the 
24-well plate and the plates were incubated for 1 hour at room temperature. (vi) After this, any 
unbound dye was washed off with PBS and lipid accumulation was marked by orange staining of 
the intracellular lipid vacuoles. This protocol was adapted from thermo scientific cell culture and 
bioprocessing. 
2.6 Toluidine blue staining 
Toluidine blue is a metachromatric cationic dye that stains proteoglycans as well as 
glycosaminoglycans (GAGs). Use of toluidine blue in tissue sections is done with the aim to highlight 
components, such as mast cells granules, mucins, and cartilage (Schmitz et al., 2010, Sridharan and 
Shankar, 2012). Toluidine blue staining was performed as follows: (i) pellets were harvested at week 
4, fixed with 10% neutral buffered formalin for 24 hours and then processed in graded strengths of 
alcohol and paraffin embedded. For histological evaluation, 5µm thick sections were cut and 
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deparaffinised, rehydrated through a series of graded alcohols, and stained with 0.04% toluidine 
blue stain (Schmitz et al., 2010). 
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Figure 2.4: Phenotypic characterisation of primary isolated BMMSCs and ATMSCs according to 
the ISCT’s minimal criteria. 
(A) Culture expanded cells from BM and AT differentiated along mesenchymal lineages, as indicated 
by the presence of ALP positive osteoblasts or Oil Red O positive adipocytes in monolayer cultures 
and metachromatic staining for glycosaminoglycans (GAGs) in pellet cultures (scale bars represent 
100μm). (B) Representative histograms are shown for positivity for CD markers in BMMSCs (left 
panels) and ATMSCs (right panels). The white histogram shows immunopositivity for each indicated 
marker, which is only clearly apparent when the extent of immunofluorescence is greater than that 
detected following immunolabelling with an isotype-matched control antibody, indicated by the 
black histogram. Figure adapted from Kohli et al., (2015).  
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2.7 Haematoxylin and Eosin staining of biopsy and curettage 
samples 
Haematoxylin and Eosin (H&E) staining on paraffin embedded biopsy and curettage sections were 
performed according to the standard operating protocol from the Department of Musculoskeletal 
Pathology, Birmingham University, Birmingham, UK. Briefly, sample sections were dewaxed and 
rehydrated with xylene and alcohol and then washed. Sections were then stained with Ehrlich’s 
haematoxylin, washed in tap water and differentiated in 0.3% acid alcohol (0.3%hydorchloric acid 
in 70% alcohol). Following this, sections were washed in running tap water and counterstained with 
1% eosin, washed again with running tap water and finally dehydrated. They were then cleared and 
a coverslip was mounted onto the sections with DPX mounting solution. Resulting staining shows: 
Nuclei – Blue to black; Cytoplasm – varying shades of pink; Cartilage – purple.  
2.8 DNA isolation for IDH1 and IDH2 mutation analysis 
As a part of the energy generating citric acid cycle, the enzymes - isocitrate dehydrogenases (IDH) 
catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate and CO2. IDH1 is found in the 
cytoplasm and peroxisomes, IDH2 within the mitochondria of cells. Mutations within IDH1 and IDH2 
are fairly frequent events (56%) in central and peripheral chondrosarcomas. Specific point 
mutations commonly found in IDH1 usually result in substitutions at R132 and within IDH2 
mutations may occur at R172 (analogous to IDH1 R132) and R140 (Amary et al., 2011). These 
mutations within the active site of the IDH do not result in terminal activity of the enzyme. Rather, 
it has been noted that the mutation R132H (arginine to histidine) in IDH1 may lead to the enzyme’s 
ability to further convert α-ketogluterate to R(-)-2-hydroxygluterate (2HG) an onco-metabolite 
(Dang, White et al. 2009). Or the mutation may lead to increased levels of hypoxia-inducible factor 
subunit 1α (HIF-1α), a transcription factor facilitating tumour growth under low oxygen 
environments (Zhao, Lin et al. 2009). 
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Specific point mutations within the isocitrate dehydrogenase genes, IDH1 (R132) and IDH2 (R140 
and R172) were investigated following extraction of DNA from paraffin embedded biopsy samples 
and culture-expanded cells, RT-PCR for the IDH1 and IDH2 genes, then sequencing the cDNA for the 
specific point mutations. All protocols were conducted according to and by the Department of 
Musculoskeletal Pathology standard operating protocols. 
2.8.1 DNA extraction from paraffin embedded tissue 
DNA was extracted from paraffin embedded blocks of the biopsy sample according to the standard 
protocol from the Department of Musculoskeletal Pathology, Birmingham University, Birmingham, 
UK.  
2.8.2 DNA extraction from culture-expanded cells 
DNA extraction from culture-expanded cells was done using the QIAmp DNA Mini Kit (QIAGEN, 
Venlo, Netherlands) according to manufacturer’s guidelines. Briefly, explant and collagenase digest 
cells isolated from the non-radio treated CS sample were individually harvested following 
trypsinisation and counted to ensure cell density ≤5x106. Following counting, cells were 
centrifuged, re-suspended in PBS, protease K was added, the cells were lysed using the Buffer AL 
and then pulse-vortexed for 15s. Cell lysates were incubated for 10mins at 56oC, pulse-vortexed for 
15s, and then ethanol (96%) was added. The entire solution was added to the QIAmp Mini spin 
column and centrifuged at 6000g for 1min. Columns were washed with Buffer AW1 and centrifuged 
at 6000g for 1min, washed in Buffer AW2 and centrifuged at 20,000g for 3mins. The columns were 
incubated in DNA/RNA free water for 5mins then the DNA was extracted from the column by 
centrifugation for 1min at 6000g. Total DNA concentration and purity was checked using a 
nanophotometer (Implen - NanoPhotometer® Pearl, Geneflow, Lichfield, Staffordshire, UK).  
2.9 RT-PCR amplification of IDH 1 and IDH2 specific genes 
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Reverse transcriptase‐PCR (RT‐PCR) for the isocitrate dehydrogenase gene mutations, IDH1 (R132) 
and IDH2 (R140 and R172) was carried out on formalin‐fixed, paraffin‐wax‐embedded tissue, and 
culture-expanded chondrosarcoma tissue. RT-PCR was performed according to the standard 
protocol from the Department of Musculoskeletal Pathology, Birmingham University, Birmingham, 
UK. The Qiagen® OneStep RT-PCR Kit (Qiagen Ltd., Cat. No. 210212) was used according to 
manufacturer’s protocol. Primer sequences used to identify the presence or absence of the 
mutations can be seen in Table 2.  
2.10 Gene sequencing of IDH1 and IDH2 cDNA 
Gene sequencing was outsourced and done according to the standard protocol from The Functional 
Genomics and Proteomics Laboratories, School of Biosciences, University of Birmingham, UK. 
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Table 2: Oligonucleotide primer sequences used during RT-PCR to identify the presence or 
absence of IDH1 and IDH2 mutations. 
Mutation type Oligonucleotide primers Product size 
R132 
Left 1: AAAATATCCCCCGGCTTGT 145 bp 
Right 1: CACATACAAGTTGGAAATTTCTGG  
Left 2: CGGTCTTCAGAGAAGCCATT 129 bp 
Right 2: GCAAAATCACATTATTGCCAAC  
R172 
IDH2-R172-F: AGCCCATCATCTGCAAAAAC  102 bp 
IDH2-R172-R: CTCCACCCTGGCCTACCT  
R140 
IDH2-R140-F: TGTGGAAAAGTCCCAATGGA 90 bp 
IDH2-R140-R: CTAGGCGTGGGATGTTTTTG  
 
Abbreviations: R, Arginine; bp, base pair; IDH, Isocitrate Dehydrogenase; F, Forward; R, Reverse.  
Point mutations located at R132 are specific for IDH1 and point mutations located at R140 and R172 
are specific for IDH2. Sequences and table adapted from Table S4 supporting information from 
Amary et al., (2011). 
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2.11 Immunocytochemistry (ICC) 
Immunocytochemical staining of cells for HCS analysis was performed as follows: (i) cells were fixed 
in 4% formaldehyde and then washed twice with PBS. (ii) Primary antibodies (1o Ab) were diluted 
as appropriate (detailed in Table 3) in Digitonin (500µg/ml) (Sigma-Aldrich). (iii) 50µl of 1o Ab was 
placed into each respective wells of a 96 well plate and incubated at room temperature for 1 hour. 
(iv) Following incubation, the 1oAb solution was decanted and the plate was washed twice with PBS 
using the plate washer (Tecan UK Ltd, Theale, Reading, UK). (v) Secondary antibodies (2o Ab) and 
the nuclei counterstained with 20µg/ml Hoechst 33342 (Invitrogen, H3570) were diluted in PBS as 
appropriate and added to the cells according to the species of the 1oAb used, then incubated for 1 
hour at room temperature. (vi) Following this, the 2oAb/Hoechst solution was decanted and the 
plate was washed twice with PBS. (vii) 100µl of PBS was added to each well for imaging and storage. 
Due to mechanical malfunction, some wells were not washed therefore cells dried and were over 
stained with very high background. These wells were excluded from fluorescence intensity 
quantification. Immunoreactivity staining for biomarkers was done in triplicate for each 
independent experiment. Triplicate readings were pooled for n=3 experiments.
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Table 3: ICC antibodies, concentrations and dilutions.  
Antibody Species Concentration Dilution Supplier 
anti-Ki67 antigen R 
30µl-Concentration cannot be 
disclosed due to propriety 
1/500 
Cellomics, 
Thermo Scientific 
anti-phospho 
Retinoblastoma 
(pRb) 
M 
300µl-Concentration cannot 
be disclosed due to propriety 
1/100 
Cellomics, 
Thermo Scientific 
anti-phospho 
Histone H3 (pHH3) 
R 0.7mg/ml 1/600 AbCam 
anti-Oct4 R 3.5µg/ml 1/200 AbCam 
anti-nanog R 0.2mg/ml 1/200 AbCam 
anti-Osteopontin R Unavailable 1/200 
Kindly donated 
by Dr G. Griffiths 
anti-Osteocalcin G 1.0µg/ml 1/200 
Santa Cruz 
Biotechnology 
anti-β-Catenin R 
150µl-Concentration cannot 
be disclosed due to propriety 
1/500 
Cellomics, 
Thermo Scientific 
anti-phospho Focal 
Adhesion Kinase 
(pFAK) (Y397) 
R 0.4µg/ml 1/500 AbCam 
Mouse anti-
αTubulin 
M 1mg/ml 1/5000 Thermo Scientific 
Alexa Fluor 488 
Goat anti-Mouse 
IgG Ab 
G 4µg/ml 1/500 Invitrogen 
Alexa Fluor 488 
Goat anti-Rabbit 
IgG Ab 
G 4µg/ml 1/500 Invitrogen 
Alexa Fluor 594 
Chicken anti-Goat 
IgG Ab 
Ch 4µg/ml 1/500 Invitrogen 
Hoechst 33342   20µg/ml 1/500 Invitrogen 
Whole cell green 
fluorescent 
membrane stain 
 
50µl-Concentration cannot be 
disclosed due to propriety 
1/100 
Cellomics, 
Thermo Scientific 
 
Abbreviations: R, Rabbit; M, Mouse; G, Goat; Ch, Chicken.  
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2.12 Cellomics HCS Reader: Compartmental Analysis Bio-Application 
and Morphology Explorer Bio-Application 
Biomarkers of interest were labelled, visualised and the intensity quantified with the Cellomics 
ArrayScan© HCS Reader: Compartmental Analysis Bio-Application (V2 Version, Thermo Scientific). 
Indirect immunofluorescence staining was used to visualise and quantitate immunoreactivity 
towards proteins of interest (listed in Table 3 above). The cell morphology; area and shape (i.e. P2A 
- perimeter to area ratio; LWR – length to width ration) of whole cell membrane stained and α-
tubulin immunostained cells were imaged and analysed with the Cellomics ArrayScan© 
Morphology Explorer Bio-Application (V2 Version, Thermo Scientific). 
Following ICC staining of the cells, and counter staining of the nuclei with Hoechst 33342, plates of 
cells were loaded into the ArrayScan and ≥8 images were taken from the centre through a spiral 
pattern outward towards the edge of each well with no less than 5000 cells imaged within the 
collected images. Images were taken in three channels: channel 1 (386nmEM), channel 2 (488nmEM) 
and channel 3 (549nmEM).  
These images were then analysed through the bio-application analysis protocols to identify the 
immunoreactivity fluorescence intensity for the regions of interest on a per cell basis (Figure 2.5). 
Firstly, the platform located cells based on their Hoechst 33342 positivity designated as channel 1 
(386nm). Then the platform measured the fluorescence intensity of the Hoechst 33342 as well as 
GFP/RFP within the nuclear area of each cell, designated the ‘circ’ cellular region (yellow dashed 
circle in Figure 2.5). Similarly, the platform measured the fluorescence intensity within the 
cytoplasmic ring area of each cells, designated the ‘ring’ region (red ring in Figure 2.5). The exact 
shape of the nucleus ‘circ’ and cytoplasmic regions of interest ‘ring’, were determined by the initial 
shape of the identified nucleus.  
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Next, within the ‘circ’ and ‘ring’ area, threshold values were used to identify ‘spots’; these were 
referred to as ‘circ spots’ and ‘ring spots’ (purple rings and areas in Figure 2.5). Fluorescence 
immunoreactivity levels for the nuclear ‘circ’ and ‘circ spot’, cytoplasmic ‘ring’ and ‘ring spot’ 
regions were taken from the channel 2 (488nm) or channel 3 (549nm) fluorescence images. The 
results were reported on a per cell basis and include the sum of or mean intensity of the nuclear 
‘circ’, nuclear spot ‘circ spot’, cytoplasmic ‘ring’, or cytoplasmic spot (ring spot) fluorescence 
intensity. The intensity is designated here as relative light units (RLU, an arbitrary annotation). Cells 
which measured immunoreactive fluorescence values greater than the set thresholds were counted 
and reported as a percentage positive (% positive) relative to all those examined within the 
population.  An example of the distribution of and threshold values quantitated from images of Ki67 
antigen immuno-stained cells can be seen in Figure 2.6. All data were corrected to values for those 
measured from the –ve 1OAb control. Data in Figure 2.6 is illustrated with the use of the TIBCO® 
Spotfire® Desktop 7.0.0 software (www.spotfire.tibco.com).   
The Morphology Explorer Bio-Application protocol used in the experiments described was used to 
provide quantitative measurements related to whole cell morphology. The platform located cells 
based on the green fluorescent whole cell membrane stain designated to channel 1 (488nm). Then 
individual cells rather than multi-cell clusters or assemblages were located based on Hoechst 33342 
positivity, and designated as channel 2 (386nm). Finally, features pertaining to the whole cell 
morphology were reported based on α-tubulin immunostaining, which was designated as channel 
3 (549nm). Features reported within this report include; cell area, cell shape (P2A - perimeter to 
area ratio; LWR – length to width ratio), nuclear area, and nuclear shape P2A and LWR.  
The P2A ratio was calculated using the following equation: 
𝑃2𝐴 =
𝑃𝑒𝑟𝑖𝑚𝑒𝑡𝑒𝑟2
4𝜋 × 𝐴𝑟𝑒𝑎
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A P2A and LWR value of 1 numerically denotes a complete circle. Therefore, objects which are more 
spherical have a value closer to 1, yet irregular shaped objects have values greater than 1. 
The raw data showing the sum of and mean intensities on a per cell basis are shown in Appendix 
7.1 within Figure 7.9 through Figure 7.16.; however, presented within this chapter is the percentage 
of cells positive for the biomarkers of interest, relative to a threshold value.
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Figure 2.5: An illustration showing the different regions of interest used to identify biomarker 
immunoreactivity differences between cell types and regions. 
The Cellomics ArrayScan© HCS and INCELL Analyser© HCS readers identify regions of interest 
within cells, then measure the intensity of the antibody or dye associated fluorescence of the 
biomarkers of interest. Fluorescence intensity was measured using the Compartmental Analysis 
BioApplication within the nuclear area (yellow dashed circle) or the cytoplasmic area (red ring). 
Using a threshold, the spot intensity was measured (purple circles) within the cytoplasm or nucleus. 
Cellular morphology was measured with the Morphology Explorer BioApplication based on a 
fluorescent membrane stain and α-tubulin staining (orange perimeter line) to reveal cell area, 
perimeter and shape.  
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Figure 2.6: The distribution of fluorescent immunoreactive cells stained for the Ki-67 antigen. 
The three graph panels detail the distribution of cells, where the nuclear intensity is shown on the x-axis and the nuclear area on the y-axis. As seen in the 
figure legend (right), the colour and shade of each spot varies according to cell type (MSC are green, SAOS2 are orange and MG63 cells are red) and according 
to fluorescence intensity (RLU) within the nucleus, categorised into three ‘bins’. Likewise, the size of each spot is dependent on the area of fluorescence 
within each nucleus. The black line on each panel shows the mean threshold value which was used as a reference value, above which, immunoreactive cells 
were counted and reported as the percentage of positive cells (% positive) within the total population.  
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2.13 Cell labelling with Cell Tracker™ Green/Red Fluorescent Probes 
To positively identify cell populations within co-cultures, MSC were labelled with Cell Tracker™ 
Green Fluorescent Probe Kit (Sigma-Aldrich) and SAOS2 or MG63 were labelled with Cell Tracker™ 
Red Fluorescent Probe Kit (Sigma-Aldrich) according to manufacturer’s protocol. The fluorescent 
dye comprises of a lipophilic aliphatic carbon tail with a fluorochrome head group, which are 
incorporated and trapped within the lipid bilayer of the cell membrane (Horan and Slezak, 1989).  
Cell Tracker™ Labelling was performed according to the manufacturer’s protocol as follows: (i) cells 
in monolayer culture were trypsinised, washed three times in serum free DMEM/F-12 then 
centrifuged for 10mins at 1000rpm (1200rcf). (ii) After the final spin, all supernatant was removed 
and cells were re-suspended in 500µl of Diluent C (Mix A). (iii) In a fresh eppendorf 500µl of Diluent 
C and 4µl of fluorescent dye were mixed (Mix B). (iv) Mix A was then added to Mix B and thoroughly 
mixed by gentle pipetting. (v) This solution was allowed to stand at room temperature for 4 
minutes, with regular inverting of the tube to maintain homogeneity. (vi) 1ml of complete media 
was added to neutralize the reaction. (vii) The solution was mixed by gentle pipetting and pelleted 
by centrifugation for 10 minutes at 1000rpm (1200rcf). (viii) Cells were washed and re-suspended 
twice in complete media. (ix) Cells were finally re-suspended in complete media, a viable cell count 
recorded and positive fluorescence staining was checked by fluorescence microscopy. Cells were 
then diluted accordingly and seeded appropriately.  
2.14 Cell-IQ live-cell imaging 
Live-cell imaging and analysis were conducted with the Cell-IQ ImagenTM live-cell imaging platform 
and Cell-IQ AnalyserTM image analysis software (Cell-IQ version 2, CM Technologies Oy, Tampere, 
Finland). The Cell-IQ is a fully integrated continuous live-cell imaging platform with phase contrast 
and fluorescence imaging capabilities; an internal incubator, which allows continues culture of cells 
within any desired plate or flask format; and direct gas supply to the cultured cells. Upon selection 
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of the desired regions of interest (ROI), the system will image in phase contrast and fluorescence 
the exact X and Y coordinates of all ROIs throughout the whole plate format sequentially until 
stopped. The system also takes a series of Z-stack images over a desired distance, then compresses 
all Z-stack images into a ‘snap all in focus’ image. This snap all in focus image is then saved as a raw 
digitised image.  
2.14.1 Imaging experimental setup 
All images presented here were gathered with a 10x objective; at a resolution of 1392 x 1040 pixels, 
with a pixel to µm ratio of 0.710, therefore each image gathered is 988.3 x 738.4µm. Two - 3 ROIs 
were placed within each well and duplicate or triplicate wells were seeded at 4x103 cells/cm3; then 
the cells were fed with either control media or treatment media and then imaged. Therefore, no 
less than 4 ROIs were imaged per cell type or condition. Intervals between each image were set as 
the minimum imaging cycle time, where a complete cycle is the time needed for all positions within 
the whole culture format to be imaged i.e. plate or flask. Each image was analysed individually and 
readouts were pooled and reported as the mean ± standard deviation of the mean per repeat 
experiment. All ROIs were imaged with phase contrast, and where cells were stained with 
fluorescent membrane stains (discussed in section 2.13); a GFP filter for green fluorescence marked 
cells was used, a Cy3 filter for red fluorescence, and a Cy 5 filter for far-red fluorescence were also 
used. Cell TrackerTM fluorescent probes (Sigma-Aldrich) were used to identify specific cells, where 
MSCs were stained fluorescent green, SAOS2 and MG63 cells were stained fluorescent red. Dead 
cells were stained with DRAQ 7.  
2.14.2 Image analysis 
Following imaging of the cells, the system used the unique Machine Vision Technology to identify, 
analyse and quantify morphological features of cells within the images gathered using the Cell-IQ 
AnalyserTM Cell Finder tool. To achieve this, the Cell-IQ ImagenTM software was “taught” 
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distinguishing morphological features from the digitised images, creating classes of each cell type 
using a stamp tool. This stamp tool record the exact pixel intensities and pattern within that region. 
Stamps were grouped into classes, namely; MSCs, SAOS2 cells, MG63 cells, round cells, dead cells 
and debris (background). A sample library of these stamp features and classes were generated into 
pattern recognition algorithms by the software (8 representative sample library images are shown 
in Figure 2.7). The two bottom panels show the morphology of confluent SAOS2 and MG63 cells 
respectively; however, these features were not used as a separate identification feature when 
analysing cultures. The debris class was included in every analysis of each experiment conducted. 
The algorithms were used to analyse pixel intensities/patterns within all images gathered. 
Identification of MSCs, SAOS2 and MG63 cells in monoculture and co-cultures are discussed in 
Chapter 4. Class specific “fine-tuning” of the cell identification parameters, which was done to 
introduce variability of each cell type, included;  
(i) Cell counting threshold: Segmentation gradient threshold value in the traditional 
meaning - a small value results more correct segmentations as it means the system is 
more sensitive to the intensity changes in the image. At the same time, the number of 
faulty segmentations may increase. 
(ii) Minimum cell distance (pixels): The cell distance value defines the distance between 
two neighbouring cells - a small value potentially results more cells to be segmented. 
(iii) Maximum cell diameter (pixels): The maximum cell diameter defines the size of the 
biggest cells in the population.  
(iv) Cell symmetry (100 = round): With the cell symmetry parameter, the user can 
emphasize the importance of cell symmetry in the cell segmentation. In this 
terminology, an exactly round cell is the most symmetrical target. 
(See Table 4 for details about the specific numerical differences between cell identification 
parameters).  
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>100 MSCs, SAOS2, MG63 cells and chondrosarcoma cells were tracked using the Cell-IQ AnalyserTM 
Manual Cell Tracking tool, over culture periods greater than 24hrs of culture and results reported 
in Figure 4.9, Figure 7.30 and Figure 4.11.  
For lineage tracking, the Cell-IQ AnalyserTM Manual Cell Lineage Tracking tool was used and results 
presented in Figure 5.5 through Figure 5.9. Phase images of cells in monocultures were used and 
individual cells were tracked from images taken throughout the culture period, where ≥3 cells were 
tracked from each repeat experiment. In some cases, it was only possible to track 3 cells per 
repeat/condition due to their mobility and proliferation, where the proliferation of the cells into a 
fully confluent monolayer and therefore inhibit tracking and identification of the cell. The numbers 
of cells tracked between the different cell types and within each treatment condition are detailed 
in Table 5. Comparisons between the trajectory distance and speed of cells within the different 
treatment conditions in Chapter 5, >10 cells were tracked per cell type, per treatment condition. In 
depth details on live-cell imaging and analysis protocol development can be seen in Appendix 7.2.1 
within Figure 7.18 through Figure 7.25. Donor to donor variability for manual cell lineage tracking 
is discussed in Appendix 7.2.3 and graphed in Figure 7.30.  
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Figure 2.7: The Cell-IQ library ‘stamps’ which were obtained from phase contrast microscopy 
images showing different cell classes.  
Eight representative images are shown making up the library of cell specific morphological features 
which were used to teach the pattern recognition software thus creating the different Algorithms. 
Classes shown (from the top panels) include: MSCs, SAOS2, MG63 cells, round cells, dead cells and 
finally debris. The two bottom panels show the morphology of confluent SAOS2 and MG63 cells 
respectively; however, these features were not used as a separate identification feature when 
analysing cultures. Original images obtained using magnification x100. 
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Table 4: Descriptive details for cell identification parameters: differences between class 
parameters. 
 
Cell counting 
threshold 
Minimum cell 
distance (pixels) 
Maximum cell 
diameter (pixels) 
Cell symmetry 
(100:round) 
MSCs 50 51 65 20 
SAOS2 40 41 45 50 
MG63 45 45 55 20 
Round 65 35 48 80 
Dead 35 25 45 20 
Debris 35 25 45 20 
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Table 5: The number of cells analysed for lineage tracking are as follows: 
 MSC 1 MSC 2 MSC 7 MSC 8 MSC 9 SAOS2 MG63 
Con 11 46 55 21 20 60 26 
BAP [Low] 18 61 53 20 14 66 44 
BAP [High] 21 79 85 25 22 126 115 
Con 10 73 50 18 13 78 28 
V-BAP [Low] 21 38 71 23 18 71 50 
V-BAP [High] 23 53 45 21 29 151 109 
 
Abbreviations: BAP, Bezafibrate (BEZ) and Medroxyprogesterone Acetate (MPA); V-BAP, BAP 
supplemented with Valpoic Acid (VPA); BAP [Low], BAP concentration at [0.5mM/5µM] BEZ/MPA; 
BAP [High], BAP concentration at [1.0mM/10µM] BEZ/MPA; V-BAP [Low], BAP concentration at 
[0.5mM/5µM] BEZ/MPA supplemented with [0.6mM] VPA; V-BAP [High], BAP concentration  at 
[1.0mM/10µM] BEZ/MPA supplemented with [0.6mM] VPA. 
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2.15 MTT assay 
The tetrazolium dye, MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is reduced 
into a purple insoluble formazan by NAD(P)H-dependent cellular oxidoreductase enzymes within 
viable cells. The formazan is then liberated by dissolving the cell with DMSO and the absorbance 
read using a spectrophotometer. MTT solution was prepared immediately prior to use and the assay 
was performed as follows: (i) 100µl of 5mg/ml MTT (Milford, Haarlem, Netherlands) was diluted 
per 1ml PBS supplemented with 4.5g/l glucose (Molekula, Gillingham, Dorset, UK). (ii) Following 
culture and/or treatment of samples, all media was removed from the wells and 100µl of 
PBS/Glucose + MTT solution was added per well in a 96 well plate. (iii) The plate was incubated in 
the dark for 3hrs and maintained in a humidified atmosphere at 37oC with 5% CO2. (iv) Following 
incubation, the solution was carefully removed and the plate was left to air dry for 10mins. (v) 100µl 
of DMSO (Sigma-Aldrich) was then added per well and the plate agitated until all cell debris was 
dissociated. (vi) The absorbance was read using a spectrophotometer at 492nm and background 
read at 650nm. (vii) Values were corrected for background and normalised to the mean of the 
control. Protocol adapted from Huang, Chen and Walker, (2004). Donor to donor variability for MTT 
results is discussed in Appendix 7.2.37.3.1 and graphed in Figure 7.31 and Figure 7.32. 
2.16 Preparation of BEZ, MPA, VPA, BAP and V-BAP for drug 
treatments 
Bezafibrate (BEZ) was maintained at a stock concentration of 0.5M in DMSO and used at a working 
concentration of 0.5mM. Medroxyprogesterone acetate (MPA) was maintained at a stock 
concentration of 5.0mM in ethanol and used at a working concentration of 5.0µM. Valproic acid 
(VPA) was maintained at a stock concentration of 0.6M in dH2O and used at a working concentration 
of 0.6mM. All chemicals were purchased from Sigma-Aldrich. Stocks were stored at -20oC. 
Combinatorial treatments with BEZ and MPA were collectively termed BAP. Treatments of BAP 
supplemented with VPA were collectively termed V-BAP. 
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The preparation of BEZ:  
For a 1ml preparation of the highest working concentration [4.0mM], a 2X concentrated solution 
[8.0mM] was prepared as follows: (i) 8µl of BEZ stock [0.5mM] were placed into a micro-centrifuge 
tube, and then 1ml of warm complete media was added swiftly and mixed by pipetting. (ii) 8µl of 
DMSO was similarly prepared with 1ml of warm media as a negative control. (iii) Four serial 
doubling dilutions were then performed using 500µl of [4.0mM] solution added to 500µl of fresh 
complete media through to [0.25mM]. (iv) For a 96 well plate, 100µl of 2X concentrated solution 
was added to 100µl of complete media already within each well.  
The preparation of MPA: 
For a 1ml preparation of the highest working concentration [40µM], a 2X concentrated solution 
[80µM] was prepared as follows: (i) 8µl of MPA stock [5.0mM] were added to 1ml complete media 
within a 1.5ml micro-centrifuge tube and mixed by pipetting. (ii) 8µl of ethanol was similarly 
prepared in 1ml of warm complete media as a negative control. (iii) Four serial doubling dilutions 
were then performed using 500µl of [40µM] solution added to 500µl of fresh complete media 
through to [1.25µM]. (iv) For a 96 well plate, 100µl of 2X concentrated solution was added to 100µl 
of complete media already within each well.  
The preparation of VPA:  
For a 1ml preparation of the highest working concentration [2.4mM], a 2X concentrated solution 
[4.8mM] was prepared as follows: (i) 8µl of MPA stock [0.6M] were added to 1ml complete media 
within a 1.5ml micro-centrifuge tube and mixed by pipetting. (ii) 8µl of dH2O was similarly prepared 
in 1ml of warm complete media as a negative control. (iii) Four serial doubling dilutions were then 
performed using 500µl of [4.8mM] solution added to 500µl of fresh complete media through to 
[0.3mM]. (iv) For a 96 well plate, 100µl of 2X concentrated solution was added to 100µl of complete 
media already within each well. 
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The preparation of BAP:  
For a 1ml preparation of the highest working concentration of BEZ at [4.0mM] and MPA at [40µM], 
a 2X concentrated solution was prepared as follows: (i) 8µl of BEZ stock [0.5mM] were placed into 
a micro-centrifuge tube, and then 1ml of warm complete media was added swiftly and mixed by 
pipetting. (ii) 8µl of MPA stock [5.0mM] were added to the solution and mixed by pipetting. (iii) 8µl 
of DMSO and 8µl of ethanol were similarly prepared with 1ml of warm media as a negative control. 
(iv) Four serial doubling dilutions were then performed using 500µl of [4.0mM/40µM] solution 
added to 500µl of fresh complete media through to [0.25mM/2.5µM]. (v) For a 96 well plate, 100µl 
of 2X concentrated solution was added to 100µl of complete media already within each well. (vi) 
For a 24 well plate, solutions were scaled up accordingly where a final volume of 1ml at 2X 
concentrated solution was added per well to 1ml complete media already within the well. Results 
obtained from the live-cell imaging examined two concentrations of BAP; namely, [0.5mM/5µM] 
BEZ/MPA or [1.0mM/10µM] BEZ/MPA. For the sake of simplicity, the lower concentration was 
referred to as BAP [Low] and the higher concentration as BAP [High] respectively. 
The preparation of V-BAP: 
Preparation of a 2X concentration BAP solution with the addition of VPA was done similarly to that 
above and prepared as follows: (i) a solution of combined BEZ [4.0mM] and MPA [40µM] solution 
was made, then serially diluted. (ii) Following serial dilutions, 2µl of VPA [0.6M] were added per 
1ml of all BEZ/MPA concentrations. This resulted in solutions ranging from [4.0mM/40µM] 
BEZ/MPA + [0.6mM] VPA to [0.25mM/2.5µM] BEZ/MPA + [0.6mM] VPA. 2µl of dH2O were similarly 
added as a negative control. (iii) For a 96 well plate, 100µl of 2X concentrated solution was added 
to 100µl of complete media already within each well. (iv) For a 24 well plate, solutions were scaled 
up accordingly where a final volume of 1ml at 2X concentrated solution was added per well to 1ml 
complete media already within the well. Again, results obtained from the live-cell imaging examined 
two concentrations of V-BAP; namely, [0.5mM/5µM/0.6mM] BEZ/MPA/VPA or 
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[1.0mM/10µM/0.6mM] BEZ/MPA/VPA. For the sake of simplicity, the lower concentration was 
referred to as V-BAP [Low] and the higher concentration as V-BAP [High]. 
2.17 DRAQ 7 staining of dead cells 
DRAQ7™ (Bio Status Ltd, Leicestershire, UK) is a far-red fluorescent DNA dye that stains the nuclei 
in dead and permeabilized cells, whilst showing no signs of toxic effect on the proliferation ability 
and rate of cells in long term culture assays. DRAQ7™ was added to control and treatment solutions 
for all selective killing drug-treatment experiments, to confirm cell death during live-cell imaging. 
10µl of DRAQ7™ was added directly per 1.0ml of control and drug treatment solutions for a final 
concentration of 3µM. Fluorescence was read and imaged at 633nmEX and >665nmEM.  
2.18 Statistical Analysis 
Data from ≥3 independent experiments have been presented here as the mean ± the standard error 
of the mean (SEM). Data from single experiments with internal replication have been presented 
within the Appendix, as the mean ± the SD. All data were presumed to be normally distributed, 
therefore parametric statistical analysis was performed to determine and verify any significant 
differences between groups. For experiments that had one independent variable across 3 or more 
experimental groups (such as biomarker immunoreactivity between MSCs, SAOS2 and MG63 cells), 
a one-way analysis of variance (ANOVA) was performed with a Tukey’s multiple comparison test 
used to identify significant differences between the means of all variables. For experiments that 
had two independent variables across 3 or more experimental groups (such as phase identification 
of MSCs, SAOS2 and MG63 cells over an extended culture period), a two-way ANOVA was 
performed. In such analysis, a Tukey’s multiple comparison test was then performed to identify 
significant differences between all the variable means. A Dunnett’s multiple comparison test was 
performed to identify significant differences between variable means when compared to an 
individual variable mean. In all cases; *indicates p≤0.05, **indicates p≤0.01, ***indicates p≤0.001. 
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3 Chapter 3: The use of high content screening platforms to 
distinguish between MSCs and osteosarcoma cell lines 
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3.1 Aims and Background 
A number of studies have suggested that MSCs may undergo spontaneous malignant 
transformation to form tumour cells, or at least can become contaminated with other cell types 
following extended periods in culture (Rubio et al., 2005, Rubio et al., 2008a, Rosland et al., 2009, 
De La Fuente et al., 2010, Torsvik et al., 2010). There is also substantial evidence that transformed 
MSCs may form the cancer stem cell for certain tumours, notably osteosarcoma, Ewing’s sarcoma 
and chondrosarcoma (Boeuf et al., 2008, Riggi et al., 2008, Suva et al., 2009, Lin, Wang and Lozano, 
2011). Possible contamination or transformation of MSCs within culture expansion prior to 
transplantation therapies is a risk, which should be taken into full account, as should the need for 
standardized identification of MSC characteristics. In addition, there is a continued need for the 
development of improved tools for monitoring safety and release criteria (Heathman et al., 2015a). 
Furthermore, automated methods of establishing MSC phenotype will enable the wide scale and 
regulated provision of MSCs in the developing field of regenerative medicine.  
Therefore, this chapter has examined whether the computerized HCS imaging platform, Thermo 
Fisher Cellomics Array Scan II could provide a means of distinguishing between human MSCs and 
osteosarcoma cell lines, SAOS2 and MG63 cells. All fluorescence intensity measurements were 
performed using the Thermo FisherTM Cellomics Array Scan. This was done via quantification of 
fluorescent intensities of fluorescently tagged immunoreactive labelled proteins. The protein 
markers of interest are associated with cell cycle progression, proliferation and survival, 
pluripotency, osteoblastic cell differentiation, cell signalling and cell migration. In addition, the 
analysis included assays of cellular and nuclear morphology. All results shown within this chapter 
detail the percentage of cells which were positive for nuclear or cytoplasmic biomarker spot 
immunoreactivity relative to the total number of immunoreactive cells within each ROI, corrected 
for the number of -10Ab immunoreactive control cells. A detailed description of this is given in 
sections 2.12 and 7.1.1. 
~ 119 ~ 
 
3.2 Cell cycle and cell proliferation 
Representative fluorescence microscopy images and quantitation of Ki67 antigen, phosphorylated 
retinoblastoma protein (pRB) and phosphorylated histone H3 (pHH3) immunoreactive cells are 
shown in Figure 3.1, Figure 3.2 and Figure 3.3 respectively. As shown, bright nuclear 
immunoreactive staining for Ki67 antigen was both punctate and diffuse in appearance in many 
SAOS2 (91.34% ± 0.56%) and MG63 cells (65.64% ± 16.94%); in contrast, significantly fewer in MSCs 
(4.98% ± 3.36%, p=0.0021 and p=0.0121 respectively), which exhibited a similar pattern of immuno-
localisation. Images and quantitation of pRb immunoreactivity shows significantly marked 
immunoreactivity in MG63 cells (55.51% ± 12.78%) rather than in MSCs (6.06% ± 7.35%, p=0.0150) 
and SAOS2 cells (non-detected, p=0.0077). Images and quantitation of pHH3 immunoreactivity 
show bright, punctate and diffuse nuclear staining seen in many MG63 cells; in contrast but non-
significantly, fewer MSCs and SAOS2 cells were pHH3 immunoreactive, which exhibited a similar 
pattern of immuno-localisation. 
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Figure 3.1: Immunoreactivity for the proliferation associated Ki67 antigen within primary human 
MSCs, SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent Ki67 antigen immunoreactivity 
in MSC, SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the 
percentage of cells positive relative to threshold values for nuclear intensity for the biomarker Ki-
67 antigen within MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 
independent experiments. **indicates p≤0.01, *indicates p≤0.05, and ns indicates there is no 
significant difference. All; one-way ANOVA with a Tukey's multiple comparisons test.  
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Figure 3.2: Immunoreactivity for the phosphorylated form of the tumour suppressor 
retinoblastoma protein (pRb) within primary human MSCs, SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent pRb immunoreactivity in MSC, 
SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the percentage 
of cells positive relative to threshold values for nuclear intensity for the biomarker pRB within MSCs, 
SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 independent experiments. 
**indicates p≤0.01, *indicates p≤0.05, ND indicates non-detected and ns indicates there is no 
significant difference. All; one-way ANOVA with a Tukey's multiple comparisons test.  
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Figure 3.3: Immunoreactivity for the phosphorylated nuclear histone protein H3 (pHH3) within 
primary human MSCs, SAOS2 and MG63 cells.  
(A) Representative images showing Hoechst 33342 and fluorescent pHH3 immunoreactivity in MSC, 
SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the percentage 
of cells positive relative to threshold values for nuclear intensity for the biomarker pHH3 within 
MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 independent experiments. 
ns indicates there is no significant difference. All; one-way ANOVA with a Tukey's multiple 
comparisons test. 
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3.3 Pluripotency markers 
Representative fluorescent microscopy images and quantitation of the immunoreactivity of the 
pluripotency and transcription factors, Oct4 and nanog, are shown in Figure 3.4 and Figure 3.5 
respectively. As shown, bright and diffuse nuclear staining for Oct4 was seen in many SAOS2 
(68.75% ± 18.61) and MG63 cells (71.39% ± 10.34%); in contrast, significantly fewer MSCs exhibited 
nuclear positivity (7.92% ± 5.76%, p=0.0344 and p=0.0289 respectively), but rather showed a diffuse 
cytoplasmic pattern of immuno-localisation. Immunoreactivity for nanog showed punctate nuclear 
staining in MG63 cells (53.45% ± 8.72%); in contrast, significantly fewer MSCs (0.47% ± 0.72, 
p=0.0103) were immunoreactive. However, there was no significant difference seen in the number 
of nanog immunoreactive SAOS2 cells (23.67% ± 11.67%, p=0.102). 
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Figure 3.4: Immunoreactivity for the pluripotency marker Oct4 within primary human MSCs, 
SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent Oct4 immunoreactivity in MSC, 
SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the percentage 
of cells positive relative to threshold values for nuclear intensity for the biomarker Oct4 within 
MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 independent experiments. 
*indicates p≤0.05 and ns indicates there is no significant difference. All; one-way ANOVA with a 
Tukey's multiple comparisons test. 
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Figure 3.5: Immunoreactivity for the transcription factor nanog within primary human MSCs, 
SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent nanog immunoreactivity in 
MSC, SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the 
percentage of cells positive relative to threshold values for nuclear intensity for the biomarker 
nanog within MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 independent 
experiments. *indicates p≤0.05 and ns indicates there is no significant difference. All; one-way 
ANOVA with a Tukey's multiple comparisons test. 
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3.4 Differentiation markers 
The biomarkers associated with osteoblastic differentiation, osteopontin and osteocalcin, were not 
able to significantly distinguish primary human MSCs from either SAOS2 or MG63 cells. 
Representative fluorescence microscopy images and quantitation of such, of cytoplasmic 
osteopontin immunoreactivity are shown in Figure 3.6. As shown, bright, perinuclear staining was 
seen in the MSCs and SAOS2 cells. MG63 cells exhibited a more diffuse cytoplasmic staining pattern. 
Similarly, fluorescence microscopy images and quantitation of the immunoreactivity for 
cytoplasmic osteocalcin are shown in Figure 3.7. As shown, a few MSCs exhibited bright, punctate 
immunoreactivity in the cytoplasm, whilst MG63 exhibited a homogenous pattern of 
immunoreactivity throughout the cytoplasm. In contrast, SAOS2 cells showed very little 
immunoreactivity throughout. No significant differences in the number of cells immunoreactive for 
osteopontin or osteocalcin were seen between the cell types. 
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Figure 3.6: Immunoreactivity for the extracellular matrix protein osteopontin within primary 
human MSCs, SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent osteopontin immunoreactivity 
in MSC, SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the 
percentage of cells positive relative to threshold values for cytoplasmic intensity for the biomarker 
osteopontin within MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 
independent experiments. ns indicates there is no significant difference. All; one-way ANOVA with 
a Tukey's multiple comparisons test. 
~ 128 ~ 
 
 
Figure 3.7: Immunoreactivity for the cytoplasmic protein osteocalcin within primary human 
MSCs, SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent osteocalcin immunoreactivity 
in MSC, SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the 
percentage of cells positive relative to threshold values for cytoplasmic intensity for the biomarker 
osteocalcin within MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 
independent experiments. ns indicates there is no significant difference. All; one-way ANOVA with 
a Tukey's multiple comparisons test. 
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3.5 Cell signalling and migration 
Imaging and quantitation of immunoreactivity for the intracellular signalling protein, β-Catenin, 
identified within the nuclear (Figure 3.8) or cytoplasmic areas (Figure 3.9), was only able to 
distinguish MG63 cells from MSCs with no significant difference seen between MSCs and SAOS2 
cells, or SAOS2 and MG63 cells. As shown, diffuse cytoplasmic staining can be seen within MSCs 
and SAOS2 cells. In contrast, MG63 cells showed a mixture of bright, diffuse and punctate 
cytoplasmic staining. A similar pattern to the cytoplasmic staining was seen within the nuclei of the 
cells, where SAOS2 and MSCs showed bright diffuse immunoreactivity and MG63 showed a mixture 
of bright diffuse and punctate nuclear immunoreactivity. MG63 cells were significantly more 
immunoreactive for cytoplasmic and nuclear β-catenin (91.77% ± 3.07% and 89.34% ± 1.66% 
respectively) compared to the immunoreactivity of MSCs (31.14% ± 22.60%, p=0.0419  and 28.97% 
± 16.17%, p=0.0099 respectively).  
Imaging and quantitation of immunoreactivity for the biomarkers associated with cell migration, 
pFAK shown in Figure 3.10, presented a distinctly unique staining pattern between each cell type. 
MSCs showed a dull diffuse cytoplasmic staining. In contrast, SAOS2 cells stained with a bright 
puncta along the outer edge of their cytoplasm and dull diffuse cytoplasmic staining. MG63 cells 
contrasted to both MSCs and SAOS2, where bright, punctate and diffuse stained was seen within 
the cytoplasm. However, quantitation of the number of immunoreactive cells was not significantly 
different between cell types. 
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Figure 3.8: Immunoreactivity for the signalling protein β-Catenin within the cytoplasm of primary 
human MSCs, SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent cytoplasmic β-Catenin 
immunoreactivity in MSC, SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar 
graph showing the percentage of cells positive relative to threshold values for cytoplasmic intensity 
for the biomarker β-catenin within MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM 
from n=3 independent experiments. *indicates p≤0.05 and ns indicates there is no significant 
difference. All; one-way ANOVA with a Tukey's multiple comparisons test. 
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Figure 3.9: Immunoreactivity for the signalling protein β-Catenin within the nuclei of primary 
human MSCs, SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent nuclear β-Catenin 
immunoreactivity in MSC, SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar 
graph showing the percentage of cells positive relative to threshold values for nuclear intensity for 
the biomarker β-catenin within MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from 
n=3 independent experiments. **indicates p≤0.01 and ns indicates there is no significant 
difference. All; one-way ANOVA with a Tukey's multiple comparisons test. 
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Figure 3.10: Immunoreactivity for the phosphorylated cytoplasmic protein focal adhesion kinase 
(pFAK) within primary human MSCs, SAOS2 and MG63 cells. 
(A) Representative images showing Hoechst 33342 and fluorescent pFAK immunoreactivity in MSC, 
SAOS2 and MG63 cells (Bar = 100µm). Inset is 4.8x magnified. (B) Bar graph showing the percentage 
of cells positive relative to threshold values for nuclear intensity for the biomarker pFAK within 
MSCs, SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 independent experiments. 
ns indicates there is no significant difference. All; one-way ANOVA with a Tukey's multiple 
comparisons test. 
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3.6 Nuclear and Cytoplasmic Biomarker Summary 
The summary heat map of nuclear biomarkers examined within this chapter is shown in Figure 3.11, 
where the average nuclear fluorescent intensity (RLU arbitrary units) for all the biomarkers are 
compared and grouped according to cell type. The area of each rectangle is relative to the average 
biomarker fluorescence area measured (µm2) within each nucleus. It can easily be seen that the 
SAOS2 and MG63 cells presented the most immunoreactive labelled cells for Ki67 antigen, nuclear 
β-catenin and pHH3 compared to the MSCs.  
Similarly, the cytoplasmic biomarkers shown in Figure 3.12 were compared, and it easily can be 
seen that β-catenin was the most immunoreactive biomarker, followed by osteopontin, pFAK and 
osteocalcin within MG63 cells; less so within MSCs and SAOS2 cells. 
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Figure 3.11: A heat map comparing the nuclear fluorescent intensity with the nuclear fluorescent 
area for a broad range of nuclear biomarkers within primary human MSCs, SAOS2 and MG63 cells. 
The heat map illustrates the range of fluorescently immunoreactive nuclear intensities (intensity of 
the red rectangles; min 5,259 RLU to max 205,847 RLU) and nuclear fluorescent area (area of 
rectangles; µm2) for all nuclear biomarkers; β-catenin, pHH3, Ki67 antigen, nanog and Oct4 within 
the primary MSCs, SAOS2 and MG63 cells. Data used are from 3 independent experiments. The 
heat map is firstly grouped by cell type, then by biomarker. 
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Figure 3.12: A heat map comparing the cytoplasmic fluorescent intensity with the cytoplasmic 
fluorescent area for a broad range of cytoplasmic biomarkers within primary human MSCs, SAOS2 
and MG63 cells. 
The heat map illustrates the fluorescently stained cytoplasmic intensities (intensity of the red 
rectangles; min 19,408 RLU to max 330,593 RLU) and cytoplasmic fluorescent area (area of 
rectangle; µm2) for all cytoplasmic biomarkers; β-catenin, osteocalcin, osteopontin and pFAK within 
the primary MSCs, SAOS2 and MG63 cells. Data used are from 3 independent experiments. The 
heat map is firstly grouped by cell type, then by biomarker. 
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3.7 Cell and Nuclear Morphology 
Measurements of cell and nuclear morphological features were only able to significantly distinguish 
human MSCs from both SAOS2 and MG63 cells based on nuclear area. Images of α-tubulin stained 
cells and the quantitation of cell area, perimeter to area (P2A) shape and length to width ratio 
(LWR) shapes of MSCs, SAOS2 and MG63 cells are shown in Figure 3.13 and Figure 3.14 respectively.  
The immunoreactivity of α-tubulin demonstrated that MSCs exhibited a fibroblastic appearance, 
with some stellate cells extending multiple slender cytoplasmic processes. In contrast, SAOS2 and 
MG63 cells were more polygonal and exhibited morphological shapes which were bipolar, 
triangular or circular. Quantitation of the morphology showed that MG63 cells had an average area 
of 2119 ± 347µm2, significantly greater than that of SAOS2 cells (1196 ± 284µm2, p=0.0284), but not 
significantly greater than the area of MSCs (1763 ± 83µm2).  The P2A and LWR measurements are 
a numerical representation of the ‘roundness’ of a cell’s shape determined by the perimeter to area 
(P2A) ratio or the Length to Width ratio (LWR), where 1.0 is a perfectly circular object. As shown, 
the P2A of SAOS2 cells (1.49 ± 0.05) were significantly less than MSCs (2.44 ± 0.10, p<0.001) and 
MG63 cells (2.18 ± 0.23, p=0.0166). Similarly, the LWR of SAOS2 cells (1 1.66 ± 0.04) were 
significantly less than MSCs (2.46 ± 0.09, p<0.001) and MG63 cells (2.13 ± 0.04, p=0.0275). 
Representative fluorescence microscopy images and quantitation of the area and shapes of 
Hoechst 33342 nuclear staining of MSCs, SAOS2 and MG63 cells are shown in Figure 3.15 and Figure 
3.16 respectively. As shown, MSCs had significantly smaller nuclei (270 ± 4.96µm2) than SAOS2 cells 
(358 ± 9.96 µm2, p<0.001) and MG63 cells (460 ± 4.50 µm2, p<0.001). Similarly, the nuclei of the 
SAOS2 cells were significantly smaller than the MG63 cells (p<0.001).  However, there were no 
significant differences in nuclear P2A or LWR between the MSCs, SAOS2 or MG63 cells. 
The quantitation of the total and mean fluorescence intensity of Hoechst 33342 stained nuclei 
significantly distinguished between all cell types; where the average intensity of MSCs (1179 ± 13 
RLU) was significantly less than SAOS2 cells (1329 ± 25 RLU, p=0.0023) and MG63 cells (1665 ± 10.6 
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RLU, p<0.001). SAOS2 cell’s average intensity was also significantly less than MG63 cells (p<0.001). 
Likewise, the significant differences in the total fluorescent intensities between the cell types were 
all significant (p<0.001) where MSCs had the lowest total intensity (193510 ± 5229 RLU) then SAOS2 
cells (300258 ± 12733 RLU), and MG63 cells showing the greatest intensity (477373 ± 2903 RLU). 
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Figure 3.13: Morphological analysis of α-Tubulin immunoreactive primary human MSCs, SAOS2 
and MG63 cells. 
(A) Representative images showing α-tubulin immunoreactive staining in MSCs, SAOS2 and MG63 
cells (Bar = 100µm). (B) Quantitative measure of average cell area of MSCs, SAOS2 and MG63 cells. 
Data shown are means ± SEM from n=9 MSCs and n≥3 osteosarcoma cells from ≥3 independent 
experiments. ns indicates no significant difference. All; one-way ANOVA with a Tukey's multiple 
comparisons test. 
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Figure 3.14: Morphological analysis of α-Tubulin immunoreactive primary human MSCs, SAOS2 
and MG63 cells. 
Quantitative measure of the average cell shapes defined as the perimeter to area ratio (P2A) (A) 
and length to width ratio (LWR) (B) of MSCs, SAOS2 and MG63 cells. Perfectly spherical objects have 
a ratio of 1. Data shown are means ± SEM from n=9 MSCs and n≥3 osteosarcoma cells from ≥3 
independent experiments. ***indicates p≤0.001, *indicated p≤0.01, and ns indicates no significant 
difference. All; one-way ANOVA with a Tukey's multiple comparisons test. 
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Figure 3.15: Morphological analysis of Hoechst 33342 stained nuclei distinguished between 
primary human MSCs, SAOS2 and MG63 cells based on nuclear area. 
(A) Representative images showing Hoechst 33342 staining of nuclei from MSC, SAOS2 and MG63 
cells (Bar = 100µm). Inset is 2.5x magnified. (B) Quantitation of the mean nuclear area of MSCs, 
SAOS2 and MG63 cells. Data shown are means ± SEM from n=3 independent experiments. 
***indicates p≤0.001. All; one-way ANOVA with a Tukey's multiple comparisons test. 
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Figure 3.16: Morphological analysis of Hoechst 33342 stained nuclei did not distinguish between 
primary human MSCs, SAOS2 or MG63 cells based on nuclear shape. 
Quantitative measure of the average nuclear shapes defined as the perimeter to area ratio (P2A) 
(A) and length to width ratio (LWR) (B) of MSCs, SAOS2 and MG63 cell nuclei. Perfectly spherical 
objects have a ratio of 1. Data shown are means ± SEM from n=3 independent experiments. ns 
indicates there is no significant difference seen. All; one-way ANOVA with a Tukey's multiple 
comparisons test. 
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Figure 3.17: Quantitation of Hoechst 33342 stained nuclear intensity distinguished between 
primary human MSCs, SAOS2 or MG63 cells based on average and total nuclear intensity. 
Quantitation is shown for the average (A) and total (B) nuclear intensity of MSCs, SAOS2 and MG63 
cells based on Hoechst 33342 staining. Data shown are means ± SEM from n=3 independent 
experiments. ***indicates p≤0.001, **indicates p≤0.01. All; one-way ANOVA with a Tukey's 
multiple comparisons test. 
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3.8 Discussion 
MSCs are an attractive candidate cell type for therapies in regenerative medicine on account of 
their ease of isolation from bone marrow throughout adult life, their evident differentiation 
potential to form bone and cartilage and a capacity to stimulate wound healing responses in other 
endogenous cells (Pittenger, 1999, D'ippolito et al., 2006, Bajada et al., 2008, Walter et al., 2010). 
This requires in vitro monolayer culture expansion to increase the number of cells. However, a 
number of studies have suggested that MSCs may undergo spontaneous malignant transformation 
to form tumour cells, or become contaminated with other cell types following extended periods in 
culture (Rubio et al., 2005, Mohseny et al., 2009, Rosland et al., 2009, Siclari and Qin, 2010, Torsvik 
et al., 2010). Therefore, this study has examined whether the computerized HCS and imaging 
platform, Thermo Fisher Cellomics Array Scan (II), may provide a means of identifying biomarker 
differences between MSCs and tumour cells, namely the human osteosarcoma cell lines SAOS2 and 
MG63.  
This HCS platform examined a wide range of fluorescently immunoreactive protein biomarkers. 
These proteins of interest are associated with cell cycle and proliferation, pluripotency, osteoblastic 
differentiation and cell signalling. In addition, the analysis included assays of cellular and nuclear 
morphology. Notable differences in immunoreactivity were seen between the MSCs compared to 
SAOS2 and MG63 cells. The biomarkers that significantly identified both SAOS2 and MG63 cells as 
different to MSCs were the Ki-67 antigen and Oct4. MG63 cells were also significantly more 
immunoreactive for pRB compared with SAOS2 and MSCs and more immunoreactive for nanog and 
β-catenin compared with MSCs alone. However, when the nuclear or cytoplasmic biomarker 
immunoreactivity intensities were compared alongside each-other as ‘heat maps’, it was clear that 
the osteosarcoma cell lines were distinctly more immunoreactive compared to the MSCs. Cellular 
and nuclear morphology distinguished MSC from SAOS2 and MG63 cells, where MSCs had a smaller 
nuclear area than SAOS2 and MG63 cells.  
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Considering the nuclear area and intensities were the most distinguishing feature between the 
MSCs and osteosarcoma cell lines, the need for further biomarker analysis may be seen as 
unnecessary. Further imaging and analysis of more patient MSC samples, transformed MSC cell 
lines as well as primary cancer cell lines may help elucidate whether the nuclear area could be a 
viable and determinant cell feature for identification. These differences between the MSCs and the 
osteosarcoma cell lines have been summarised in Table 6. 
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Table 6: Cell type specific identification by fluorescent immunoreactive labelling and high content 
screening.  
Cell Type Distinguishing Features 
MSC Small nuclear area cf SAOS2 and MG63 
SAOS2 Lowest P2A and LWR cf MSC and MG63 
High Ki-67 cf MSC 
High Oct4 cf MSC 
MG63 
High pRb cf MSC and SAOS2 
High β-catenin and Nanog cf MSC 
All Cells Significantly different fluorescent nuclear intensities 
 
Abbreviations: MSC, Mesenchymal stem cells; cf, compared with; pRb, phosphorylated 
retinoblastoma protein. 
(Green) Cell type specific features unique to primary human MSCs was a small nuclear area 
compared with those of SAOS2 and MG63 cells. (Orange) The most spherically shaped cell type, 
hence the lowest P2A and LWR value was unique to SAOS2 cells when compared to the more 
complex shapes of the primary human MSCs and MG63 cells. (Red) High immunoreactivity for pRb, 
β-catenin and Nanog was unique to MG63 cells compared to low immunoreactive labelling in 
primary human MSCs and SAOS2 cells. (Blue) High immunoreactive labelling for the Ki-67 antigen 
and Oct4 were unique to both the SAOS2 and MG63 cells compared to low immunoreactive 
labelling in MSCs. (Yellow) However, the most significantly distinguishing feature between all cell 
types was the difference in the average or total nuclear fluorescence intensity.  
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Each of the biomarkers examined, have been discussed briefly. β-catenin is central in the canonical 
Wnt/β-catenin signalling pathway, which plays an important role in the regulation of MSC self-
renewal, proliferation and differentiation. Low levels of canonical Wnt signalling are associated with 
the maintenance of an undifferentiated state and high levels of Wnt signalling are involved in 
osteogenic differentiation (Gaur et al., 2005, Ling, Nurcombe and Cool, 2009). Canonical Wnt 
signalling in osteoblastic differentiation has been shown to stimulate the proliferation of 
osteoprecursor cells, increasing the number of osteoprogenitor cells available for further 
differentiation and mineralisation (Cook et al., 2014). It has been shown that β-catenin 
translocation into the nucleus leads to transcriptional activation of β-catenin target genes 
(Couffinhal, Dufourcq and Duplàa, 2006). Interestingly, abnormally high β-catenin nuclear 
accumulation has been used as a diagnostic tool specific to a subset of mesenchymal tumours, but 
not osteosarcomas (Ng et al., 2004). Low β-catenin immunoreactivity was observed within the 
cytoplasm and nucleus in MSCs. In contrast, high β-catenin immunoreactivity was observed within 
the cytoplasm and nucleus of MG63 cells, which may suggest that MG63 cells are more 
differentiated than the MSCs and SAOS2 cells along the osteoblastic lineage. In either case, these 
observations demonstrate that β-catenin alone cannot be used to identify all osteosarcomas. 
In contrast to β-catenin, immunoreactivity for the activated (phosphorylated) form of focal 
adhesion kinase (pFAK) showed no significant differences between the osteosarcoma cells 
compared with MSCs. A difference was seen as expected, although this difference was not 
significant. A difference in pFAK expression and detection is consistent with the known involvement 
of pFAK in cancers (Wozniak et al., 2004), where its over expression and aberrant functioning is 
commonly associated with increased cell proliferation and cancer metastasis (Gabarra-Niecko, 
Schaller and Dunty, 2003, Tilghman and Parsons, 2008). The greater levels of pFAK 
immunoreactivity associated with significantly increased Ki-67 immunoreactivity in the 
osteosarcoma cell lines, compared to the MSCs, would therefore have suggested that the main 
difference in cell phenotypes are in their proliferative and migratory capacity. Further analysis was 
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performed to examine the differences in migratory behaviour between the MSCs, SAOS2 and MG63 
cells as noted in the following chapter. 
Immunoreactivity for Oct4 was significantly more highly seen in SAOS2 and MG63 cells than in 
MSCs. Oct4 is expressed at high levels in embryonic stem cells; it is a transcription factor that plays 
a vital role in stem cell self-renewal and pluripotency (Pierantozzi et al., 2011). The high Oct4 
immunoreactivity detected in SAOS2 and MG63 cells in this study is consistent with the work of 
Tirino et al., (2008), where the presence of Oct4 within a highly proliferative CD133+ve sub-
population of SAOS2 and MG63 cells was described as a cancer stem cell characteristic (Tirino et 
al., 2008). Hence, Oct4 may be involved in the self-renewal of the osteosarcoma cells. In contrast, 
the low levels of Oct4 seen in MSCs may reflect a more restricted differentiation potential 
compared to embryonic stem cells. However, the role of Oct4 in osteosarcoma cells and MSCs, 
including any aberrant functioning in tumourigenesis, remains to be determined.  
It is interesting to compare the immunoreactivity of Oct4 with that of nanog. Nanog 
immunoreactivity detected in the MSCs was low. Pierantozzi et al., (2011) described an observation 
with MSCs, where they noted a lack of nanog expression in freshly isolated cells, yet increased 
expression detected following in vitro culture expansion. Additionally, they stated that this change 
in expression did not directly relate to MSC proliferation or differentiation capacity, but rather, it 
may be associated with a transition from in vivo quiescence to adaptation of growth in vitro 
(Pierantozzi et al., 2011). High expression of both Oct4 and nanog within subpopulations of SAOS2 
and MG63 cells may be a characteristic of tumour initiating cells (Huang, Dai and Guo, 2012). 
The morphology of each cell type was observed following α-tubulin immunoreactivity and Hoechst 
33342 nuclear counterstaining. Differences in cell and nuclear shapes were observed and 
quantitated. The heterogeneous population of cells commonly labelled as MSCs have been 
described in many ways, such as fibroblastic, spindle shaped, large and polygonal and even cuboidal 
when in confluent tightly packed cultures (Javazon, Beggs and Flake, 2004, Miao et al., 2006, 
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Chamberlain et al., 2007). Classically though, freshly isolated MSCs have been described as stromal 
and fibroblastic in appearance (Pittenger, 1999). In contrast to the fibroblast-like shape of young 
MSCs, aged and senescent MSCs have been described as large, flattened cells (Kim et al., 2011) with 
a large cell surface area and volume (Toussaint, Medrano and Von Zglinicki, 2000). SAOS2 cells are 
large, polygonal cells with an ellipsoid nuclei (Muff et al., 2007) although highly metastatic sub-
clones of SAOS2 cells have a smaller cell volume, cell area and nuclear area (Jia, Worth and 
Kleinerman, 1999). MG63 cells are oval to spindle-shaped and do not have branching cell processes 
(Pautke et al., 2004). In this study, the total cell area of the MSCs was not significantly different to 
that of the SAOS2 and MG63 cells. However, the P2A and LWR of the SAOS2 was significantly 
different to that of the more complex shaped MSCs and MG63 cells. The MSCs had significantly 
smaller nuclei than both the SAOS2 and the MG63 cells.  
As shown and discussed by (Heathman et al., 2015b, Heathman et al., 2016a, Heathman et al., 
2016b) the morphology of MSCs was seen to vary considerably from donor to donor, when cultured 
within different culture conditions; additional, the mean diameter of the cells was seen to increase 
over serial passage. These observations are critical to the manufacture and characterisation of the 
cells intended for therapeutic applications. The mean diameter of the MSCs determined during the 
study by Heathman et al., (2016b) was performed on cells within suspension; however, here the 
morphology of adherent cells in monoculture have been presented. It was shown that a full profile 
of morphological readouts can be simply obtained from few cells examined.   
The quantitative differences in biomarker immunoreactivity and morphology provide a rationale 
for the development of diagnostic platforms that could identify transformed cells within an MSC 
culture. One such platform would include antibodies for the Ki-67 antigen, Oct-4, pFAK, pRB and β-
catenin, with α tubulin and Hoechst 33342 counterstaining for morphological criteria. However, 
further analysis of more MSC cultures and primary osteosarcoma cells lines is required to verify 
such an approach. In particular, only 3 MSC cultures were tested in this series of experiments. These 
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were of different donor ages (57-90 years) and passage numbers (P1-P6). Similarly, a 
multiparametric approach, as demonstrated by (Chan et al., 2014), to the HCS of the biomarkers 
examined within this chapter, as well as the addition of other biomarkers of interest, could render 
this tool to be very productive in the screening and characterisation of cells intended for clinical 
therapies. 
This study has also seen some donor-to-donor variation in the readouts (data not shown), but it is 
difficult to draw any firm conclusions on the relationship between donor age or MSC age in culture 
with such a low number of donors tested, e.g. one MSC sample was cultured from a 90 year old 
donor and was tested at P1. 
A second example illustrating the need to examine more MSC donors of different passages as well 
as samples isolated from different locations is shown in the results seen for osteopontin 
immunoreactivity. All MSC cultures presented here were derived from adipose tissue and it is 
known that high osteopontin expression is associated with osteogenesis, whereas low levels of 
osteopontin expression associates with adipogenic differentiation (Chen et al., 2014). Hence, 
osteopontin immunoreactivity may relate to the “memory” that each cultures maintains of their 
differentiation potential and that as the MSCs cultures were passaged, they may have become less 
adipogenic in phenotype and gained a more osteogenic phenotype. Examining the immuno-profile 
or MSCs from bone marrow over increased passage would help establish whether such differences 
in differentiation potential over time still occur. 
An additional weakness in this study is the fact that well established osteosarcoma cell lines were 
used rather than primary tumours. There is likely to have been significant phenotypic drift within 
the SAOS2 and MG63 cell lines over time, as this is well known to occur during cell culture (Barnes, 
Moy and Dickson, 2006). An improvement to the current analysis would be to examine either 
freshly isolated primary tumours of MSC derivation (see Chapter 4) or to induce transformation of 
normal MSCs. Ivan Stamenkovic and co-workers (Riggi et al., 2008) have demonstrated that MSCs 
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can be induced to form Ewing’s type sarcomas following induced expression of the EWS-Fli-1 
oncoprotein. It would be interesting to examine the immunophenotype of these newly transformed 
cells compared to their non-transformed parental MSCs. Similarly, if MSCs from non-human sources 
(or human sources if this can occur) undergo spontaneous malignant transformation, then these 
would provide the most relevant target cell with which to test differences in phenotype that occur 
during this process.  
Nonetheless, the data generated in this chapter provides details towards the potential for HCS as a 
useful tool to evaluate these various limitations of approach. That is to say, the immunoreactivity 
and morphological assays can be used repeatedly in further analysis of other cell types.  
In addition, the immunoreactivity of the different cultures tested may also provide information 
about the nature of the tumours that have been tested. For example, the profiles observed for 
SAOS2 and MG63 may be useful in identifying when the process of osteoblastic differentiation may 
have been disrupted to give rise to osteosarcoma. Alkaline phosphatase (ALP) is an early and 
transient biomarker signifying commitment toward osteoblastic differentiation, increasing early in 
differentiation then decreasing when mineralization is well under way. Osteopontin peaks twice, 
during proliferation and later prior to the appearance of osteocalcin. Osteocalcin is a late marker 
of osteoblastic differentiation, appearing with mineralization of the cells (Aubin, 2001, Luo et al., 
2008, Birmingham et al., 2012). Hence, osteoblastic differentiation is associated with the sequential 
expression of ALP followed by osteopontin and then osteocalcin. This is supported by work from 
Weinreb, Shinar and Rodan, (1990), who examined the expression levels of such markers in long 
bone formation and calvariae during bone development. They reported that ALP was present in a 
large number of cells, including pre-osteoblasts, which were many layers removed from the bone-
forming surface; high levels of osteopontin were expressed in osteoblasts within close proximity 
(one to two cell layers) to the bone surface; and osteocalcin expressed within osteoblasts in direct 
contact with bone (Weinreb, Shinar and Rodan, 1990).  
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High ALP enzymatic activity (appendix Figure 7.17), low osteopontin and osteocalcin 
immunoreactivity were seen in SAOS2 cells. In addition, SAOS2 cells were Ki-67 immunoreactive. 
This pattern may signify that SAOS2 cells were committed towards osteoblastic differentiation at a 
stage that is prior to mineralization yet still actively proliferating (see *** in Figure 3.18), which is 
consistent with other published findings (Rodan et al., 1987, Farley et al., 1991, Aubin, 2001, Pautke 
et al., 2004, Bullwinkel et al., 2006, Luo et al., 2008). The absence of RB in SAOS2 is thought to play 
a role in the inability of these cells to undergo terminal differentiation (Thomas et al., 2001).  
The relatively low ALP activity observed within the MG63 cells, consistent with other studies 
(Pautke et al., 2004, Luo et al., 2008), implies that these cells were either immature osteoprogenitor 
cells or that they had differentiated into a post mitotic osteocytic phenotype (Aubin, 2001). In 
support for a mature osteocytic phenotype, MG63 cells were more strongly immunoreactive for 
osteocalcin than SAOS2. However, the cells were also highly Ki-67 and pHH3 immunoreactive. 
MG63 cells are known to have a doubling time of between 30hrs and 47hrs (Billiau et al., 1977, 
Pautke et al., 2004). In addition, MG63 cells can be induced to become ALP positive following 
treatments with osteogenic reagents (Carmeliet, Nys and Bouillon, 1997). Osteopontin 
immunoreactivity within MG63 cells was high, although not significantly different to the other cell 
types; however, this immunoreactivity may be indicative of the first peak associated with 
proliferation, as previously mentioned (Aubin, 2001). Therefore, the immunoreactive profile of 
MG63 for the osteoblastic and cell cycle markers more likely indicates an immature osteoprogenitor 
cell that is highly proliferative (see ** in Figure 3.18), where the elevated reactivity for osteocalcin 
is aberrant. 
In summary, as shown in Figure 3.18, the HCS platform was able to differentiate between the 
different cell types examined using biomarkers associated with osteogenic differentiation (A) and 
normal cell cycle proliferation (B). Differentiation progresses from pluripotent embryonic stem cells 
(ESC) through to multipotent MSCs, which under osteo-inductive signals, further differentiate into 
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osteoblasts as well as further differentiate into osteocytes. The MSCs (*) examined here were not 
seen to be committed along osteoblastic differentiation. MG63 cells (***) are shown to have 
transformed prior to ALP expression. Similarly SAOS2 cells (**) are shown to have transformed 
following the stage of high ALP expression, yet prior to mineralization.  
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Figure 3.18: A schematic diagram showing biomarkers associated with osteoblastic 
differentiation and proliferation, which were distinguishing features between primary human 
MSCs, SAOS2 and MG63 cells. 
Cells and biomarkers examined during osteoblastic differentiation (A) cell proliferation (B) from 
MSCs, SAOS2 and MG63 cells (C). Differentiation shown from the embryonic stem cell (ESC) through 
MSCs and osteoblasts (ALP +ve) then to a mineralised osteocyte (von Kossa +ve) with biomarkers 
associated with different stages of osteoblastic differentiation. MSC’s multipotential differentiation 
capacities depicted with colours according to traditional colorimetric stains for chondrogenic (alcian 
blue), osteogenic (ALP -red) and adipogenic (oil red O - red spots) differentiation. The asterisks 
indicate where the cells examined here fall within the osteogenic differentiation process, where: * 
indicate MSCs, ** indicate SAOS2 cells and *** indicate MG63 cells.  
~ 154 ~ 
 
3.9 Conclusion 
This study has shown that it is possible to image and quantitate unique cellular immunoreactive 
biomarkers with the use of simple automated HCS of in vitro culture-expanded cell cultures for the 
purposes of cell based therapies within regenerative medicine. However, this quantitation did not 
significantly distinguish between the cell types examined. In contrast, the nuclear area and nuclear 
intensity, based on Hoechst 33342 staining, did significantly distinguish between all cell types 
examined.   
The methods developed in this initial investigation help to enhance the understanding of MSCs’ 
safe use; as well as the provision and description of a screening tool which is able to extract much 
data from few cells. Similarly, it has been shown here that normal human MSCs show a distinctly 
different immunoreactivity profile to the two osteosarcoma cell lines, SAOS2 and MG63 cells.  
However, the need to remove and fix cells from a donor’s sample is a major disadvantage for the 
HCS platforms used thus far. Therefore, the next chapter examines the use of the Cell-IQ live-cell 
imaging and analysis platform to distinguish between the same cell types based on total cell area, 
counting the number of total cells, as well as pattern recognition of cell morphology from phase 
contrast images that have been gathered during standard cell culture expansion.  
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4 Chapter 4: The use of automated live-cell imaging and 
image analysis characterised, identified and distinguished 
between primary human MSCs, SAOS2 and MG63 
osteosarcoma cell lines 
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4.1 Aims and Background 
The previous chapter presented the use of HCS to distinguish between cultured human MSCs from 
the osteosarcoma cell lines, SAOS2 and MG63 cells. The technique described, involved the use of 
ICC staining of formaldehyde-fixed samples harvested from cultures. This technique presents many 
advantages, such as intricate detailed examination of the cells, on a cell-to-cell basis; however, the 
major disadvantage of such screening is the need to permanently remove and fix cells from the 
primary culture. This means that not all cells are examined, only a sample there of. 
Evidence of cell transformation may include changes in the rate of cell division and proliferation, 
cell death and cell shape in a highly localised area of a culture flask (Lowe and Lin, 2000). It is 
noteworthy that the live-cell imaging and image analysis platform, Cell-IQ v 2.0, can be used to 
develop a recognition algorithm which can identify cell features over time (Toimela, Tahti and 
Ylikomi, 2008). Therefore, the system can provide a dynamic evaluation of cell cultures, rather than 
a single end point ‘snap-shot’ and help to monitor the safe provision of primary human cells within 
clinical applications. The comparison between imaging the whole area of a culture flask, to a select 
representative area was investigated and elegantly demonstrated by David Smith (Smith, 2014). 
Therefore, this chapter has examined the use of the Cell-IQ to provide a means of characterising 
and distinguishing between monolayers of cultured human MSCs compared to the osteosarcoma 
cell lines, SAOS2 and MG63 cells, and primary chondrosarcoma derived cells. Live-cell imaging 
presents many advantages over the previously discussed HCS technique. These include kinetic 
observation through long periods of in vitro culture expansion; marker-free identification and 
classification of cells without the need to remove cells from the culture as samples, or interfere 
with patient’s cells; and, to a certain extent, the whole population of cells can be monitored 
although this was not performed in this project. Most importantly, with the use of this system, 
isolated cells grown within GMP facilities can be imaged and then transplanted back into the patient 
when necessary.  
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The Cell-IQ was used to continuously capture digitised phase contrast images of cells grown in 
traditional cell culture conditions. Initially, the confluence of each culture was measured using the 
Area Measurement tool based on phase contrast thresholds. Then, the Cell Finder tool counted the 
total number of cells within each monoculture. Following on from this, the automated pattern 
recognition software was “taught” distinguishing features of each cell type from the digitised 
images. A sample library of these features was then produced (8 representative sample library 
images are shown in Figure 4.3 A) and generated into a pattern recognition algorithm by the 
software. The algorithm was used to analyse pixel intensities/patterns within all images gathered. 
Differences between cell class parameters included; (i) A cell counting threshold, (ii) Minimum cell 
distance, (iii) Maximum cell diameter, (iv) Cell symmetry (100=round). A more detailed description 
of these algorithms and methods of identification can be seen in the materials and methods chapter 
(section 2.14.2).  
Images gathered from monocultures of MSCs, SAOS2 and MG63 cells were used to generate the 
aforementioned algorithm. Then, this algorithm was applied to images of the aforementioned cell 
monocultures, mixed cell cultures grown in a 50:50 ratio co-culture and finally monocultures of cells 
isolated from a primary chondrosarcoma.  
Finally, the Manual Cell Tracking and Manual Cell Lineage Tracking tools were used to determine 
migration behaviours of the MSCs, SAOS2 and MG63 cells in monoculture. 
Therefore, the aim of this study was to use the Cell-IQ live-cell imaging platform to identify MSCs in 
culture and distinguish them from SAOS2 and MG63 cells in monocultures, as well as in co-cultures. 
Similarly, we used the Cell-IQ platform to characterise and compare the phenotype of adherent 
cells isolated from a primary Low grade I chondrosarcoma to that of MSCs, SAOS2 and MG63 cells.  
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4.2 The Cell-IQ Area Measurement and Cell Finder tools 
characterised MSCs, SAOS2 and MG63 cells in monoculture 
The phase contrast images shown in Figure 4.1  are representative images of MSCs (left column 
panels), SAOS2 (middle column panels) and MG63 cells (right column panels) taken at a single time 
point 48hrs post seeding. The original images (top row panels) were taken from those collected 
during live imaging from 24hrs post seeding through 144hrs post seeding. These images were then 
analysed using the Cell-IQ AnalyserTM Area Measure tool (middle row panels) to measure the area 
and hence confluence of the cells; as well as, the Cell Finder tool (bottom row panels) to count the 
total number of cells within the monocultures. The graph in Figure 4.2 (A) shows the confluence of 
the cultured cells, where the area is shown as a percentage of the total image area of MSCs, SAOS2 
and MG63 cells through 5 days of culture. It should be noted that the confluence of the MG63 cells 
was significantly greater (p≤0.0370) than that of the MSCs and SAOS2 cells from 80hrs of culture. 
Similarly, the graph in Figure 4.2 (B) shows the total number of cells counted within the same 
monocultures over the 5 days of culture, where the total number of MG63 cells was also 
significantly greater (p≤0.0492) than those counted within the MSC and SAOS2 cell monocultures 
from 84hrs post seeding. Videos of the original, area measure and cell count images from the ROIs 
shown can be seen on the supplementary DVD (Appendix 7.4). 
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Figure 4.1: Phase contrast microscopy images of primary human MSCs, SAOS2 and MG63 
osteosarcoma cells captured by the automated live-cell imaging platform, Cell-IQ.  
Phase contrast images (top row panels) were gathered by the automated live-cell imaging platform, 
Cell-IQ of MSCs (left column panels), SAOS2 (middle column panels) and MG63 cells (right column 
panels) from 24hrs post seeding, through 140hrs post seeding. Images shown were taken at 48hrs 
post seeding. From these images, the area of the cells (middle row panels) providing the cell 
confluence, as well as the number of cells (bottom row panels) were measured using the Cell-IQ 
AnalyserTM Area Measure and Cell Finder tools respectively. 
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Figure 4.2: The Cell-IQ live-cell imaging platform measured the confluence of and counted the 
number of primary human MSCs, SAOS2 and MG63 cells cultured in the respective cell 
monocultures. 
Cell confluence based on the area of the cells (A), and the cell counts (B) for the total number of 
MSCs (green), SAOS2 cells (orange), MG63 cells (red) per ROI are reported for each cell type within 
cell monocultures. Data shown are mean ± SEM cell counts, from MSC n=5, SAOS2 and MG63 n=4 
independent experiments with ≥3 ROIs per experiment. *p≤0.05; All, Two-way ANOVA with a 
Dunnett’s post-test where MG63 cell confluence and cell count is significantly greater than both 
MSCs and SAOS2 cells between the times indicated. 
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4.3 Digitised phase contrast images taken of distinguishing cell 
features provided information to create algorithms necessary 
for analysis  
The phase contrast images shown in Figure 4.3  are representative images of each cell type which 
form a part of the algorithms used to identify the cells. As shown (from the top panel), MSCs, SAOS2, 
MG63 cells, rounded cells’ unique characteristics were identified and used to form the phase 
contrast library. Similarly included are dead cells and debris. The two bottom panels show the 
morphology of confluent SAOS2 and MG63 cells observed during extended culture periods; 
however, these features were not used as a separate identification feature.  
It can be seen that MSCs had a broad flat cell appearance, elongated fibroblastic appearance as 
well as irregular shapes, with some low contrasting features. That is, the cells did not show as strong 
contrast between the tissue culture plastic (TCP) and the edge of the cell membrane as that seen 
in some SAOS2 and MG63 cells.  
The SAOS2 and MG63 cells were more distinctly identified apart from MSCs. Both cell types had 
bright and dark areas which we distinctively contrasting from the TCP. Similarly, both SAOS2 and 
MG63 cells had granular puncta within the nucleus, yet MG63 cells’ puncta were larger and the cells 
also showed more granularities in the perinuclear area. SAOS2 were more commonly seen growing 
within colonies making cell to cell contact; however, MG63 cells would often migrate along the TCP 
independent of other cells. 
Rounded cells were identified by a bright circular ring on the outer edge of the cells, with a dark 
central core. These cells were presumed to be rounded during the stages of cell division. Dead cells 
were identified by apoptotic blebs protruding from the edge of the cell as well as fragmentation of 
the cell membrane and/or organelles as described in Ziegler and Groscurth, (2004). 
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Figure 4.3: Phase contrast microscopy sample images used for the recognition of primary human 
MSCs, SAOS2 and MG63 cells captured by the automated live-cell imaging platform, Cell-IQ. 
A library of cell specific morphological features were collected as shown above, and used to teach 
the pattern recognition software to identify (from the top panel to bottom panel) MSCs, SAOS2 
cells, MG63 cells, Round cells, Dead Cells and Debris. The two bottom panels show the morphology 
of confluent SAOS2 and MG63 cells; however, these features were not used as a separate 
identification feature. 
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4.4 The identification of MSCs, SAOS2 and MG63 cells in mono and 
co-cultures 
Identification of the three different cell types in monocultures and co-cultures using the Cell-IQ live-
cell imaging Cell Finder tool, was variable between cell types. Identification of MSCs was most 
specific. However, identification of SAOS2 and MG63 cells was often seen with a high proportion of 
misidentification of MSCs. 
The graphs in Figure 4.4 show the average number of cells counted per ROI imaged in MSC (A), 
SAOS2 (B) and MG63 (C) monocultures from 24hrs through 140hrs post seeding. Within the MSC 
monoculture, as seen in panel A, significantly more MSCs (p≤0.0380) were counted from 28hrs 
through 140hrs of culture compared to SAOS2, MG63 cells and round cells. Within the SAOS2 cell 
monoculture (panel B) significantly more SAOS2 cells (p≤0.0053) were counted from 136hrs of 
culture, apart from MSCs, MG63 cells and Round cells. Similarly, within the MG63 monoculture, 
significantly more MG63 cells (p≤0.0223) were counted from 124hrs through 140hrs of culture, 
more than MSCs, SAOS2 cells and round cells.  
In Figure 4.5, the numbers of identified MSCs, SAOS2, MG63 and round cells are graphed as a 
percentage relative to the total number of cells shown in Figure 4.4. Within the MSC monoculture, 
(panel A) the cell library significantly identified the cells as MSCs (p˂0.001) throughout the culture 
period, compared to SAOS2 cells, MG63 cells and round cells. However, within the SAOS2 
monoculture (panel B), the cell library significantly identified the cells as SAOS2 cells (p≤0.0367) 
only from 132hrs of culture, apart from MSCs, MG63 cells and round cells. Within the MG63 cell 
monoculture (panel C). MG63 cells were identified as such, however the identification of these 
MG63 cells was not significantly different to both MSCs and SAOS2 cells at any point through the 
culture period. 
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The graphs in Figure 4.6 show the average number of cells counted per ROI imaged in MSC/SAOS2 
(A) and MSC/MG63 (B) co-cultures seeded at a 50/50 ratio, from 24hrs through 140hrs post 
seeding. Within the MSC/SAOS2 co-culture (panel A), significantly more MSCs were counted than 
SAOS2 cells, from 36hrs of culture through 140hrs (p≤0.0370). Throughout the culture period, the 
number of MSCs or SAOS2 cells were not equally identified as would be expected. Similarly within 
the MSC/MG63 co-culture (panel B), significantly more MSCs were counted between 68hrs 
(p≤0.0387) and 112hrs (p≤0.0249) of culture. At 128hrs of culture, the mean difference between 
the identification of MSCs and MG63 cells was the lowest at 1.00 (ɸ); however it can be seen that 
the identification of the MSCs or MG63 cells did not remain constant. 
Figure 4.7 shows the number of identified cells graphed as a percentage relative to the total number 
of cells. As shown, in the MSC/SAOS2 co-culture (panel A), significantly greater MSCs were 
identified (p˂0.001) than SAOS2 cells throughout the culture period. Likewise, within the 
MSC/MG63 co-culture (panel B), a significantly greater proportion of MSCs were identified from 
24hrs through 124hrs of culture (p˂0.001) than MG63 cells. 
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Figure 4.4: The Cell-IQ live-cell imaging platform counted the number of primary human MSCs, 
SAOS2 and MG63 cells cultured in the respective cell monocultures. 
Cell counts for the average number and identification of MSCs (green), SAOS2 cells (orange), MG63 
cells (red) and round cells (blue) per ROI are reported for each cell type within MSC (A), SAOS2 (B) 
and MG63 (C) cell monocultures. Data shown are mean ± SEM cell counts, from MSC n=5, SAOS2 
and MG63 n=4 independent experiments with ≥3 ROIs per experiment. **indicates p≤0.01, 
*indicates p≤0.05 and ns indicates no significance; All, Two-way ANOVA with a Dunnett’s post-test 
where the cell count within the monoculture is significantly greater than misidentification of other 
cell types examined, within the times indicated. 
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Figure 4.5: The Cell-IQ live-cell imaging platform used pattern recognition to distinguish between 
primary human MSCs, SAOS2 and MG63 cells cultured in monoculture.  
Cell specific identification reported as a percentage of the total for MSCs (green), SAOS2 cells 
(orange), MG63 cells (red) and round cells (blue) per ROI are reported for each cell type within MSC 
(A), SAOS2 (B) and MG63 (C) cell monocultures. Data shown are mean ± SEM cell counts, from MSC 
n=5, SAOS2 and MG63 n=4 independent experiments with ≥3 ROIs per experiment. **indicates 
p≤0.01, *indicates p≤0.05 and ns indicates no significance; All, Two-way ANOVA with a Dunnett’s 
post-test where the cell count within the monoculture is significantly greater than misidentification 
of other cell types examined, within the times indicated. 
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Figure 4.6: The Cell-IQ live-cell imaging platform counted the number of primary human MSCs, 
SAOS2 and MG63 cells cultured in the respective cell co-cultures. 
Cell counts for the average number and identification of MSCs (green), SAOS2 cells (orange), MG63 
cells (red) and round cells (blue) per ROI are reported for each cell type within MSC/SAOS2 (A) and 
MSC/MG63 (B) co-cultures. Data shown are mean ± SEM cell counts, from MSC n=5, SAOS2 and 
MG63 n=4 independent experiments with ≥3 ROIs per experiment. *indicates p≤0.05 and ns 
indicates no significance; the sigma sign (ɸ) indicates the least mean difference between MSC and 
MG63 cell identification; All, Two-way ANOVA with a Dunnett’s post-test where the cell count for 
MSCs was significantly greater than that for SAOS2 or MG63 cells within the respective co-culture, 
between the times indicated. 
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Figure 4.7: The Cell-IQ live-cell imaging platform used pattern recognition to distinguish between 
primary human MSCs, SAOS2 and MG63 cells cultured in co-culture. 
Cell specific identification reported as a percentage of the total for MSCs (green), SAOS2 cells 
(orange), MG63 cells (red) and round cells (blue) per ROI are reported for each cell type within 
MSC/SAOS2 (A) and MSC/MG63 (B) co-cultures. Data shown are mean ± SEM cell counts, from MSC 
n=5, SAOS2 and MG63 n=4 independent experiments with ≥3 ROIs per experiment. ***p˂0.001; 
All, Two-way ANOVA with a Dunnett’s post-test where the cell count for MSCs was significantly 
greater than that for SAOS2 or MG63 cells within the respective co-culture, between the times 
indicated. 
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4.5 Cell isolation, culture and characterisation of chondrosarcoma 
derived cells (CS) using the Cell-IQ live-cell imaging platform 
Samples of non-radiotherapy and post-radiotherapy treated chondrosarcoma were received and 
viable cells were isolated. A total of 17x106 cells were isolated from the non-radio treated 
chondrosarcoma tissue sample. 14.0x106 cells (82.3%) were viable and 3.0x106 cells (17.7%) were 
non-viable. In contrast, only 12.1x106 cells were isolated from the post-radio treated 
chondrosarcoma tissue sample. 8.6x106 cells (71.1%) were viable and 3.5x106 (28.9%) cells were 
non-viable. 
Representative phase contrast microscopy images of these isolates in culture are shown in Figure 
2.2. As shown, 10-11 days post seeding, cells from the non-radio treated sample adhered to the 
tissue culture plastic from both the explant sample (top left panel) 11 days post seeding and the 
24hr collagenase digest sample (top right panel) 10 days post seeding. These appeared as 
proliferative viable cultures. In contrast, from the post-radio treated sample, only debris was found 
within the explant prepared sample (bottom left panel) and single stressed cells were identified in 
the collagenase digested sample (bottom right panel). With further time in culture, the non-radio 
treated cells continued to proliferate and colonies increased in size. In contrast, the post-radio 
treated cells showed no signs of proliferation throughout the culture period where only single cells 
were observed from 13 through 56 days post seeding. 
Over 321 days of culture, the viable cell count of the 24hr digest isolated chondrosarcoma cells 
increased at each passage from 3.6x104 cells at P1 to 14.7x104 cells at P4 (Figure 2.3). In contrast, 
at P1, there were no post-radio treated sample chondrosarcoma cells within the culture. Over 302 
days of culture, the viable cell count of non-radio treated explant isolated chondrosarcoma cells 
proliferated from 1.6x104 cells at P1 to then 60x104 cells at P4. In contrast, no viable cells were 
isolated from the post-radio treated culture.  
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The Cell-IQ platform was used to compare the isolated chondrosarcoma derived cells (CSs) with 
MSC, SAOS2 and MG63 osteosarcoma cells.  
In terms of the appearance (i.e. Cell-IQ analysis of digitised images when compared to MSCs, SAOS2 
and MG63 cells - Figure 4.8 A), the chondrosarcoma derived cells at P0, were identified as most 
similar to MSCs at 13 days (71.43 ± 14.51), 25 days (56.43 ± 13.89) and 56 days (49.67 ± 17.10) post 
seeding. However, identification as MSCs decreased between 13 to 56 days, with an increased 
identification of MG63 cells from 13 to 56 days, although these were not significant.  
Following passage of the chondrosarcoma derived cells, no significant alteration to the 
identification profile was seen. The graph in Figure 4.8 B shows the cell count and classification of 
P1-2 chondrosarcoma derived cells from seeding through to 44hrs of culture expansion. As shown, 
classification of the cells from seeding, were most similar to MSCs and least similar to SAOS2, MG63 
and round cells.  The graph in Figure 4.8 C shows the classification of the P1-2 chondrosarcoma 
derived cells as a percentage relative to the total. This simply illustrates the classification of the cells 
as most similar to MSCs rather than SAOS2, MG63 or round cells. A video of cultured 
chondrosarcoma cells can be seen on the supplementary DVD (Appendix 7.4).  
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Figure 4.8: The Cell-IQ live-cell imaging platform classified non-radio chondrosarcoma derived 
cells according to morphological features. 
Cultured chondrosarcoma derived cells (CS) prior to passage at 13, 24 and 56 days post seeding (A, 
P0) and following 44hrs of post seeding of subsequent passaged cells (B & C, P1-2) were imaged 
and identified using the sample library of MSCs, SAOS2 and MG63 cells (Figure 4.3). Identification 
is shown as a percentage of the total (A, C) and the number of cells counted are also shown (B) to 
be more morphologically similar to MSCs, (green), than SAOS2 (orange), MG63 (red) and round cells 
(blue). Data shown are means ± SD from n=1 CS sample imaged within n≥3 ROIs during n=3 
independent experiments.  
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4.6 Manual cell tracking and manual lineage tracking of MSCs, 
SAOS2 and MG63 cells 
To further characterise the different cell types examined, the Cell-IQ platform’s Manual Cell 
Tracking tool was used to measure the trajectory length (distance of migration) and the speed via 
trajectory, comparing >100 of each cell type of MSCs, SAOS2, MG63 cells and P1/2 chondrosarcoma 
derived cells (CS), as shown in Figure 4.9 A-D respectively. It can be seen that MSCs (A) and MG63 
cells (C) migrate over larger areas when compared to SAOS2 (B) and chondrosarcoma derived cells 
(D). The SAOS2 cells show the most compact cell migration. 
Figure 4.10 illustrates lineage trees of MSCs, SAOS2 and MG63 cells obtained using the Manual 
Lineage Tracking tool. It can be clearly seen that SAOS2 and MG63 cells proliferated more through 
120hrs of culture. Quantitation of this data is shown in Figure 4.11 where the average divisions (A), 
trajectory length (B) and speed via trajectory (C) are presented for each cell type. It should be noted 
that through the culture period, MG63 cells were in fact significantly more proliferative (18.3 ± 5.48 
divisions per cell) than the MSCs (2.52±0.54 divisions per cell, p<0.001), SAOS2 cells (9.38 ± 0.85 
divisions per cell, p=0.0079) and CS cells (0.03±0.03 divisions per cell, p<0.001).  MSCs (1685 ± 
533µm) and MG63 cells (1879 ± 353µm) migrated significantly more than the SAOS2 cells (407 ± 
35µm, p= 0.0238 and p=0.0194 respectively) and CS cells (409 ± 24µm, p=0.0014 and p=0.0024 
respectively). SAOS2 cells (3.44 ± 0.32µm/h) were the only significantly slower migrating cells 
compared to MSCs (14.30 ± 4.50µm/h, p=0.0306) and MG63 cells (15.80 ± 2.87µm/h, p=0.0278). 
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Figure 4.9: Manual Cell Tracking of live-cells using the Cell-IQ live-cell imaging platform showed 
the centred trajectory migration paths of primary human MSCs, SAOS2, MG63 and CS cells. 
The single cell tracked lineage paths are shown for MSCs from primary human MSCs, osteosarcoma 
derived cell lines SAOS2 and MG63 cells, and primary chondrosarcoma derived cells (CS) tracked 
through ≥40hrs of culture. MSC data shown is from n=4 independent samples. Osteosarcoma data 
shown is from n=4 independent experiments. CS data shown is from n=1 CS sample imaged within 
n≥3 ROIs during n=3 independent experiments. 
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Figure 4.10: Manual cell lineage tracking of primary human MSCs, SAOS2 and MG63 cells showed differences in proliferation behaviour. 
Lineage trees illustrating the proliferation of MSCs (green – top panel), SAOS2 (orange – middle panel) and MG63 cells (red – bottom panel) were gathered 
by tracking cells through 120hrs of culture with the Cell-IQ Manual Cell Lineage Tool. Twenty lineage trees are shown for MSCs, compared with 10 for SAOS2 
and MG63 cells. Manual cell tracking data was gathered from n≥3 samples imaged during ≥3 independent experiments. The length of the lineage tree indicates 
cell survival through 120hrs of treatment. Interrupted or short lineage branches indicate cell death. 
~ 175 ~ 
 
 
Figure 4.11: Manual Cell Tracking of live-cells significantly distinguished between primary human 
MSCs, SAOS2, MG63 and CS cells based on the average number of cell divisions, but not the 
trajectory length or speed via trajectory. 
Cells from five human MSCs, SAOS2, MG63 and CS cells were tracked with the Manual Cell Lineage 
tracking tool. The average number of divisions (A), trajectory length (B) and speed via trajectory (C) 
are shown. Data shown for all call types are mean ± SEM. SAOS2 and MG63 cell data are from n≥3 
independent experiments tracked through 120hrs of culture. CS data are from n=3 independent 
experiments tracked 60hrs of culture. 
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4.7 Discussion 
The Cell-IQ live-cell imaging platform was able to measure the confluence of and count the total 
number of primary human MSCs, SAOS2 and MG63 cells within adherent monocultures; however 
there was a limited ability to identify and distinguish between cells in co-culture based on pattern 
recognition image analysis. Even in monocultures, correct identification was not exclusive to each 
cell type and misidentification was seen. In contrast, cell tracking markedly but not significantly 
distinguished cell migration patterns. Similarly, quantitation of cell proliferation, trajectory length 
and speed via trajectory measure by lineage tracking, significantly distinguished between some of 
but not all the cell types. 
The identification demonstrated here, was based on a collection of images of each cell type grown 
in monoculture conditions and cell specific parameters were assigned to each cell class to assist the 
identification. This therefore allowed for heterogeneity between the cell types, yet not within the 
cultures.  
MSCs are a phenotypically and functionally heterogeneous population of cells, which is reflected 
by differences in cellular morphology, differential marker expression and variable differentiation 
potentials, as reviewed by Pevsner-Fischer, Levin and Zipori, (2011). On the other hand, SAOS2 and 
MG63 cells are well-established and characterised osteosarcoma cells which show little 
heterogeneity (Rodan et al., 1987, Pautke et al., 2004). SAOS2 cells were established in 1973 and 
originate from a primary osteosarcoma from an 11 year old female Caucasian patient (Fogh and 
Trempe, 1975). Similarly, MG63 cells were first examined by Billiau et al., (1977) for their mass 
production of human interferon (Billiau et al., 1977). Although the SAOS2 and MG63 cells are not 
monoclonal and some phenotypic drift over long-term culture has been described (Hausser and 
Brenner, 2005, Barnes, Moy and Dickson, 2006), these cells can still be expected to be homogenous 
(Pautke et al., 2004).  
~ 177 ~ 
 
The identification of the MSCs, SAOS2 and MG63 cells was performed over a 120hr time period 
following 24hrs of cell adhesion to the TCP, through 140hrs of culture. Identification was heavily 
biased toward identification of the MSCs, where more specific identification of the SAOS2 and 
MG63 cells occurred from approximately 130hrs of culture. This stronger identification at the later 
culture period may be due to the specific confluent morphology of each cell type. However, the 
number of cells identified within the cultures clearly showed a greater and increasing number of 
total cells within the osteosarcoma samples compared to the slow proliferating MSCs.  This was 
also evident within the co-cultures.  
A comprehensive investigation into the heterogeneity of bone marrow stromal cells was performed 
by Whitfield, Lee and Van Vliet (2013). Using live-cell imaging and advanced image analysis 
software, they were able to track cells and record the number of cell divisions, cell migration details, 
as well as cell morphology and area. From these results they constructed cell lineage maps which 
showed that all the cells examined steadily grew larger over time, and the growth was only 
interrupted when a cell divided, thus producing two equally sized morphologically similar daughter 
cells. They also showed that these larger cells had most likely exited the cell cycle and had high 
levels of senescence associated β-galactosidase activity (Whitfield, Lee and Van Vliet, 2013). Their 
study only examined normal stromal cells, rather than what has been discussed in this chapter, i.e., 
the comparison of normal versus tumorigenic stromal cells; however, their approach to 
differentiating between cells and characterising the cells during culture expansion, provides a very 
powerful tool which can identify cell phenotypic differences which will assist in detecting 
tumorigenic transformation or aberrant cell behaviour of cells intended for cell-based therapy.  
It has also been shown that the Cell-IQ live-cell imaging platform was able to identify and distinguish 
between cells derived from a primary low grade I chondrosarcoma compared to human MSCs and 
the osteosarcoma cell lines, SAOS2 and MG63 cells.  
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Viable cells isolated from a non-radio therapy treated primary low grade I chondrosarcoma  (CS) 
following plastic adherence, showed clear signs of colony formation and proliferation through 13, 
24 and 56 days of culture. Although it was evident that viable cells were isolated from the post-
radio treated sample, and cells adhered to the plastic, there was no proliferation seen throughout 
the same culture period. Electromagnetic radiotherapy delivers energy through photons, which 
upon collision with human tissue or cells results in the release of free radicals and chemical bond 
breaks, leading to widespread damage throughout the cell. Single and double strand breaks to the 
DNA can be fatal, effecting cell division and proliferation, halting the cell cycle and ultimately 
leading to cell death if it is not repaired (Laval, 1980). Absorbed radiation doses, measured as 
joules/Kg, are expressed in the unit gray (Gy) (Ahmad et al., 2012). Chondrosarcomas are highly 
resistant to radiotherapy, therefore to achieve local control after aggressive surgical resection, 
doses greater than 60 Gy are needed (Bovée et al., 2005, Boeuf et al., 2008, Gelderblom et al., 
2008). 
Cell-IQ identification of the CS cells cultured at P0 between 13 through 56 days post seeding showed 
that the cells were most similar to MSCs. However, with time, the identification decreased non-
significantly, with a slight and non-significant increase in identification as MG63 cells. Following 
culture expansion of the CS cells at P1/2, greater than 50% of the CS cells were still identified as 
most similar to MSCs, compared to SAOS2 and MG63 cells. CS cells categorised as most similar to 
MSCs may be due to similarities in their stromal appearance. Whole CS tissue was digested and 
cultured, which will most certainly contain a heterogeneous population of stromal cells; namely, 
cells which have a very similar appearance to MSCs. In contrast, the minor identification of CS cells 
as MG63 cells over time during P0 may be indicative of a clonal outgrowth of cell which are 
morphologically similar to MG63 cells in the chondrosarcoma sample.  
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Further imaging and identification of this sample and more samples of primary chondrosarcoma, 
or other mesenchymal derived cancer samples, over serial passages, would be needed to enhance 
the identification profile for these cells.  
To further identify whether these cultured CS cells were in fact tumorigenic chondrosarcoma cells, 
specific point mutation analysis was done comparing a biopsy sample with the culture-expanded 
cells (data not shown). 
As a part of the energy generating citric acid cycle, isocitrate dehydrogenases (IDHs) catalyse the 
oxidative decarboxylation of isocitrate to α-ketoglutarate and CO2. IDH1 and IDH2 are NADP(+) 
dependent isocitrate dehydrogenases (compared to the other three forms IDH3α, IDH3β and IDH3γ 
which are NAD(+) dependant isocitrate dehydrogenases). IDH1 is found in the cytoplasm and 
peroxisomes, IDH2 within the mitochondria.  
Mutations within IDH1 and IDH2 are fairly frequent events (56%) in central and peripheral 
chondrosarcomas. Specific point mutations commonly found in IDH1 usually result in substitutions 
at R132 and within IDH2, mutations may occur at R172 (analogous to IDH1 R132) and R140 (Amary 
et al., 2011, Van Oosterwijk et al., 2012, Monderer et al., 2013). These mutations within the active 
site of the IDH do not result in terminal activity of the enzyme. Rather, it has been noted that the 
mutation R132H (arginine to histidine) in IDH1 may lead to the enzyme’s ability to further convert 
α-ketoglutarate to R(-)-2-hydroxygluterate (2HG), an onco-metabolite (Dang et al., 2009); or lead 
to increased levels of hypoxia-inducible factor subunit HIF-1α, a transcription factor facilitating 
tumour growth under low oxygen environments (Zhao et al., 2009).  
Here, the aforementioned point mutations were not observed in either the biopsy sample CS cells, 
nor in the culture-expanded CS cells. Unfortunately this does not confirm that the isolated culture-
expanded cells were the same as the chondrosarcoma, however it does show that culture 
expansion does not induce these specific point mutations.  
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Manual cell tracking of all cell types during culture expansion showed very noticeable differences 
between the MSCs, SAOS2, MG63 cells and CS cells migratory behaviours when plotted on centred 
trajectory graphs. MSCs appeared to migrate the furthest, then MG63 cells. SAOS2 and CS cells 
showed little migration from their point of origin, with compact migration paths for most cells. 
Quantitation from the manual lineage tracking significantly differentiated between the MSCs, 
SAOS2 and MG63 cells based on the number of cell divisions observed through the culture period, 
and as expected the two osteosarcoma cell lines were significantly more proliferative than the 
MSCs. However, the MSCs and MG63 cells migrated significantly further throughout the culture 
period compared to the SAOS2 and CS cells. SAOS2 cells had the slowest migration compared to all 
the other cell types, notably and significantly slower than the MSCs and MG63 cells.   
As discussed in Chapter 3, the SAOS2 cells are more osteoblastic than MG63 cells based on ALP 
positivity, thus the motility of the cells may reduce as they progress towards either a mature 
mineralised osteoblast, or an osteocyte. It would be interesting to examine the trajectory speed 
and distance of MSCs whilst being differentiated along the osteoblastic lineage, and comparing that 
to the trajectory speed and distance of the SAOS2 and MG63 cells.  
The chondrosarcoma sample examined was diagnosed as a low grade I, thus the least metastatic of 
chondrosarcomas. Therefore, it would also be interesting to compare and contrast the migratory 
capacity of these cells in vitro to those from a highly metastatic grade III or dedifferentiated 
chondrosarcoma to see if in vitro cell migration is a good indicator or metastasis.  
Unfortunately all of these findings do not conclusively show that the isolated chondrosarcoma 
derived cells are in fact chondrosarcoma cells. Therefore alternative means to identify the cultured 
cells as chondrosarcoma or normal cells would need to be done. This may include using the HCS 
platform discussed in Chapter 3. However, since there is no antibody target specifically for 
chondrosarcoma, primary samples would need to be compared to known chondrosarcoma cell lines 
(Calabuig-Fariñas et al., 2012, Van Oosterwijk et al., 2012, Monderer et al., 2013).  
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4.8 Conclusion 
The previous chapter showed the identification of normal human MSCs compared to SAOS2 and 
MG63 cells, using a HCS platform to identify biomarker immunoreactivity differences. This assay 
was an endpoint assay and required cells to be removed from a donor’s sample, then terminally 
fixed, stained by ICC and analysed.  
In contrast, this chapter has shown the identification of MSCs, SAOS2, MG63 and CS cells based on 
phase contrast images which were collected non-invasively during cell culture expansion. Both 
monocultures and co-cultures of MSCs and osteosarcoma cells were imaged and analysed. Analysis 
showed variable degrees of accuracy based on a large sample library composed of images of each 
cell type along with strict cell-type specific identification parameters.  
The two osteosarcoma cell lines examined have been established for many years (Billiau et al., 1977, 
Rodan et al., 1987), and although they are likely to have undergone some sort of phenotypic drift 
as a result of this extended culture time (Hausser and Brenner, 2005), they represent a small 
example of MSC-derived tumours. Bearing this in mind, the phenotype of primary tumours may 
well be different to that of established tumour cell lines. Furthermore, the phenotype of cells which 
undergo spontaneous malignant transformation in culture might be considered or presumed to be 
more likely to resemble that of a primary tumour than an established cell line.  
Here we have also shown that following excision and irradiation of a primary chondrosarcoma 
sample, followed by re-implantation of the humerus (Section 2.1.2), viable cells can be isolated and 
cultured from the excised chondrosarcoma tissue both before and after a very high dose (90Gy) of 
DXT radiotherapy. And, as expected, non-radiotherapy cells proliferated and post-radiotherapy 
cells did not. It was also demonstrated that these CS derived cells were morphologically similar to 
MSCs, had a low rate of proliferation to those of MSCs, and yet with a migration speed and 
trajectory distance similar to that of SAOS2 cells.  
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The first two chapters of the thesis have shown that the HCS and live-cell imaging platform may 
have application as screening platforms in determining whether cells that are being culture-
expanded in vitro for regenerative cell therapies are safe, exhibit normal and expected behaviour, 
or may contain a malignant sub-population. There was a mixed degree of success using both 
platforms, which suggests that it is unlikely that these techniques, a least in the current formats 
and application procedures, would be able to guarantee that culture expanded MSCs do not contain 
transformed cells. The experiments reported in the next chapter were designed to address what 
could be done had such a scenario occurred. In particular, the next chapter has examined whether 
it may be possible to selectively inhibit the growth or kill tumour cells versus normal MSCs. 
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5 Chapter 5: Selective killing of sarcoma cell lines versus 
MSCs by treatment with a novel drug regime 
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5.1 Aims and Background 
The previous chapters discussed the use of HCS and live-cell imaging to distinguish between primary 
human MSCs from the osteosarcoma cell lines SAOS2 and MG63 cells, and freshly isolated cells 
from a low grade I chondrosarcoma derived cells. These studies were performed with a view to 
developing improved safety and screening capabilities of cells intended for cell-based regenerative 
medicine. However, there remains the possibility that any tumour cells would remain undetected 
using the screening methods or that transformation would arise in vivo following transplantation. 
A further means of increasing the safety of MSC-based cell therapies would be the ability to 
eliminate any MSC-derived tumour cells, especially without affecting non-transformed MSCs to 
reduce harmful side-effects. Alternatively, the development and provision of an alternative 
treatment which can selectively target osteosarcoma cells whilst having little to no effect on 
resident stem cells, would help advance conventional chemotherapy.  
The aim of this chapter was to identify a combination and concentration of drugs which may 
selectively inhibit the growth of human osteosarcoma cells, SAOS2 and MG63, compared with 
culture-expanded human MSCs.  
A combinatorial drug regime of the lipid-regulating drug - bezafibrate (BEZ) and the sex hormone - 
medroxyprogesterone acetate (MPA) was recently demonstrated to target acute myeloid 
leukaemia cells (AML) with little effect on the survival of the normal adult myeloid progenitors 
(Khanim et al., 2009). Following a clinical trial of these drugs within elderly patients with AML, 
strong evidence was shown for their safety, anti-AML activity and improved haemopoiesis in a 
proportion of the patients (Murray et al., 2010).  
Similarly, over a 5 year period, children in Malawi with relapsed or resistant endemic Burkitt 
lymphoma (eBL) were treated with a combination of BEZ and MPA at low, intermediate or high 
dose alone, or concurrently with other chemotherapies. The treatments were shown to be safe and 
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efficacious, and since eBL normally increases in size substantially in a week without anti-BL therapy, 
No Clinical Change (NCC) was seen and considered to be significant evidence of the treatment’s 
anti-eBL activity. Comparison between the progression of the disease, NCC, partial response and a 
complete clinical response between the three dose cohorts showed a significant difference driven 
by the difference in progressive disease in the patients receiving low dose treatment (Molyneux et 
al., 2014).  
As reviewed by Činčárová et al., (2013), valproic acid (VPA) has been used in clinical practice as an 
anticonvulsant for more than four decades, and is known to function as a histone deacetylase 
(HDAC) inhibitor (Gurvich et al., 2004). Due to VPA’s ability to; induce differentiation of a number 
of cancer cells in vitro and decrease tumour growth and metastases in animal models, restore or 
improve responsiveness of tumours to conventional therapeutic agents, to sensitize TRAIL-resistant 
tumour cells to apoptosis, and to enhance radiosensitivity of tumour cells, VPA is an attractive drug 
for cancer therapy (Činčárová, Zdráhal and Fajkus, 2013). 
Therefore, we have hypothesised that a similar drug regime of BEZ and MPA alone (designated BAP) 
or supplemented with VPA (designated V-BAP), may selectively target osteosarcoma cells, whilst 
preserving non-transformed primary human MSCs.  
To investigate this, MSCs, SAOS2 and MG63 cells were cultured in monocultures and co-cultures, 
then treated with a combined two fold dilution series of BAP or V-BAP, over a period of 5 days.  
Viability of cells in monolayer cultures to individual drug treatments at doubling concentrations, 
followed by combined treatments of BAP and V-BAP were initially assessed by MTT assay. The Cell-
IQ live-cell imaging platform was then used to visualise drug-induced effects in cell monolayers 
compared to control conditions, over time. These effects were quantitated by tracking specific cell 
lineages in control and treated conditions; quantitating the number of divisions, lineage trajectory 
length, speed via trajectory and cell survival. 
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5.2 The effects of BEZ, MPA and VPA treatments on single cell 
cultures of MSCs, SAOS2 and MG63 cells  
The graphs in Figure 5.1 show the concentration-dependent effects of BEZ (A), MPA (B) and VPA (C) 
on the viability of five separate human MSC samples compared to SAOS2 and MG63 cells, which 
were tested on 3 independent occasions, by MTT assay following 5 days of treatment. The cell 
viability was normalised relative to the mean of the carrier-only control treated cells and reported 
as a percentage (%) of that control value.  
There was a concentration-dependent decrease in the viability of SAOS2 and MG63 cells in 
response to drug treatments. The SAOS2 and MG63 cell cultures were both significantly less viable 
than the MSC cultures at the high concentrations of BEZ ([1.0mM], p≤0.008; [2.0mM] p≤0.001) and 
MPA ([20µM], p≤0.0111). VPA significantly inhibited SAOS2 cell viability compared to MSCs; 
however, no significant difference was seen between MG63 and MSCs cell viability, therefore no 
significance was indicated on the graph. 
The graphs in Figure 5.2 show the concentration-dependent effects of combined treatments of BAP 
(A) and V-BAP (B) on the viability of five human MSC samples compared to SAOS2 and MG63 cells, 
where cell viability was again normalised to control levels and reported as a percentage (%). 
Following combined treatments, the viability of all MSC cultures was significantly greater than that 
of both SAOS2 and MG63 cells following treatments with BAP and V-BAP. Specifically, MSC were 
significantly more viable than the SAOS2 and MG63 cells from [0.25mM]/[2.5µM] BAP (p≤0.0446) 
and from [0.125mM]/[1.25µM]/[0.6mM] V-BAP (p≤0.0048).  
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Figure 5.1: BEZ and MPA significantly inhibited SAOS2 and MG63 cells in a concentration-
dependent manner compared to primary human MSCs, according to MTT assay; however, VPA 
did not. 
The cell viability normalised to the percentage of the carrier-alone control is shown. Human MSCs, 
SAOS2 and MG63 osteosarcoma cell lines were treated for 5 days with two-fold increasing doses of 
BEZ (A), MPA (B) or VPA (C). Data shown are mean ± SEM n≥3 independent experiments. 
***indicates p≤0.001, **indicates p≤0.01, *indicates p≤0.05; where MSC viability is significantly 
greater than both SAOS2 and MG63 cells. All; two-way ANOVA with a Tukey’s post-test. 
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Figure 5.2: BAP and V-BAP significantly inhibited primary human MSCs, SAOS2 and MG63 cells in 
a concentration-dependent manner according to MTT assay. 
The cell viability normalised to the percentage of the carrier-alone control is shown. Human MSCs, 
SAOS2 and MG63 osteosarcoma cell lines were treated for 5 days with two-fold increasing doses of 
BAP (A) or V-BAP (B). Cells were seeded and assayed in triplicate wells. Data shown are mean ± SEM 
from n≥4 independent experiments. ***indicates p≤0.001, **indicates p≤0.01, *indicates p≤0.05; 
where MSC viability is significantly greater than both SAOS2 and MG63 cells. All; two-way ANOVA 
with a Tukey’s post-test.  
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5.3 The use of the Cell-IQ live-cell imaging HCS platform to examine 
combined drug treatments on five donor MSCs, SAOS2 and 
MG63 cells in monoculture 
To quantitate the specific effects following combined treatments of BAP and V-BAP on cell 
behaviour using the live-cell imaging platform; monocultures of MSCs, SAOS2 and MG63 cells were 
seeded, then treated 24hr post seeding. Images were gathered with the Cell-IQ live-cell imaging 
platform from 0hrs to 120hrs post treatment. Treatment concentrations used were determined 
from the MTT results (Figure 5.1 and Figure 5.2) bridging the two concentrations where MG63 cell 
line’s viability decreased more than tenfold from >50% to <5%. The concentrations were; BAP [Low] 
= 0.5mM/5µM, BAP [High] = 1.0mM/10µM, V-BAP [Low] = 0.5mM/5µM/0.6mM and V-BAP [High] 
= 1.0mM/10µM/0.6mM. 
Figure 5.3 shows representative combined phase contrast and fluorescence images of MSCs, SAOS2 
cells, and MG63 cells in monoculture. Images show control cells at 0hrs of treatment, and control 
compared to V-BAP [High] treated cells at 120hrs post treatment. All control and treatment 
conditions included the nuclear stain DRAQ7. When the membrane of a cell is compromised and 
permeable, DRAQ7 is able bind to the DNA, producing a fluorescent signal (shown as blue). White 
arrows indicate dead DRAQ7 positive MSCs, SAOS2 or MG63 cells. During cell death, fluorescent 
DRAQ7, which has bound to DNA was seen to dissipate as the DNA dissipated from the dead cell 
and into the media. Therefore, rather than relying on automated quantitation of dead cells, DRAQ7 
positivity was instead used as a positive control whilst Manual Cell Tracking and Manual Lineage 
Tracking tools were used; tracking specific cell migration paths (Figure 5.4) and cell lineages (Figure 
5.5); quantitating the number of cell divisions (Figure 5.6); determining cell trajectory lengths 
(Figure 5.7); determining cell’s speed via trajectory (Figure 5.8) and the survival rate of the cells 
(Figure 5.9) in control and treated conditions.  
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Figure 5.4 graphically illustrates the cell trajectory paths of MSCs, SAOS2 and MG63 cells within 
control and V-BAP [High]. It can be clearly seen that there is a marked difference in cell trajectory 
distance and migratory behaviour between these culture conditions. Similarly, Figure 5.5 
graphically illustrates up to five representative lineage trees of MSCs, SAOS2 or MG63 cells within 
BAP control, BAP [Low], BAP [High], V-BAP control, V-BAP [Low] and V-BAP [High] treatment 
conditions, from 0hrs of treatment (top of the tree) to 120hrs post treatment (bottom of the tree). 
It can clearly be seen that the treatments with BAP and V-BAP at both [Low] and [High], affected 
both the cell survival as well as capacity for division; notably more so in the SAOS2 and MG63 cells 
than the MSCs. 
Quantitation of the number of cell divisions following BAP control treatments presented in Figure 
5.6A, shows; MG63 cells as the most proliferative cell type with an average of 18.30 ± 4.47 cell 
divisions per cell, SAOS2 cells with significantly fewer average divisions with 9.38 ± 0.70 cell divisions 
per cell (p<0.001); and significantly the least proliferative cell was the MSCs with 2.52 ± 0.49 cell 
divisions per cell (p=0.0019 cf SAOS2, p<0.001 cf MG63). BAP [High] treatments significantly 
decreased SAOS2 proliferation ~4 fold to 2.64 ± 0.47 (p=0.006) divisions per cell; BAP [Low] and BAP 
[High] both significantly decreased the proliferative potential of MG63 cells ~3 fold to 5.71 ± 0.38, 
and ~8 fold 2.30 ± 0.31 (both p<0.001) divisions per cell respectively. 
Similarly, following V-BAP control treatments (Figure 5.6B); MG63 cells divided 14.85 ± 4.43 times 
per cell, SAOS2 cells divided 9.36 ± 0.82 times (p=0.0212), and MSCs divided 2.48 ± 0.52 (p=0013 cf 
SAOS2, p<0.001 cf MG63) times through the culture and imaging period. V-BAP treatments also 
resulted in a significant decrease in both SAOS2 and MG63 cell divisions; notably following V-BAP 
[Low] and [High] treatments, the SAOS2 cells underwent fewer divisions than the control, 
decreasing ~2 fold to 4.35 ± 0.11 (p=0.368) and ~4 fold 2.16 ± 0.32 (p=0.0025) respectively. V-BAP 
[Low] and [High] treatment on the MG63 cells significantly decreased the number of cell divisions 
~3 fold to 4.65 ± 0.17 (p<0.001) and ~7 fold to 2.033 ± 0.33 (p<0.001) divisions per cell, respectively.  
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The distance of trajectory of each cell type was quantitated and within the BAP and V-BAP control 
conditions, SAOS2 cells migrated significantly less than MSCs (p=0.0344 and p=0.0094, respectively) 
and MG63 cells (p=0.0289 and p=0.0060, respectively). V-BAP [High] was the only treatment which 
significantly reduced the migration trajectory of MG63 cells, reducing their trajectory ~3 fold from 
1927 ± 549µm to 733 ± 243µm (p=0.0310). 
Similarly, SAOS2 cells had the slowest speed via trajectory determined between all cell types within 
the BAP and V-BAP control conditions compared to that of MSCs (p=0.0267 and p=0.0107, 
respectively) and MG63 cells (p=0.0244 and p=0.0067, respectively).  
Throughout the culture, imaging and tracking period, the death and survival of cells were noted and 
as shown in Figure 5.9, presented as a percentage positive relative to the control. MSC viability did 
not significantly decrease; however, SAOS2 cell viability significantly decreased from 98.32 ± 0.56% 
in control conditions to 69.32 ± 23.84% following BAP [High] treatments (p=0.0387), and MG63 cell 
viability significantly decreased from 98.92 ± 0.84% in control conditions to 51.63 ± 28.04% in BAP 
[High] treatments (p<0.001). Although the viability of MSCs within BAP [High] treatment conditions 
was significantly greater than that of the MG63 cells (p=0.0027), these was no significant difference 
of these to the viability of the SAOS2 cells at the same treatment conditions.  
Similarly, V-BAP [High] treatment conditions significantly affected the viability of the SAOS2 and 
MG63 cells compared to the controls, where the viability of SAOS2 cells decreased from 97.30 ± 
1.01% to 51.18 ± 21.84%  (p=0.0018) and the viability of MG63 cells decreased from 96.16 ± 3.14% 
to 41.54 ± 27.70% (p<0.001). However, it should be noted that following V-BAP [High] treatments, 
MSCs viability was significantly greater than those of both SAOS2 (p=0.0130) and MG63 cells 
(p=0.0014). 
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Figure 5.3: Representative phase contrast and fluorescence microscopy images of control and 
combined BAP treatment on monocultures of primary human MSCs, SAOS2 and MG63 cells at 
0hrs and 120hrs post treatment. 
Representative combined phase contrast and fluorescence images of MSCs (left column panels), 
SAOS2 cells (middle column panels) and MG63 cells (right column panels) grown in monocultures. 
Images show control cells at 0hrs of treatment (top row panels) and 120hrs post treatment (bottom 
two row panels) within control conditions in contrast to BAP [High] treatment conditions. White 
arrows indicate dead MSCs, SAOS2 and MG63 cells stained with the fluorescent DNA dye, DRAQ7 
(blue). 
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Figure 5.4: Manual Cell Tracking of live-cells using the Cell-IQ live-cell imaging platform showed 
the centred trajectory migration paths of primary human MSCs, SAOS2, MG63 cells in control 
versus V-BAP [High] treatment conditions. 
The centred trajectory cell migration paths are shown for MSCs, SAOS2 and MG63 cells, tracked 
through 120hrs of culture within control (A) and V-BAP [High] (B) treatment conditions. Data shown 
was gathered from MSC n≥4 donors and SAOS2 and MG63 cells analysed over ≥3 independent 
experiments. 
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Figure 5.5: Treatments of BAP and V-BAP inhibited growth and induced cell death of primary 
human MSCs, SAOS2 and MG63 cells in monoculture, compared to the control. 
Lineage trees of MSCs (green), SAOS2 (orange) and MG63 cells (red) following 120hrs of culture and 
treatment with BAP (left panels) and V-BAP (right panels) show effects of inhibited cell division and 
induced cell death compared to controls. Up to 5 representative lineage trees of each cell type are 
shown from ≥10 cells of each cell type tracked in each treatment condition. Manual cell tracking 
data was gathered using the Cell-IQ Manual Lineage Tracking tool from n≥3 independent 
experiments. The length of the lineage tree indicates cell survival through 120hrs of treatment. 
Interrupted or short lineage branches indicate cell death. 
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Figure 5.6: BAP and V-BAP affected the average number of cell divisions of SAOS2 and MG63 cells 
in a concentration-dependent manner, with little effect on MSCs, according to manual lineage 
tracking. 
The average number of cell divisions per cell was quantitated following cell lineage tracking of 
MSCs, SAOS2 and MG63 cells in monoculture over 120hrs in control treatments, and doubling 
concentrations of BAP (A) and V-BAP (B). Data shown are means ± SEM from n≥3 independent 
experiments from ≥10 cells of each cell type tracked in each treatment condition. ***indicates 
p≤0.001, **indicates p≤0.01 and *indicates p≤0.05. All; two-way ANOVA with a Tukey’s multiple 
comparison test. 
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Figure 5.7: BAP and V-BAP affected the average cell trajectory length of MSCs, SAOS2 and MG63 
cells in a concentration-dependent manner, according to manual lineage tracking. 
The average trajectory length per cell was quantitated following cell lineage tracking of MSCs, 
SAOS2 and MG63 cells in monoculture over 120hrs following control treatments, and doubling 
concentrations of BAP (A) and V-BAP (B). Data shown are mean ± SEM from n≥3 independent 
experiments. **indicates p≤0.01 and *indicates p≤0.05. All; two-way ANOVA with a Tukey’s 
multiple comparison test. 
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Figure 5.8: BAP and V-BAP affected the average cell speed via trajectory of MSCs, SAOS2 and 
MG63 cells, according to manual lineage tracking. 
The average cell speed via trajectory was quantitated following cell lineage tracking of MSCs, SAOS2 
and MG63 cells in monoculture over 120hrs following control treatments, and doubling 
concentrations of BAP (A) and V-BAP (B). Data shown are mean ± SEM from n≥3 independent 
experiments. **indicates p≤0.01 and *indicates p≤0.05. All; two-way ANOVA with a Tukey’s 
multiple comparison test. 
~ 198 ~ 
 
 
Figure 5.9: BAP and V-BAP affected the viability of MSCs, SAOS2 and MG63 cells in a 
concentration-dependent manner, according to manual lineage tracking. 
The cell viability as a percentage (%) of the total, was determined in MSCs, SAOS2 and MG63 
osteosarcoma cell lines by manual cell tracking following 120hrs of treatment with doubling 
concentrations of BAP (A) and V-BAP (B). Data shown are mean ± SEM from n≥3 independent 
experiments. * indicates p≤0.05; where MSC viability is significantly greater than both SAOS2 and 
MG63 cells. All; two-way ANOVA with a Tukey's multiple comparisons test. 
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5.4 Discussion 
A combinatorial drug regime of bezafibrate (BEZ) and medroxyprogesterone acetate (MPA) 
designated as BAP, was recently demonstrated to target acute myeloid leukaemia (AML) with little 
effect on the survival of normal adult myeloid progenitor cells (Khanim et al., 2009). Khanim et al., 
(2009) proposed that the mechanism of action following combinatorial treatment of BEZ and MPA 
was due to increased synthesis and reduced metabolism of prostaglandin D2 (PGD2) resulting in 
elevated levels of the downstream product, 15-deoxy Δ12, 14prostaglandin J2 (15d-PGJ2). 15d-PGJ2 is 
an endogenous ligand for peroxisome proliferator-activated receptor-γ (PPARγ), which itself is an 
inducer of adipogenesis and inhibitor of osteoblastogenesis (Takada, Yogiashi and Kato, 2012).  
The proposed mechanism of action was shown to be via separate and overlapping actions of 
reactive oxygen species (ROS), prostaglandin D2 (PGD2) and 15-deoxy Δ12,14 PGJ2 (15d-PGJ2), 
resulting in growth arrest, apoptosis and cell differentiation of AML cells with little effect on the 
survival of normal myeloid progenitor cells (Murray et al., 2010). Later studies suggest that the 
critical anticancer actions of BAP disrupt lipogenesis by decreasing fatty acid and phospholipid 
biosynthesis from 13C D-glucose. Specifically, BAP treatments caused a decrease in stearoyl CoA 
desaturase 1 (SCD1) protein levels and fatty acid synthase (FASN) protein levels; therefore leading 
to a reduction in monounsaturated fatty acid and fatty acid synthesis (Southam et al., 2015). 
Previously, increased activation of PPARγ has been associated with: (i) induced growth inhibition of 
human hepatocellular carcinoma (Rumi et al., 2001); (ii) inhibition of cell growth and induced 
apoptosis of human oral squamous cell carcinoma (Nikitakis et al., 2002) (iii) induced apoptotic cell 
death in neuroblastoma cell lines (Kondo et al., 2002); (iv) a differential ability to inhibit 
proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines 
(Morosetti et al., 2004); (v) altering the growth or invasive properties of the malignant potential of 
anaplastic carcinoma cell lines (Hayashi et al., 2004); (vi) increased and induced apoptosis in normal 
~ 200 ~ 
 
and malignant human B lymphocytes (Ray, Akbiyik and Phipps, 2006); (vii) inhibition of cell growth 
via apoptosis and cell cycle arrest in human colorectal cancer (Lin et al., 2007).  
Treatment of mesenchymal-derived chondrosarcoma cells with Pioglitazone, which is a selective 
ligand for PPARγ, as well as treatment with 15d-PGJ2, the endogenous PPARγ ligand, inhibited cell 
proliferation and induced apoptosis in a dose-dependent manner (Nishida et al., 2002). The 
mechanism of cytotoxic affect in the process of 15d-PGJ2-induced apoptosis was later shown to be 
due to down-regulation of anti-apoptotic Bcl-xL and up-regulation of pro-apoptotic Bax and p21, a 
cyclin-dependent kinase inhibitor (Shen et al., 2005).  
15d-PGJ2 has also been shown to induce and increase death receptor 5 (DR5) expression through 
mRNA stabilization independently of PPARγ, potentiating tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) induced apoptosis (Nakata et al., 2006). Furthermore, combined treatment 
with 15d-PGJ2 and TRAIL induced apoptotic cell death in Jurkat human leukaemia calls and PC3 
human prostate cancer cells (Nakata et al., 2006). In a study conducted by Mitsiades et al., (2001), 
it was demonstrated that Ewing’s sarcoma family tumours were sensitive to TRAIL through its 
binding to the DR5 (Mitsiades et al., 2001).  
It was therefore hypothesised that a similar drug regime of BAP may selectively target 
osteosarcoma cells, whilst preserving non-transformed MSCs. We determined to see if we could 
observe reduced viability or proliferation and increased cell death of the SAOS2 and MG63 cells, 
with little effect on non-transformed MSCs within monoculture conditions. 
Based on the concentrations used by Khanim et al (2009) and those previously published (Bunce et 
al., 1996, Fenton et al., 1999, Fenton et al., 2003, Murray et al., 2010), we examined individual drug 
treatment effects on cell viability with MTT assay in a two-fold dilution series of BAP alone and 
supplemented with VPA at 0.6mM, designated V-BAP.  
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Following individual drug treatments for 5 days, it was seen that BEZ or VPA treatments reduced 
SAOS2 and MG63 cell viability to a greater extent than MPA, and in a concentration-dependent 
manner. Combinatorial treatments with BAP showed osteosarcoma-specific inhibitory effects from 
concentrations of and above 0.5mM BEZ and 5.0µM MPA. The addition of 0.6mM VPA to the BAP 
treatments significantly increased the osteosarcoma-specific inhibitory effects by reducing the 
viability of the SAOS2 and MG63 cells compared to the MSCs. This was seen for treatment 
conditions as low as V-BAP concentrations of 0.125mM BEZ, 1.25µM MPA, and 0.6mM VPA.  
Lineage tracking of cells within monoculture showed that within control conditions, the MSCs were 
slow to proliferate and did not undergo many population doublings; however, they remained viable 
throughout the culture period with a trajectory path and speed via trajectory equal to that of MG63 
cells. On the other hand, the SAOS2 and MG63 cells proliferated many times, where a single cell 
divided to produce many daughter cells; similarly remaining viable throughout the culture period. 
The SAOS2 were the least migratory cell with a short trajectory distance and a slow speed via 
trajectory. Following BAP [Low] and [High] treatments, the number of cell divisions and viability of 
MG63 cells significantly decreased. This trend was similarly seen to a greater extent following 
treatment with V-BAP [Low] and BAP [High]. SAOS2 cells were less affected by BAP [Low] and BAP 
[High] treatments; however, the number of cell divisions and viability significantly decreased 
following V-BAP [Low] and [High] treatments.  
It should be noted that within the BAP and V-BAP treatment conditions; the MSCs’ cell divisions, 
trajectory distance, speed via trajectory or cell survival did not significantly decrease relative to 
controls; as opposed to the responses seen by both the SAOS2 and MG63 cells, where proliferative 
and migratory potential were inhibited, and cell death was observed.  
These observed concentration-dependent effects of BAP and V-BAP, alone and in combination, on 
the viability of SAOS2 and MG63 cells compared to the MSCs, and also that seen between MSC 
donors (data discussed in Appendix 7.2.3 and graphed in Figure 7.30), may be due to differences in 
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proliferation rate of each cell type. Fibrates and MPA were shown by Fenton et al., (2003) to inhibit 
the proliferation and induce apoptosis of Burkitt’s lymphoma (BL) cells, which are characterised by 
their uncontrolled proliferation, rapid growth and abnormal survival (Fenton et al., 2003). SAOS2 
and MG63 cells have rapid growth with doubling times of approximately 53hrs and 47hrs 
respectively (Pautke et al., 2004), compared to that of adipose-derived MSCs which is greater than 
60hrs (Choudhery et al., 2014). Therefore the faster proliferating osteosarcoma cells may be more 
susceptible to the drug treatments than the MSCs.  
A study performed by Lee et al., (2008), demonstrated that 15d-PGJ2 induced apoptotic cell death 
through the mitochondrial apoptotic pathway, which was mediated by ROS generation and JNK 
activation in osteoblastic cells (Lee et al., 2008). Cytotoxic effects of 15d-PGJ2 against SAOS2, MG63 
and U2OS osteosarcoma cells through ROS-mediated AKT and cell cycle inhibition was recently 
reported (Yen et al., 2014). 15d-PGJ2 induced significant G2/M arrest and exerted time- and dose-
dependent cytotoxic effects against the osteosarcoma cells; and, western blot analysis showed that 
both AKT and PKA-PLK1 were down-regulated in osteosarcoma cell lines after treatment. These 
reports are similar to Khanim et al., (2009), where BEZ increased PGD2 synthesis via the generation 
of ROS and activation of the lipid peroxidation pathway, and MPA directed prostaglandin synthesis 
towards 15d-PGJ2. Therefore, this may be the mechanism of action of the BAP treatments reported 
here; however, further investigation would need to be conducted to confirm this.  
Adipogenic differentiation of the MSCs following BAP treatments may have occurred, since it has 
been shown that 15d-PGJ2 binding to PPARγ induces adipogenic differentiation of the BOSC23 
human kidney cell line (Forman et al., 1995). However, induced adipogenic differentiation would 
need to be confirmed; firstly by examining if BAP in fact increased 15d-PGJ2 production in the MSCs, 
then testing if there was a direct correlation with adipogenic differentiation. Bearing that in mind, 
a study conducted by Chi et al., (2013) examined the effect of 15d-PGJ2 treatment on MSCs and 
reported that although the MSC underwent apoptosis and detached from the culture dish at 
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>20µmol/L, PPARγ mRNA levels were significantly higher within <10µmol/L treated MSCs than un-
treated cells (Chi et al., 2013). However, they did not report whether there was an increase in 
adipogenic differentiation.  
As previously mentioned, VPA has been used in clinical practice as an anticonvulsant for more than 
four decades, and is known to function as a histone deacetylase (HDAC) inhibitor (Gurvich et al., 
2004). VPA has been shown to restore or improve responsiveness of tumours to conventional 
therapeutic agents, to sensitize TRAIL-resistant tumour cells to apoptosis, and to enhance radio 
sensitivity of tumour cells. However, drawbacks in the medical application of VPA include its 
teratogenicity and an incomplete understanding of the complexity of its effects (Činčárová, Zdráhal 
and Fajkus, 2013). As reviewed by de Ruijter et al., (2003), HDACs remove acetyl groups from 
histones, creating a more compact chromatin structure. Inhibition of HDACs can result in a general 
hyperacetylation of histones, which is followed by the transcriptional activation of certain genes 
through relaxation of the DNA conformation (De Ruijter et al., 2003). 
The pre-treatment of BMMSC and ATMSC with increasing concentrations of VPA before induction 
towards osteogenic differentiation was shown to enhance the differentiation capacity of the cells 
in a concentration dependent manner (Cho et al., 2005). Similarly, the in vitro effects of VPA on 
doxorubicin (DOX) sensitivity in canine and human osteosarcoma cell lines was examined, and 
treatment resulted in increased histone acetylation. Pre-incubation of osteosarcoma cells with VPA, 
followed by treatment with DOX resulted in significant growth inhibition of the osteosarcoma cells 
and potentiation of apoptosis, associated with a dose-dependent increase in nuclear DOX 
accumulation (Wittenburg et al., 2011). 
Therefore, the addition of VPA to the BAP treatments may have enhanced the PPARγ induced 
cytotoxic effects toward the osteosarcoma cell lines, whilst driving the MSCs along an adipogenic 
differentiation lineage. Further experiments would need to be conducted to examine the levels of 
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PPARγ and any direct correlation with osteosarcoma cell death, and adipogenic differentiation of 
the MSCs.  
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5.5 Conclusion 
In summary, a combination and concentration of BEZ, MPA and VPA has been identified and shown 
to inhibit the growth of human osteosarcoma cells compared with culture-expanded human MSCs. 
Notably, the live-cell imaging platform was able to monitor and characterise the cells throughout 
the culture and treatment periods non-invasively, whilst showing drug induced inhibition of growth, 
the selective inhibition of cell proliferation and effect on cell survival of cells in monoculture. 
Whilst the mechanisms of action of each of these drugs and the V-BAP drug combination remains 
to be resolved, as does whether the drugs induce any potential deleterious effects on the 
regenerative and differentiation activity of MSCs, this work provides a proof of concept that drugs 
re-deployed in the treatment of one type of malignancy, i.e. leukaemias and lymphomas, may also 
be used to treat a different type of malignancy, i.e. osteosarcomas. Furthermore, the study goes 
some way to further improving the safety of MSC-based cell therapies in which cell contamination 
or spontaneous malignant transformation are risk factors.  
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6 Chapter 6: Discussion 
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The work described in this thesis was aimed at improving the safety of autologous cell therapies 
that require cell culture in the provision of increased cell numbers, with a focus on human 
mesenchymal stem cells (MSCs). A high content screening (HCS) platform was employed in 
collaboration with an industrial partner (Imagen Therapeutics Ltd, formally Imagen Biotech Ltd) 
that specialises in the use of HCS to assess cell phenotype, particularly through immunological 
techniques that label cells in standard 2D cell cultures combined with digitised image analysis. The 
live-cell imaging platform, Cell-IQ was also employed to further assess cell phenotype and 
identification based on digitised images collected under phase contrast and fluorescence 
microscopy during live-cell culture.  
Several key questions were addressed, all of which related to the potential risk of MSC cultures 
becoming transformed into MSC-derived tumours or containing tumour cells via some other route, 
e.g. through culture contamination. These questions were: 
• Can a HCS platform be used to identify a non-transformed MSC versus a tumour cell 
thought to derive from MSCs during monolayer culture expansion using fixed cell samples? This 
was examined in Chapter 3 by quantitating immunoreactive phenotypes of MSC cultures versus 
established osteosarcoma cell lines, SAOS2 and MG63.  
• Can live-cell imaging and analysis do the same screening procedure, i.e. correctly 
distinguish between a non-transformed MSC and a MSC-derived tumour cell without the need to 
fix cell samples? Similarly, does live-cell imaging and analysis enable the identification of non-
transformed MSC versus primary tumour cells as well as established tumour cells? This was 
examined in Chapter 4 by using the Cell-IQ platform to analyse digitised phase contrast microscopy 
images captured during live-cell culture of MSCs, a primary chondrosarcoma, SAOS2 and MG63.  
• In the worse-case scenario, where tumour cells are thought to be present in an MSC culture, 
can they be treated by drugs in such a manner that the tumour growth is inhibited or deleted 
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without causing harmful effects to non-transformed MSCs? This was examined in Chapter 5 by 
testing a novel combination of drugs known to target leukaemia and lymphoma without affecting 
normal haematopoietic stem cells. 
6.1 HCS imaging and analysis key findings 
To summarise the findings of work presented in Chapter 3, it was possible to demonstrate that the 
Cellomics HCS platform was able to determine to some extent an immunoreactive profile of 
biomarkers that distinguished osteosarcoma cells (SAOS2 and MG63) from MSCs. Immunoreactivity 
for protein markers associated with cell cycle progression, cell proliferation, cell survival, 
pluripotency, osteoblastic differentiation, cell signalling and cell migration were examined. 
However, significant differences between the non-transformed MSC versus the osteosarcoma cells 
were noted only in the proliferation associated Ki-67 antigen and the pluripotency marker, Oct4. As 
might be expected, significantly more of the SAOS2 cells and highly proliferative MG63 cells were 
immunopositive for the Ki67 antigen compared to the MSCs. Likewise, significantly more SAOS2 
and MG63 cells were more immunopositive for Oct 4 compared to MSCs. In addition, significant 
differences between MSC versus the osteosarcoma cell lines were seen in some of the cell 
morphological features; namely, nuclear area and fluorescence intensity based on Hoechst 33342 
staining. 
The key finding of this work is that HCS is of value in determining cell phenotype, but there are 
possible limitations. Not least, the findings shown in this thesis would benefit from increased 
analysis of a great many more donors to further establish donor-donor variation in each of the 
parameters examined. It is generally well recognised that both the proliferative capacity and 
differentiation capacity of cultured MSCs can vary significantly between donors [references]. In 
addition, although a fairly broad range of different biomarkers were examined in this study for each 
MSC donor, the study may be improved by increasing the number of parameters examined by HCS. 
This could help to create a more in-depth immunophenotypic profile of each cell type.  
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Further work is required to optimise the use of HCS for MSC-based therapies, but, ultimately, it can 
be concluded that the adoption of HCS by cell therapy providers will provide useful additional 
information to improve the safety release criteria of MSCs for clinical transplantation. This is a key 
finding. 
One potential area of improvement may be combining the immunophenotyping and morphological 
analysis of the Cellomics platform with other more established techniques that have been used to 
characterise MSCs. Indeed, it would be necessary to compare the quantitated immunoposivity data 
for MSC-biomarkers seen using the HCS platforms with that seen in flow cytometry, which is 
currently the gold standard for such MSC immunophenotyping, although usually only for cell 
surface markers. In order to measure risk of tumourigenesis, high throughput genotyping could be 
done to assess karyotypes and identify specific genetic alterations seen in MSC-derived tumours 
(Choy et al., 2012). Similarly, fluorescence in situ hybridisation and RT-PCR have been used to 
identify translocations associated with MSC-derived tumours, such as the EWS1/Fli-1 translocation 
in Ewing’s sarcoma (Riggi et al., 2008, Machado et al., 2009). The use of short tandem repeat 
analysis would help identify cross-contamination between samples should it occur, as shown 
previously by the identification of the HT1080 fibrosarcoma cell line within primary MSC cultures 
that had been reported to have spontaneously transformed (Rubio et al., 2005, Torsvik et al., 
2010)article retracted by (Torsvik et al., 2010).  
It must be borne in mind, however, that all of these analyses use cells that have been sampled from 
the cultures that will be transplanted into a patient. Therefore, this sampling procedure reduces 
the number of cells available for transplantation, which could be a problem when cell number is 
limited and related to functional outcome, whilst also carrying a risk of not including tumour cells 
within the sample, or at levels below detection, e.g. if they were only present in small numbers 
during their initial clonal expansion.   
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6.2 Live-cell imaging and analysis key findings 
For these reasons, live-cell imaging of MSCs and tumour cultures was undertaken using the Cell-IQ 
platform, because in principal this analysis can be done directly on all those cells which will be 
transplanted. The findings of work presented in Chapter 4 showed that following live-cell imaging 
and image analysis, the identification of MSCs compared to the SAOS2 and MG63 osteosarcoma 
cell lines by the pattern recognition algorithms had variable accuracy, depending on time in culture. 
This variability in accurately identifying each cell type related to the degree to which each cell type 
exhibited homogeneity and heterogeneity in cell morphology, as well as the confluence of the cells. 
Furthermore, it was clear that the variation in cell shape meant that the live-cell imaging and 
analysis performed was not able to distinguish between the different cell types with complete 
accuracy. This is a key finding and obvious limitation to the approach. The variability in MSC 
morphology is expected  (Whitfield, Lee and Van Vliet, 2013).  Further research and the additional 
development and refinement of algorithms to examine each cell type is needed and will likely 
improve the use of the Cell-IQ platform for identification of different cell types.  
As described above, it would be advantageous to examine more donor-derived MSCs to gain a 
better understanding of morphological variation within this cell type, applying different cell-specific 
parameters within the algorithm developed in this thesis. This potentially would improve the 
correct identification of either homogeneous populations or heterogeneous sub-populations in 
donor-derived MSCs. However, it may be that there are only a limited number of MSC phenotypes 
that need to be identified, so only a limited number of algorithms or parameters are required. A 
similar argument can be applied to the assessment of MSC-derived tumours, where several 
algorithms may be needed to identify the tumour cells, e.g. one for osteosarcoma and a different 
one for Ewing’s sarcoma.  
More successfully, live-imaging and image analysis of cell division based on lineage tracking 
demonstrated MSCs divided significantly less frequently than the osteosarcoma cell lines. This key 
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finding matches the significant differences seen in Ki-67 antigen immunopositivity in Chapter 3. 
However, although the migratory behaviour of each cell type differed, MSCs were not significantly 
different to MG63 cells, with both significantly more migratory than SAOS2 cells. Whether the 
migratory behaviour of tumour cells in vitro reflects metastatic potential in vivo requires further 
work, but the findings here suggest that cell migration per se cannot be used reliably to distinguish 
MSCs from all tumour cells. 
HCS and live-cell imaging has been successfully applied to assess heterogeneous populations of 
MSCs, where their osteogenic differentiation potential was determined based on morphological 
differences during live-cell culture (Matsuoka et al., 2013). Therefore, it would be interesting to 
compare alkaline phosphatase activity with cell morphological features using the Cellomics and Cell 
IQ platform to see if this data might verify those previously published.  
The Cell-IQ platform was also able to distinguish cells that were derived from a low grade 
chondrosarcoma (CS) from non-transformed MSCs, based on trajectory length of migrating cells. 
However, based on morphology the CS cells were more similar to MSCs compared to the 
osteosarcoma cells, although this drifted (albeit non-significantly) towards the identification of 
MG63 cells prior to the first passage of the CS cells. Following their first passage, the CS cells were 
still identified as being phenotypically more alike to MSCs than SAOS2 and MG63. Hence, the use 
of live-cell imaging and image analysis may be of limited use in identifying primary tumour cells 
from non-transformed cells from tissues that may well contain both cell types. This conclusion 
requires confirmation of whether the cells isolated and cultured from the CS tissue were actually 
tumorous or not. Although PCR analysis was performed using the cultured CS cells for the most 
common point mutations seen in chondrosarcoma, i.e. IDH1:IDH2, this was negative. Therefore, 
this aspects also requires further work.   
This issue of identifying a primary population of tumour cells alongside a primary non-transformed 
cell population remains to be resolved. The outgrowth of primary chondrosarcomas has been 
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achieved previously (Calabuig-Fariñas et al., 2012, Van Oosterwijk et al., 2012), but it is a difficult 
process requiring multiple attempts and extended culture times. The advantage of using primary 
tumour cells in vitro goes beyond identifying how they may differ from non-transformed cells to 
inform the safety of cell therapy programmes, as these cells would provide a valuable resource in 
the development of drugs with anti-tumour activity. 
A question arises as to how these screening techniques can be applied to MSC-based therapies?  
The primary advantage of the Cell-IQ live-cell imaging platform compared to the Cellomics HCS 
platform is the ability to monitor cell cultures without any interference. This makes it an invaluable 
tool for screening cell behaviour within a GMP compliant facility, when the cells are intended to be 
transplanted into the patient. On the other hand, the Cellomics platform, which can also be installed 
within a GMP facility, can provide substantial identification and characterisation data of cells on a 
single cell level. The combined provision of these two platforms towards the phenotypic profiling 
for the safety of cells used for cell based therapies has been shown diagrammatically in Figure 6.1. 
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Figure 6.1: Workflow for Stem Cell-Derived Therapeutic Development 
The major findings of Chapters 3-5 of this thesis (orange box) complement and enhance current 
GMP standards in the assessment of genetic stability and phenotypic profiling of cells to be used as 
“products” in cell therapies. Genetic and phenotypic analysis must be a continuous process 
throughout product development. After assessment of safety, the differentiation status and bio-
distribution of cells within recipients also need to be assessed and tracked closely to further ensure 
safety and to evaluate whether clinical effects are predictable and controllable. Thus, HCS and live-
cell imaging are able to screen and monitor the safety of cell intended cell therapies. Figure adapted 
from Goldring et al., (2011).  
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6.3 Novel drug combination towards selective cell killing 
The final aspect of the research reported in this thesis is an experimental approach to address a 
worse-case scenario in MSC-based therapies, where the transplanted cells may contain tumorous 
cells. Culture expansion of cells on tissue culture plastic in vitro is obviously a complete contrast to 
the micro environment of cells in vivo; this process itself causes genetic abnormalities to occur 
(Mayshar et al., 2010, Ben-David, Mayshar and Benvenisty, 2011), hence compromising the safe 
provision of the cells for cell based therapy. Similarly, if a very small sample of cancer cells were 
amongst the primary cell isolate, the process of culture expansion may boost their proliferative 
capacities. Should a malignant colony arise, it would be beneficial to be able to target and kill this 
population of cells whilst preserving the normal cells. 
To summarise and discuss the findings of the work presented in Chapter 5, a unique combination 
of drugs was identified, i.e., BEZ, MPA and VPA (termed V-BAP), which selectively targeted SAOS2 
and MG63 osteosarcoma cells (at a specific concentration), whilst having little effect on normal 
MSCs. The drug combination inhibited the growth and induced cell death of the osteosarcoma cells 
in monocultures, as determined using a traditional method of quantitating viable cell numbers 
(MTT assay). Donor-to-donor variability was observed between the MSCs (discussed in Appendix 
7.2.3 and7.3.1 and graphed in Figure 7.31 and Figure 7.32), where only four of five MSC cultures 
were resistant to drug treatment, which shows the need to screen newly emerging anti-cancer 
drugs in a patient-specific manner to generate personalised medicines. The Chapter also described 
experiments using the Cell-IQ live-cell imaging platform to analyse the effects of the same drug 
regime using the manual lineage tracking tool, over 5 days of treatment. This live-cell imaging and 
analysis platform was advantageous in that it demonstrated selective targeting of the 
osteosarcoma cells compared to MSCs.  
The key finding of this research was that the novel combination of drugs, i.e. V-BAP has been 
identified as a potential therapy for the treatment of osteosarcoma. Importantly, the MSCs were 
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not adversely affected, suggesting minimal side effects. A similar drug redeployment of BAP has 
proven successful in the treatment of myeloid and lymphoid malignancy. However, much work will 
need to be done prior to successful clinical trials and application of this novel drug regime towards 
the treatment of osteosarcoma.  
Further work is also needed to determine the mechanisms by which V-BAP targets osteosarcoma 
cells without affecting MSCs, e.g., to examine whether this differential effect may relate to the 
proliferative status of the different cell types (Pautke et al., 2004, Choudhery et al., 2014), or 
whether it is a result of differential effects on metabolic pathways (Lee et al., 2008, Khanim et al., 
2009). In addition, and as described in Chapter 5, it would be particularly advantageous to test the 
drugs on primary MSC-derived tumours rather than established cell lines. This aspect was 
complicated by an inability to culture cells from the chondrosarcoma. An alternative approach 
might be to induce sarcoma formation in non-transformed MSCs, e.g. by EWS/Fli-1 translocation 
(Riggi et al., 2008) and then use these cells for drug screening. Similarly, it would be very interesting 
to explore the relationship of drug induced effects on each cell type when cultured in co-culture 
conditions. Specifically, might one cell type provide protective mechanisms of behaviour towards 
another cell type, altering the effectiveness of the drugs?  
The ISCT have stated that MSCs should be routinely characterised and identified by flow cytometry 
according to the presence and absence of immunolabelled cell surface antigens (Dominici et al., 
2006). Similarly, HSCs intended for clinical application and cell therapy are put through stringent 
characterisation by flow cytometry prior to transplantation. However, flow cytometry may not be 
the best method for spotting morphological malignant transformation of adherent cells cultured in 
vitro prior to transplantation. Morphological changes and the loss of adherence to tissue culture 
plastic is characteristic of the transformative process or alternatively contamination by another cell 
type (Riggi et al., 2008, Torsvik et al., 2010). Thus, this highlights the need for screening platform 
which provide automated and semi-automated analysis of fluorescence and phase contrast images, 
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both samples and non-invasively for phenotypic characterisation of cells cultured in vitro prior to 
their intended use in cell-based therapies.   
Overall, this thesis has demonstrated the use of a HCS screening platform and a live-cell imaging 
platform to screen MSCs intended for cell-based therapies. It has compared and contrasted MSCs 
to two well-known osteosarcoma cell lines, as well as primary cells grown from a tumour sample. 
There were some interesting, novel and potentially clinically relevant findings regarding the 
differences between the cell types that provide a basis to improve the safety of MSC 
transplantation. However, larger donor groups are required to enhance the accuracy of MSC 
profiling and the identification of MSC specific distinguishing features. Similarly, larger donor 
groups of tumour tissues are required to enhance our understanding of these cells, and to help 
identify differential cell behaviours. The next stage of the V-BAP studies should focus on 
determining mechanisms of action. The HCS and live-cell platforms and approach will enable each 
of these overriding goals, thus improving the safe provision of MSCs in regenerative medicine, as 
well as targeting MSC-derived tumours. 
6.4 Further Work 
It is the author’s opinion that the provision of cell imaging systems, including both the required 
software and hardware, will help improve monitoring systems of MSC cultures in traditional 2D 
systems. These systems would ideally be relatively easy or automated and would analyse images of 
cells in real time throughout the culture period in a non-invasive manner. Although such systems 
are or have been available, e.g. the Cell-IQ platform, IncuCyte® and Nikon BioStation CT, these 
systems are bulky and costly. In addition, much work has still to be undertaken to install such or 
similar systems within cGMP facilities. Nonetheless, their uptake by users and central pooling of 
the images collected could help many people involved in MSC-based research and therapies 
advance their recognition and analysis of MSC-specific features and behaviours. This ultimately 
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would help lead to the provision of a standard to which cells can be compared for their safer culture 
and therapeutic use.  
At this point, multiparametric ICC and HCS of a sample of cells taken from a MSC culture to be used 
in cell therapies can be used to provide an enhanced profile of biomarkers for differentiation status, 
proliferation, cell morphology and cell signalling. Although, further work is required to examine 
how these cell-based readouts align to genetic monitoring and alterations, the adoption of these 
techniques in a cGMP facility would help enhance the safe provision of therapeutic MSCs. However, 
these measures are only indicative of safety. Additional work is also needed to clarify that cells that 
are predicted to be safe, through their biomarker profile, actually are safe when transplanted into 
model systems. In an ideal world, these transplantation studies would be using human MSCs into a 
humanised rodent model, so that the immune system remains engaged.   
As previously noted, the mechanism of anticancer action of BAP within AML cells was reported to 
be a disruption of lipogenesis by decreasing fatty acid and phospholipid biosynthesis from 13C D-
glucose. Specifically, BAP treatments of the AML cells caused a decrease in stearoyl CoA desaturase 
1 (SCD1) protein levels and fatty acid synthase (FASN) protein levels   This lead to a reduction in 
monounsaturated fatty acid and fatty acid synthesis ,respectively (Southam et al., 2015). Therefore, 
it is important to investigate whether BAP and V-BAP treatments on MSCs, SAOS2 and MG63 cells 
similarly disrupt lipogenesis, particularly and possibly specifically within the SAOS2 and MG63 cells 
through the same mechanism of action, i.e. decreasing SCD1 and FASN protein levels. As detailed 
by Southam et al., (2015), supplementation with the SCD1 enzymatic product, oleate, rescued AML 
cells from the effects of BAP. Thus, rescue of the BAP and V-BAP effects on SAOS2 and MG63 cells 
would similarly help verify that the treatments work through a shared mechanism to that of AML 
cells.  It would also be interesting to examine whether the effect of V-BAP treatment is consistent 
in co-cultures of normal MSCs with osteosarcoma cells. Examination of possible synergistic 
behaviours between the MSCs and osteosarcoma cells could be performed through imaging and 
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image analysis systems described within this thesis, e.g. to examine selective cell death in relation 
to ICC for SCD1 and FASN levels. Ultimately, it would be highly desirable to direct the use of BAP 
and V-BAP within a clinical study towards the treatment of osteosarcoma; however, the mechanism 
of action, potential toxicity and potential side effects still need to be firmly established through 
both in vitro and in vivo experiments.
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7.1 Chapter 3: Supplementary figures and data 
7.1.1 HCS imaging protocol development, image analysis and data 
presentation 
MSC, SAOS2 and MG63 cells were seeded in monoculture within 96 well multiwell plates (detailed 
in section 2.1.8), allowed to adhere and cultured for 24hrs, formalin fixed (section 2.3), then ICC 
stained for biomarkers of interest (section 2.11). Following this, HCS analysis was performed 
(section 2.12). The following figures detail the protocol development stages. 
 Figure 7.1 shows a typical plate layout for ICC staining for biomarkers of interest on SAOS2 cells. 
Control wells were imaged where the 10Ab was excluded (designated -10Ab control cells). Following 
image collection of fluorescent immunoreactive cells, the appropriate plate, wells and cells were 
inspected (Figure 7.2) for image pre-processing (Figure 7.3) and analysis protocol development 
(Figure 7.4 through Figure 7.8).  
Images were initially processed where background was removed (Figure 7.3). Figure 7.4 shows a 
typical screenshot of Hoechst 33342 (Ch1) and Ki67 antigen immunoreactive GFP (Ch2) labelled 
SAOS2 cells. Primary objects are initially identified based on Hoechst 33342 staining and then 
excluded if the location of the nucleus is touching the boarder of the cells or the area of the cell is 
smaller or greater than set thresholds (Figure 7.5).  Following primary object selection, a circ or ring 
ROI was applied to Ch2 and Ch3 images where the fluorescent intensity for these channels can be 
measured within this nuclear (circ) or cytoplasmic (ring) ROI respectively. Pixels with a fluorescent 
intensity which was higher than a threshold value within the circ (circ spots) or ring (ring spots) 
were identified (Figure 7.6) and then counted as positive relative to the total number of cells 
identified within the ROI. Figure 7.7 and Figure 7.8 show the identification and selection of 
immunoreactive circ spots and ring spots within Ki67 antigen and B-catenin immunoreactive SAOS2 
cells. 
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Figure 7.1: HCS plate layout and imaging 
Screenshot of a 96 well multiwell plate seeded with SAOS2 cells, where cells have been fixed and 
fluorescently marked following ICC for selected markers. 75/96 wells were imaged, showing 8 raw 
images obtained per well. The RED rectangle indicates wells which were ICC immunoreactive for 
the Ki67 antigen. The BLUE rectangle indicates wells which were the ICC -10Ab control. ICC for all 
biomarkers presented within this thesis were performed on triplicate wells as shown.
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Figure 7.2: Image selection for processing and data analysis. 
Screenshot showing the selected plate (B), plate layout (C), well groups (A) and selection of images 
being viewed within each well (D) using the Cellomics Array Scan HCS software. Here images of Ki67 
antigen ICC immunoreactive stained cells are being compared to the -10Ab control images. 
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Figure 7.3: Image pre-processing. 
The figure shows fluorescent images of ICC immunoreactivity for the Ki67 antigen within SAOS2 
cells taken using a GFP filter, designated as channel 2. A single ROI raw image (left) is compared to 
the same ROI image with the background removed (right). 
~ 240 ~ 
 
 
Figure 7.4: Screenshot of Thermo Scientific HCS Studio: Cellomics Scan Version 6.6.0. 
The screen shot shows the comparison of a single ROI of Ki67 antigen ICC immunoreactivity within 
SAOS2 (B) compared to a single ROI of the -10Ab control (A). Images show Hoechst 33342 stained 
nuclei (designated to Ch1 - blue) with nuclear Ki67 antigen ICC (designated to Ch2 – green). 
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Figure 7.5: Screenshot of primary object selection 
The screen shot shows the selection within two ROI images of cells based on Hoechst 33342 stained 
nuclei (designated to Ch1) in -10Ab control cells (top left image) and Ki67 antigen ICC stained cells 
(bottom left image). Only Ch1 nuclear staining is shown. Objects highlighted by the white arrows 
indicate cells which have been rejected due to the location of the nucleus on the boarder of the 
ROI, or the area of the object is smaller or larger than the designated threshold (left panel). 
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Figure 7.6: Screenshot of nuclear (circ) spot object identification 
The screenshot shows the nuclear (circ) ROI for SAOS2 cells based on Hoechst 33342 staining 
(designated to Ch1) with overlaid RED indicating pixels within the circ which have a fluorescent 
intensity in Ch2 (GFP) which is greater than the set threshold value shown in the panel to the right. 
White arrows highlight -10Ab control SAOS2 cells (top panel image) and Ki67 antigen ICC 
immunoreactive SAOS2 cells (bottom panel image) with and without bright fluorescent spots within 
the nucleus. 
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Figure 7.7: Screenshot of nuclear (circ) spot object selection. 
The screen shot shows the nuclear (circ) ROI selection within two images of cells based on Hoechst 
33342 stained nuclei (designated to Ch1 - blue) in -10Ab control cells (top left image) and Ki67 
antigen ICC stained cells (bottom left image; designated to Ch2 - green). The white arrow in the top 
panel image indicates cells which have been rejected (red circle) due to the fluorescent nuclear spot 
intensity to be lower than that of a threshold (right panel). The white arrow in the bottom panel 
image indicates cells which have been selected (highlighted in red) and counted as positive for 
immunoreactive staining within the nuclear area. The graphs (right panels) show the circ spot total 
intensity versus the object area where selected cells (green spot with black circle) within the 
threshold parameters are counted, compared to rejected (green spot with red circle) cells. 
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Figure 7.8: Screenshot of cytoplasmic (ring) spot object selection 
The screen shot shows the cytoplasmic (ring) ROI selection within two images of cells based on 
Hoechst 33342 stained nuclei (designated to Ch1 - blue) in -10Ab control cells (top left image) and 
B-catenin ICC stained cells (bottom left image; designated to Ch2 - green). The white arrow in the 
top panel image indicates cells which have been rejected (red circle) due to the fluorescent nuclear 
spot intensity to be lower than that of a threshold (right panel). The white arrow in the bottom 
panel image indicates cells which have been selected (highlighted in red) and counted as positive 
for immunoreactive staining within the cytoplasmic area. The graphs (right panels) show the ring 
spot total intensity versus the object area where cells are included or excluded based on threshold 
parameters (right panel). 
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7.1.2 HCS image analysis and raw data 
The average fluorescent intensities (Figure 7.9 and Figure 7.13), sum fluorescent intensities (Figure 
7.10 and Figure 7.14), average spot fluorescent intensities (Figure 7.11 and Figure 7.15) and sum 
fluorescent spot intensities (Figure 7.12 and Figure 7.16) of fluorescent immuno-labelled 
biomarkers located within the nuclear or cytoplasmic regions of interest respectively, of MSCs, 
SAOS2 and MG63 cells are shown.   
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Figure 7.9: Average fluorescent intensity of biomarkers located within the nuclear (circ) region of 
interest. 
The average fluorescent intensity (RLU) of the nuclear biomarkers; Ki67, pHH3, pRB, nuclear β-
catenin, Oct4 and nanog were quantitated and shown for MSCs (green), SAOS2 (orange) and MG63 
cells (red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along with SAOS2 and 
MG63 cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s post-test, ns 
indicates no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001.  
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Figure 7.10: Sum fluorescent intensity of biomarkers located within the nuclear (circ) region of 
interest. 
The sum fluorescent intensity (RLU) of the nuclear biomarkers; Ki67, pHH3, pRB, nuclear β-catenin, 
Oct4 and nanog were quantitated and shown for MSCs (green), SAOS2 (orange) and MG63 cells 
(red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along with SAOS2 and MG63 
cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s post-test, ns indicates 
no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 7.11: Average fluorescent spot intensity of biomarkers located within the nuclear (circ) 
region of interest. 
The average fluorescent spot intensity (RLU) of the nuclear biomarkers; Ki67, pHH3, pRB, nuclear 
β-catenin, Oct4 and nanog were quantitated and shown for MSCs (green), SAOS2 (orange) and 
MG63 cells (red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along with SAOS2 
and MG63 cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s post-test, ns 
indicates no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 7.12: Sum fluorescent spot intensity of biomarkers located within the nuclear (circ) region 
of interest. 
The sum fluorescent spot intensity (RLU) of the nuclear biomarkers; Ki67, pHH3, pRB, nuclear β-
catenin, Oct4 and nanog were quantitated and shown for MSCs (green), SAOS2 (orange) and MG63 
cells (red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along with SAOS2 and 
MG63 cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s post-test, ns 
indicates no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 7.13: Average fluorescent intensity of biomarkers located within the cytoplasmic (ring) 
region of interest. 
The average fluorescent intensity (RLU) of the cytoplasmic biomarkers; osteopontin, osteocalcin, 
cytoplasmic β-catenin and pFAK were quantitated and shown for MSCs (green), SAOS2 (orange) and 
MG63 cells (red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along with SAOS2 
and MG63 cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s post-test, ns 
indicates no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 7.14: Sum fluorescent intensity of biomarkers located within the cytoplasmic (ring) region 
of interest. 
The sum fluorescent intensity (RLU) of the cytoplasmic biomarkers; osteopontin, osteocalcin, 
cytoplasmic β-catenin and pFAK were quantitated and shown for MSCs (green), SAOS2 (orange) and 
MG63 cells (red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along with SAOS2 
and MG63 cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s post-test, ns 
indicates no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 7.15: Average fluorescent spot intensity of biomarkers located within the cytoplasmic 
(ring) region of interest. 
The average fluorescent spot intensity (RLU) of the cytoplasmic biomarkers; osteopontin, 
osteocalcin, cytoplasmic β-catenin and pFAK were quantitated and shown for MSCs (green), SAOS2 
(orange) and MG63 cells (red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along 
with SAOS2 and MG63 cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s 
post-test, ns indicates no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001. 
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Figure 7.16: Sum fluorescent spot intensity of biomarkers located within the cytoplasmic (ring) 
region of interest. 
The sum fluorescent spot intensity (RLU) of the cytoplasmic biomarkers; osteopontin, osteocalcin, 
cytoplasmic β-catenin and pFAK were quantitated and shown for MSCs (green), SAOS2 (orange) and 
MG63 cells (red). Data shown are Mean ± SEM from n=3 donor MSCs analysed along with SAOS2 
and MG63 cells over 3 independent experiments. All; two-way ANOVA with a Tukey’s post-test, ns 
indicates no significant difference, *p≤0.05, **p≤0.01, ***p≤0.001. 
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7.1.3 IN CELL Analyzer Multi Target Analysis method 
Following ALP enzymatic activity staining (section 2.4), HCS of cells was performed using the IN CELL 
Analyzer 1000 platform (GE Healthcare, Buckinghamshire, UK). Similarly to the Cellomics ArrayScan, 
9 images were taken from the centre through a spiral pattern outward towards the edge of the well 
with no less than 5000 cells imaged within the 9 images. Images were taken in two channels: 
channel 1 (386nmEM), channel 2 (bright field). These images were then analysed through the 
standard bio-application analysis protocol to measure the pixel intensity for the ‘Ring’ regions of 
interest on a per cell basis. The software reported the mean cytoplasmic intensity on a per cell 
basis, designated here as relative light units (RLU, an arbitrary annotation). The inverse of the 
intensity was then calculated and plotted. 
7.1.4 Alkaline phosphatase enzymatic activity in MSCs, SAOS2 and MG63 
cells 
Representative bright-field, monochromatic images of alkaline phosphatase (ALP) enzymatic 
activity are shown in Figure 7.17 A. As shown, SAOS2 cells showed dark cytoplasmic and nuclear 
ALP staining activity. In contrast, few MSCs and MG63 cells were stained by the ALP activity. The 
graph in Figure 7.17 B shows the mean intensity of ALP activity within three donor MSCs compared 
to SAOS2 and MG63 cells. As shown, quantitation of the staining for ALP activity inSAOS2 (158.4 ± 
13.7 AU) was 12 fold higher than that for ALP activity in MSCs (13.0 ± 1.4 AU) and approximately 10 
fold greater than staining for ALP activity in MG63 cells (16.1 ± 3.0 AU). Staining intensity of the 
SAOS2 cells was significantly higher than both MSCs and MG63 cells (p<0.001; one-way ANOVA with 
a Tukey’s post-test).  
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Figure 7.17: Increased activity of the differentiation associated marker Alkaline Phosphatase 
(ALP) distinguished primary human MSCs from SAOS2 cells, but not MG63 cells. 
(A) Representative images showing increased ALP activity in MSC, SAOS2 and MG63 cells (Bar = 
100µm). Inset is 3x magnified. (B) Quantitation of the mean cytoplasmic intensity of ALP within 
MSCs, SAOS2 and MG63 cells, determined using the IN CELL Analyser© HCS platform. Data shown 
are means ± SD from n=1 experiment. 
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7.2 Chapter 4: Supplementary figures and data 
7.2.1 Live-cell imaging protocol development, image analysis and data 
presentation. 
Cell-IQ AnalyserTM software analysis must be performed in a stepwise process prior to the 
production of results. Initially images are segmented using a threshold, where an image is 
segmented by parameters determined for distances between cells, area of cells as well as cell 
symmetry (Figure 7.18). Segmentation parameter settings were initially used to identify all cells 
within the population (Error! Reference source not found.); however, these were later fine-tuned 
or cell type specific segmentation aiming towards better cell type identified. Images of two MSC 
samples, SAOS2 and MG63 cells cultured in monoculture at 48hrs post seeding, were initially used 
to define cell type specific segmentation parameters. 
The cell type specific segmentation parameters were then used for the next step of cell 
classification. The classification step groups the segments of the images into separate classes based 
on a user built sample library. Prior to adding samples, a predefined ‘Recognition window size’ must 
be selected (Figure 7.19).  During cell sample collection, only a single recognition window size can 
be used whilst adding samples to the sample library (Figure 7.22), therefore several recognition 
windows were selected and protocols formed (Table 8). When the recognition area was specified, 
samples/stamps of each cell type were added to the cell classes, the cell counting segmentation 
parameters were set (Figure 7.21), then the protocol algorithms were written and the images of 
the MSC, SAOS2 and MG63 cell monocultures were analysed. Figure 7.22 shows phase contrast 
images of two MSC samples, SAOS2 and MG63 cells at 48hrs post seeding, in their original form 
(top row), following segmentation with RED dots indicating identified points of interest (middle 
row), then following classification of the segmented dots into cell classes (bottom row) and the 
protocol used in the bottom left corner of the image. The number of events identifying a specific 
cell type in monoculture was then calculated relative to incorrect identification events and graphed 
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as identification (% of total) as shown in Figure 7.23. It can be seen that Protocol 5 was most 
accurate for identifying MSC (BMS003) (68%), Protocol 1 for MSC (BMS006) (68%), Protocol 5 for 
SAOS2 cells (92%) and Protocol 6 for MG63 cells (94%). 
These protocols were then enhanced where cell samples were added taken from images collected 
through the full culture period. Analysis was of the monocultures was performed and the results 
can be seen in Figure 7.24.  
Images of MSC, SAOS2 and MG63 cell monocultures, showing the identification points were 
examined and incorrect identification of cells was noted.  The events where cells were misidentified 
were noted and the cell sample library was adjusted appropriately where possible.  Figure 7.25 
shows the identification of MSCs, SAOS2 and MG63 cells at 72 and 96hrs post seeding, where the 
inserts show incorrect identification with a RED box and correct identification by a GREEN box.  
Misidentification of MSCs and SAOS2 cells as MG63 cells can be seen in inserts b, d, f and n. This is 
due to the phase bright 'halo' seen around the cells, a distinctive characteristic of the MG63 cells 
throughout their growth cycles. Misidentification of the spaces between MSCs as MG63 cells seen 
in insert j, is similarly due to the phase bright 'halo' effect. This was counteracted by teaching the 
library to identify these areas as background. Misidentification of the MG63 cell as an MSC seen in 
inserts h and p may have been identification of the cell based on the large flat cytoplasm with less 
punctate markings within and around the nucleus. Misidentification of MSCs as SAOS2 cells seen in 
insert l is not clear and may be due to the particular cytoplasmic pattern displayed at that time.  
Since many of these misidentifications were due to similarities between cell morphology, there was 
little that could be changed within the identification library; therefore, to address these, the sample 
size of each cell type class was increased, ensuring samples had distinctive differences. 
Review of the analysed images, as shown in, highlighted areas of incorrect identification of cell 
types within the monocultures. As shown; inset images with a green boarder highlight cells which 
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have been correctly identified, inset images with a red boarder highlight cells which have been 
incorrectly identified. 
The process of protocol development was continued, where images of identified cells were 
reviewed and the sample library adjusted accordingly. Similarly the cell segmentation parameters 
were adjusted. Analysis was re-run and the results reviewed. This was performed several times 
whilst including images and samples taken from repeat experiments. Videos showing the Cell Finder 
tool analysis of representative ROIs of two culture expanded MSCs, SAOS2 and MG63 cells can be 
seen on the supplementary DVD (Appendix 7.4).  
~ 259 ~ 
 
 
Figure 7.18: Cell counting segmentation parameters. 
This screenshot illustrates the option for adding multiple parameter settings, then applying those 
settings towards the analysis and classification of cells within the images collected. Settings D 
through G which were manipulated specific to MSCs, SAOS2 and MG63 cells are shown in Table 4.  
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Table 7: Table showing the cell counting parameter settings for segmentation of images for 
analysis during protocol development. 
Cell Type Parameter set 
ID 
Parameter 
A 
Parameter 
B 
Parameter 
C 
Parameter 
D 
Parameter 
E 
Parameter 
F 
Parameter 
G 
MSC 
(BMS003) 
1 - - - 50 50 65 20 
MSC 
(BMS006) 
2 - - - 50 50 65 20 
SAOS2 3 - - - 40 40 45 50 
MG63 4 - - - 45 45 55 20 
~ 261 ~ 
 
 
Figure 7.19: Cell-IQ AnalyserTM Recognition window settings. 
The recognition window options shown above allow for variability during the selection process for 
stamps used towards the collection and composition of a library. Within this thesis, the Two Areas 
recognition window was used. 
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Table 8: Table showing the cell counting parameter settings for recognition windows used during 
protocol development. 
Protocol Recognition Area Window Size (Outer Circle) Window Size (Inner Circle)
Protocol 1 One Area 130
Protocol 2 Two Areas 130 50
Protocol 3 One Area 100
Protocol 4 Two Areas 100 50
Protocol 5 One Area 120
Protocol 6 Two Areas 120 45
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Figure 7.20: Sample images used to form the cell sample library which classifies cells following 
segmentation. 
Stamps of specific cell morphologies are collected and classified by the user. Following stamp 
collection, the library images and categories are digitized into a pattern recognition algorithm which 
is then used to analyse and classify the cells within other images collected. 
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Figure 7.21: Details of cell identification analysis for Cell-IQ AnalyserTM protocols. 
The screenshot shows the development process for the identification and classification of two MSC 
samples (BMS003 and BMS006), SAOS2, MG63 and Round cells, as well as background/debris. Each 
class is designated a colour, shape, shape size and the cell counting and classification parameters 
can be set. 
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Figure 7.22: Images of cells 48hrs post seeding prior to and after segmentation using Cell-IQ AnalyserTM. 
Images show the development process of the pattern recognition process where original images were collected and then the area of the cells was determined 
based on threshold analysis. Following this, cell counting with variable parameters and accuracy was performed. Finally, classification of the counted cells 
was performed. 
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Figure 7.23: Graph showing the percentage of correct identification of cells in monoculture 
according to different protocols. 
During the development of the image recognition algorithm, several protocols were established 
and tested for their efficiency to recognise and categorise two MSCs, SAOS2 and MG63 cells 
cultured in monocultures at a single time point. The percentage (%) identification of the cells 
relative to the total is shown for each protocol and call type.   
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Figure 7.24: Analysis using 1TC, 5TC and 6TC protocols for identification of MSC, SAOS2 and MG63 cells. 
Graphs illustrate the efficiency of three protocols to count and classify two MSCs, SAOS2 and MG63 cells over 120hrs of monoculture. The total number of 
cells (black line), MSCs, (green line), SAOS2 cells (yellow line), MG63 cells (red line) and debris (blue line) are shown within each graph from 0hrs of imaging 
(left of the graph) through 120hrs of imaging (right of the graph). 
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Figure 7.25: Correct and incorrect identification of MSCs, SAOS2 and MG63 cells. 
The identification and classification of cells seen in images of MSC1 (left column), MSC2 (second left column), SAOS2 cells (third left column) and MG63 cells 
(right column) grown in monoculture are shown at 72hrs post seeding (top row) and 96hrs post seeding (bottom row). Inserts highlight cells and areas which 
have been correctly identified (green box - a, c, e, g, I, k, m, o) according to that cell type, or misidentified (red box - b, d, f, h, j, l, n, p) as an alternative cell 
type. 
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7.2.2 Chondrosarcoma diagnosis and treatment 
The image in Figure 7.26 A shows a tomogram from a computerised tomography (CT) scan of the 
patient’s upper left humerus. As shown, the tissue within the medullar cavity of the upper left 
humerus presented with a non-uniform pattern, where bright spots were seen (top arrow). The 
density of the bone was also seen to be variable above the deltoid tuberosity (bottom arrow). The 
image in Figure 7.26 B shows a magnetic resonance imaging (MRI) scan. As shown, the suspected 
lesion was seen as a large dark area (arrow) within the medullar cavity of the left upper proximal 
humerus. The image in Figure 7.26 C shows a dynamic contrast MRI scan. As shown, the lesion 
appeared as a large bright area (arrow) within the medullar cavity of the upper left proximal 
humerus. The lesion was measured by radiologists to be greater than 8.5cm in length. The initial 
diagnosis was a suspected tumour encased within the bone cavity, without signs of metastasis.  
A biopsy of tissue was removed for histological analysis. Histological staining of the biopsy 
confirmed diagnosis of the tumour as a low grade I chondrosarcoma. Representative images of 
haematoxylin and eosin (H&E) staining of the cancerous lesion biopsy are shown in Figure 7.27 A-
D. Cartilaginous tissues were stained blue with haematoxylin, and bone tissue stained pink with 
eosin. The lesion was identified and diagnosed as a well differentiated hyaline cartilaginous lesion. 
The image in Figure 7.27 A shows malignant permeating tumour cells encompassed within the host 
bony trabeculae (arrow). The image in Figure 7.27 B shows entrapment of host bone by 
cartilaginous tumour (arrow). The image in Figure 7.27 C shows the formation of a distinctive low 
cellular enchondromatic nodule (arrow). The image in Figure 7.27 D shows endochondral 
ossification within areas of the cancerous lesion (bracket and arrow). This appearance was 
considered consistent with diagnosis as a grade I chondrosarcoma. 
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The surgical procedure detailing the excision of an infected humerus, irradiation and re-
implantation of the post-irradiated humerus packed with bone cement, can be seen in Figure 7.28. 
As shown, the central section of the humerus (a) was excised from the left arm (b). The tumour was 
curettaged from the medulla cavity of the excised bone fragment (c). A sample of tumour tissue 
was taken directly from the curettaged tissue (d). This sample has been referred to as the non-radio 
sample. A second sample of curettaged tumour tissue (e) and the bone fragment (f) were then 
treated with a single fraction of 90Gy deep X-ray therapy (DXT). This second sample has been 
referred to as the post-radio sample. Following irradiation, the bone fragment was packed with 
non-vascularised bone cement and fixed back into place within the left arm (g). The weight of the 
non-radio and post-radio therapy treated samples were 0.860g and 1.103g respectively. 
H&E staining of the curettage confirmed diagnosis of the tumour as a low grade I chondrosarcoma, 
shown in Figure 7.29. As shown, the curettaged tissue presented as a well differentiated hyaline 
cartilaginous lesion. Areas of interest within Figure 7.29 A are highlighted and presented in Figure 
7.29 B-D, showing malignant permeating tumour cells encompassed within host bone (Figure 7.29 
B), a distinctive low cellular enchondromatic nodule (Figure 7.29 C), and endochondral ossification 
(Figure 7.29 D).  
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Figure 7.26: Radiological examination identified the chondroid lesion.  
Radiological examination by CT (A), MRI (B) and dynamic contrast MRI (C) scans were used to 
identify the chonroid lesion, and offer a more definitive opinion on how to manage the patient’s 
lesion. The lesion was measured to be greater than 8.5 cm in length and described as a low grade 
chondrosarcoma contained within the host bone, as indicated by the arrows. Patient’s scans were 
provided by ROH. 
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Figure 7.27: Histological analysis of the biopsy diagnosed the chondroid lesion as a low grade I 
chondrosarcoma.  
Biopsy and imaging were consistent with a well differentiated cartilaginous lesion suspected to be 
a grade I chondrosarcoma. Examination of cartilage stained with haematoxylin (blue) and bone 
stained with eosin (pink) on sections of the biopsy material shows well differentiated hyaline 
cartilaginous lesions consisting of (A) malignant permeating tumour cells (arrow) permeating host 
bony trabeculae (4x), (B) entrapment of host bone by the tumour (10x), (C) distinctive low cellularity 
enchondromatic nodule formation (4x) and (D) endochondral ossification (10x). 
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Figure 7.28: A schematic diagram showing the surgical procedure of excision, irradiation and re-
implantation.  
Clockwise from left. The central section of the humerus (a) was excised from the left arm (b) and 
the tumour was curettaged from the medulla cavity of the excised bone fragment (c). A sample of 
tumour tissue was taken from the curettaged fragment (d). This sample is referred to as the non-
radio therapy sample. The bone fragment and another sample of tumour tissue were treated with 
a single fraction of 90Gy deep X-ray therapy (DXT) (e-f). This sample is referred to as the post-radio 
therapy sample. Following irradiation, the bone fragment was packed with non-vascularised bone 
cement and fixed back into place (g). Image adapted from www.lifesciencedb.jp  
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Figure 7.29: Histological analysis of the curettaged chondrosarcoma confirmed diagnosis and 
showed similar histological material to the pre-operative biopsy.  
Examination of cartilage stained with haematoxylin (blue) and bone stained with eosin (pink) on (A) 
a curettage chondrosarcoma section (2x) show well differentiated hyaline cartilaginous lesions 
consisting of (B) malignant permeating tumour cells, (C) a low cellularity enchondromatic nodule 
and (D) minor endochondral ossification. Images B-D are 3.2x magnified insets from image A. 
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7.2.3 Manual cell lineage tracking of MSCs, SAOS2 and MG63 cells 
distinguishes donor to donor variability, as well as distinguishes 
between cell types 
Data obtained from the Manual Lineage Tracking is shown in Figure 7.30 where the average 
divisions (A), trajectory length (B) and speed via trajectory (C) are presented for each cell type, 
specifically detailing the patient to patient and sample variability of 5 primary human MSCs, SAOS2, 
MG63 and CS cells. It can be seen that MG63 cells divided most compared to the other cell types 
(A); two of the five MSCs and MG63 cells migrated the furthest with high trajectory lengths (B) and 
these same samples had the greatest speed via trajectory.  
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Figure 7.30: Manual cell lineage tracking of live-cells distinguishes between five primary human 
MSCs, SAOS2, MG63 and chondrosarcoma derived cells based on the average number of cell 
divisions, trajectory length and speed via trajectory. 
Cells from five human MSCs, SAOS2, MG63 and CS cells were tracked with the Manual Cell Lineage 
tracking tool. The average number of divisions, trajectory length and speed via trajectory were 
recorded and reported. Data shown for all call types are mean ± SD since individual donor 
measurements are shown. SAOS2 and MG63 cell data are from n=3 independent experiments. CS 
data are from n=1 sample, imaged and analysed over n=3 independent experiments. 
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7.3 Chapter 5: Supplementary figures and data 
7.3.1 Donor to donor variability response to BEZ, MPA, VPA, BAP and V-
BAP treatments according to MTT assay 
Within the MSC cultures, marked donor to donor variation in response to the treatments were seen 
(Figure 7.31) where; BEZ inhibited the growth of MSC8 cells more than other MSCs; MPA enhanced 
cell growth of MSC1 and MSC9 cells, whilst inhibiting MSC7 and MSC8 cells, with little effect to 
MSC2 cells; whilst VPA inhibited MSC8 cells and enhancing the cell growth of MSC2 cells. 
In terms of combined treatment effects on the MSCs, similar donor to donor variability was seen 
(Figure 7.32); yet, viability of all MSCs decreased at the highest concentration of BAP and V-BAP. 
However, four of five MSCs (MSC1, MSC2, MSC7, and MSC9) remained viable ≥85% following 
treatment with ≤[0.5mM/5.0µM] BAP and ≤[0.5mM/5.0µM/0.6mM] V-BAP. The viability of MSC8 
was similar to that of SAOS2 and MG63 cells. 
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Figure 7.31: BEZ, MPA and VPA affected the viability of five primary human MSCs, SAOS2 and 
MG63 cells in a concentration-dependent manner according to MTT assay.  
The cell viability normalised to the percentage of the carrier-alone control is shown. Five human 
MSCs, SAOS2 and MG63 osteosarcoma cell lines were treated for 5 days with two-fold increasing 
doses of BEZ (A), MPA (B) or VPA (C). Cells were seeded and assayed in triplicate wells. MSC data 
shown are mean ± SD since individual donor measurements are shown. Osteosarcoma data shown 
are mean ± SEM from n=3 independent experiments. 
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Figure 7.32: BAP and V-BAP affected the viability of five primary human MSCs, SAOS2 and MG63 
cells in a concentration-dependent manner according to MTT assay. 
The cell viability normalised to the percentage of the carrier-alone control is shown. Five human 
MSCs, SAOS2 and MG63 osteosarcoma cell lines were treated for 5 days with two-fold increasing 
doses of BAP (A) or V-BAP (B). Cells were seeded and assayed in triplicate wells. MSC data shown 
are mean ± SD since individual donor measurements are shown. Osteosarcoma data shown are 
mean ± SEM from n=4 independent experiments. 
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7.4 Digital content on accompanying DVD 
#1 Live-Cell Imaging Protocols: Cell-IQ live-cell imaging Cell Finder protocols used in Chapter 4 for 
counting and classifying MSCs, SAOSs, MG63 and CS cells. 
#2 Live-Cell Imaging Videos: 
#2.1 Cell-IQ Original Images: Videos of original ROI images showing the culture expansion 
of MSCs, SAOS2 and MG63 cells prior to analysis obtained using the Cell-IQ live-cell 
imaging platform. 
#2.2 Cell-IQ Area Measure tool: Videos of the above ROIs of culture expanded MSCs, SAOS2 
and MG63 cells following analysis with the Cell-IQ Area Measure tool. 
#2.3 Cell-IQ Cell Finder tool: Videos of ROIs of culture expanded MSCs, SAOS2 and MG63 
cells following analysis and classification with the Cell-IQ Cell Finder tool used during 
the protocol development process detailed in Appendix 7.2.1. 
#2.4 Cell-IQ Imaging of CS cells: Videos of ROIs of culture expanded CS cells following 
passage.  
#2.5 Cell-IQ Imaging of Control and V-BAP treatments: Videos of ROIs of culture expanded 
MSCs, SAOS2 and MG63 cells following culture in control and V-BAP culture conditions. 
